



**National Toxicology Program**  
**Toxicity Report Series**  
**Number 92**

**NTP Technical Report**  
**on the Toxicity Studies of**

**Octahydro-tetramethyl-naphthalenyl-**  
**ethanone (OTNE)**

**Administered Dermally**  
**to F344/NTac Rats and B6C3F1/N Mice**

**June 2016**

**National Institutes of Health**  
**Public Health Service**  
**U.S. Department of Health and Human Services**

## FOREWORD

The National Toxicology Program (NTP) is an interagency program within the Public Health Service (PHS) of the Department of Health and Human Services (HHS) and is headquartered at the National Institute of Environmental Health Sciences of the National Institutes of Health (NIEHS/NIH). Three agencies contribute resources to the program: NIEHS/NIH, the National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention (NIOSH/CDC), and the National Center for Toxicological Research of the Food and Drug Administration (NCTR/FDA). Established in 1978, the NTP is charged with coordinating toxicological testing activities, strengthening the science base in toxicology, developing and validating improved testing methods, and providing information about potentially toxic substances to health regulatory and research agencies, scientific and medical communities, and the public.

The Toxicity Study Report series began in 1991. The studies described in the Toxicity Study Report series are designed and conducted to characterize and evaluate the toxicologic potential of selected substances in laboratory animals (usually two species, rats and mice). Substances selected for NTP toxicity studies are chosen primarily on the basis of human exposure, level of production, and chemical structure. The interpretive conclusions presented in the Toxicity Study Reports are based only on the results of these NTP studies. Extrapolation of these results to other species, including characterization of hazards and risks to humans, requires analyses beyond the intent of these reports. Selection *per se* is not an indicator of a substance's toxic potential.

The NTP conducts its studies in compliance with its laboratory health and safety guidelines and FDA Good Laboratory Practice Regulations and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use are in accordance with the Public Health Service Policy on Humane Care and Use of Animals. Studies are subjected to retrospective quality assurance audits before being presented for public review.

NTP Toxicity Study Reports are indexed in the NIH/NLM PubMed database and are available free of charge electronically on the NTP website (<http://ntp.niehs.nih.gov>).

**National Toxicology Program  
Toxicity Report Series  
Number 92**

**NTP Technical Report  
on the Toxicity Studies of**

# **Octahydro-tetramethyl-naphthalenyl- ethanone (OTNE)**

**Administered Dermally  
to F344/NTac Rats and B6C3F1/N Mice**

**K.R. Ryan, Ph.D., Study Scientist**

**National Toxicology Program  
Post Office Box 12233  
Research Triangle Park, NC 27709**

**June 2016**

**National Institutes of Health  
Public Health Service  
U.S. Department of Health and Human Services**

## CONTRIBUTORS

### **National Toxicology Program**

*Evaluated and interpreted results and reported findings*

K.R. Ryan, Ph.D., Study Scientist  
 R.A. Herbert, D.V.M., Ph.D., Study Pathologist  
 C.R. Blystone, Ph.D.  
 M.C. Cora, D.V.M.  
 D.R. Germolec, Ph.D.  
 P.M. Foster, Ph.D.  
 M.J. Hooth, Ph.D.  
 A.P. King-Herbert, D.V.M.  
 G.E. Kissling, Ph.D.  
 B.S. McIntyre, Ph.D.  
 D.E. Malarkey, D.V.M., Ph.D.  
 S.L. Smith-Roe, Ph.D.  
 M.D. Stout, Ph.D.  
 G.S. Travlos, D.V.M.  
 M.K. Vallant, B.S., M.T.  
 S. Waidyanatha, Ph.D.  
 N.J. Walker, Ph.D.  
 K.L. Witt, M.S.

### **BioReliance Corporation**

*Conducted studies and evaluated pathology findings*

M.L. Wenk, Ph.D., Principal Investigator  
 M. Paranjpe, D.V.M., Ph.D.

### **Experimental Pathology Laboratories, Inc.**

*Provided pathology review*

M.H. Hamlin, II, D.V.M., Principal Investigator  
 E.T. Adams, D.V.M., Ph.D.

### **RTI International**

*Provided andrology analyses*

R.W. Tyl, Ph.D., Principal Investigator

### **Southern Research Institute**

*Provided vaginal cytology analyses*

C.D. Hébert, Ph.D., Principal Investigator  
 E. Mylchreest, Ph.D.

### **Dynamac Corporation**

*Prepared quality assessment audits*

S. Brecher, Ph.D., Principal Investigator  
 S. Iyer, B.S.  
 V.S. Tharakan, D.V.M.

### **NTP Pathology Working Group**

*Evaluated slides and contributed to pathology report  
 (March 10, 2011)*

K.R. Hobbie, D.V.M., Ph.D., Coordinator  
 ILS, Inc.  
 G.P. Flake, M.D.  
 National Toxicology Program  
 R.A. Herbert, D.V.M., Ph.D.  
 National Toxicology Program  
 M.J. Hoenerhoff, D.V.M., Ph.D.  
 National Toxicology Program

### **Social & Scientific Systems, Inc.**

*Provided statistical analyses*

M.V. Smith, Ph.D., Principal Investigator  
 L.J. Betz, M.S.  
 S.F. Harris, B.S.

### **Biotechnical Services, Inc.**

*Prepared Toxicity Study Report*

S.R. Gunnels, M.A., Principal Investigator  
 L.M. Harper, B.S.  
 D.C. Serbus, Ph.D.  
 G.E. Simmons, M.A.

## PEER REVIEW

The draft report on the toxicity studies of OTNE was evaluated by the reviewers listed below. These reviewers serve as independent scientists, not as representatives of any institution, company, or governmental agency. In this capacity, reviewers determine if the design and conditions of these NTP studies are appropriate and ensure that this Toxicity Study Report presents the experimental results and conclusions fully and clearly.

Laura A. Hanson, Ph.D.

Director, Molecular Mechanisms of Carcinogenesis Program  
Creighton University School of Medicine  
Omaha, NE

Greg Erexson, Ph.D.

Principal Occupational and Environmental Toxicologist  
AbbVie  
North Chicago, IL

# CONTENTS

<b>ABSTRACT</b> .....	7
<b>INTRODUCTION</b> .....	13
Chemical and Physical Properties .....	14
Production, Use, and Human Exposure .....	14
Regulatory Status .....	15
Absorption, Distribution, Metabolism, Excretion, and Toxicokinetics .....	16
Toxicity .....	17
Reproductive and Developmental Toxicity .....	19
Carcinogenicity .....	19
Genetic Toxicity .....	19
Study Rationale .....	20
<b>MATERIALS AND METHODS</b> .....	21
Procurement and Characterization .....	21
Preparation and Analysis of Dose Formulations .....	21
Animal Source .....	22
Animal Welfare .....	22
3-Month Studies .....	22
Statistical Methods .....	27
Quality Assurance Methods .....	28
Genetic Toxicology .....	28
<b>RESULTS</b> .....	31
3-Month Study in Rats .....	31
3-Month Study in Mice .....	36
Genetic Toxicology .....	45
<b>DISCUSSION</b> .....	47
<b>REFERENCES</b> .....	51
<b>APPENDIXES</b>	
Appendix A      Summary of Lesions in Rats and Mice .....	A-1
Appendix B      Clinical Pathology and Liver Toxicity Results .....	B-1
Appendix C      Organ Weights and Organ-Weight-to-Body-Weight Ratios.....	C-1
Appendix D      Reproductive Tissue Evaluations and Estrous Cycle Characterization .....	D-1
Appendix E      Genetic Toxicology .....	E-1
Appendix F      Chemical Characterization and Dose Formulation Studies .....	F-1
Appendix G      Ingredients, Nutrient Composition, and Contaminant Levels 	

## SUMMARY

### Background

OTNE is used as a perfume ingredient in personal and household products, such as soaps, shampoos, liquid detergent compounds, antiperspirants or deodorants, and air or fabric fresheners. We conducted short-term (3 month) tests to determine if there were any toxic effects of OTNE on rats or mice. Because skin contact is common in humans, a dermal route of exposure was selected for this study.

### Methods

We applied solutions of OTNE in ethanol to the skin of rats and mice 5 days per week for 3 months. There were 10 rodents in each dose group. Doses were 6.25%, 12.5%, 25%, and 50% OTNE in ethanol and 100% OTNE. These doses correspond approximately to 31.25 to 500 milligrams (mg) of OTNE per kilogram (kg) of body weight in rats and 125 to 2,000 mg/kg in mice. One group received ethanol alone and served as the control group for the dose groups that were exposed to 6.25% to 50% OTNE in ethanol. Another control group received no administration of ethanol and served as the control group for the dose group exposed to 100% OTNE, which had no ethanol. During the course of this study, samples were collected for clinical chemistry and estrous cycle characterization. At the end of the study, samples were collected for reproductive tissue evaluations, genetic toxicology studies, and more than 40 tissues were collected from each animal for histopathology diagnosis.

### Results

All animals survived to the end of the studies. Small but significant decreases in body weights were observed in male mice. The skin at the site of application was considered the primary target of OTNE toxicity across both sexes and species; skin toxicity was more prominent in mice than rats. There was a significant increase in the incidence of skin irritation and thickness (hyperplasia and hyperkeratosis) in rats receiving 12.5% or greater OTNE. In most exposure groups of mice, there was an increase in the incidence of skin lesions (hyperkeratosis, hyperplasia, chronic active inflammation, fibrosis, epidermal suppurative inflammation, and hair follicle hyperplasia).




### Conclusions

We conclude that dermal exposure to OTNE for 3 months resulted in skin lesions at the site of OTNE application in both rats and mice.





## ABSTRACT



### OCTAHYDRO-TETRAMETHYL-NAPHTHALENYL-ETHANONE (OTNE)

CAS Nos. 54464-57-2 ( $\beta$ -isomer), 68155-67-9 ( $\alpha$ -isomer), 68155-66-8 ( $\gamma$ -isomer)

Chemical Formula:  $C_{16}H_{26}O$       Molecular Weight: 234.38

**Synonyms:** 1',2',3',4',5',6',7',8'-Octahydro-2',3',8',8'-tetramethyl-2'-acetonaphthone; 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-acetonaphthone; 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)ethanone; 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one; 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one; 1-(1,2,3,4,5,6,7,8-octahydro-2,3,5,5-tetramethyl-2-naphthyl)ethan-1-one

**Trade Names:** Amberonne, Ambralux, Boisvelone, Iso Ambois Super, Iso E Super<sup>®</sup>, Isocyclemon, Isocyclemon E, Orbitone

Octahydro-tetramethyl-naphthalenyl-ethanone (OTNE) is a fragrance ingredient that is formed as a mixture of isomers with a basic unsaturated alkyl cyclic ketone structure. The main isomer is 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)ethanone ( $\beta$ -isomer). Two other predominant isomers within the mixture are 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)ethanone ( $\alpha$ -isomer) and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)ethanone ( $\gamma$ -isomer). OTNE is used as a perfume ingredient in soap, shampoo, cologne, liquid detergent compounds, and malodor-reducing compounds. Male and female F344/NTac rats and B6C3F1/N mice were administered OTNE (greater than 92.3% pure with respect to the 3 prominent isomers)

dermally for 3 months. Genetic toxicology studies were conducted in *Salmonella typhimurium*, *Escherichia coli*, and rat and mouse peripheral blood erythrocytes.

Groups of 10 male and 10 female core study rats and mice received no treatment (untreated control) or dermal application of OTNE in 95% aqueous ethanol at concentrations of 0% (vehicle control), 6.25%, 12.5%, 25%, 50%, or 100% (neat) 5 days per week for 3 months. Animals in the 100% OTNE groups were compared to untreated controls, and the remaining dosed groups were compared to the vehicle controls. Groups of 10 male and 10 female special study rats received the same doses for 22 days. Formulations were administered at a volume of 0.5 mL/kg body weight (rats) or 2.0 mL/kg body weight (mice), which resulted in mice receiving higher doses (mg/kg) of OTNE than rats. Dose ranges for rats and mice were estimated as 31.25 to 500 mg OTNE/kg body weight and 125 to 2,000 mg/kg, respectively. All rats and mice survived to the end of the study. Final mean body weights and body weight gains of dosed male and female rats were similar to those of the respective control groups with the exception of the 100% OTNE male rats, which had a statistically significant decrease in mean body weight gain compared to the untreated controls. The final mean body weights of 6.25%, 25%, and 50% OTNE male mice and mean body weight gains of 6.25% and 25% OTNE male mice were significantly less than those of the vehicle control group; those of 100% OTNE male mice were significantly less than those of the untreated controls. Body weights of female mice were unaffected by OTNE treatment. In rats, alanine aminotransferase activities were significantly decreased in all dosed groups of males and in 25% to 100% OTNE females; furthermore, alkaline phosphatase activities were significantly decreased in 100% OTNE males and females. Erythrocyte counts, hemoglobin concentrations, and hematocrit values were significantly decreased in male mice administered 25% OTNE or greater and in 100% OTNE female mice. OTNE exposure via dermal application exhibited the potential to be a reproductive toxicant in male and female B6C3F1/N mice.

In rats, relative liver weights of 50% OTNE males and the absolute and relative liver weights of 100% OTNE males and 50% and 100% OTNE females were significantly greater than those in the respective control groups. In male and female mice, the absolute and relative liver weights of all dosed groups were significantly greater than those of the respective control groups with the exception of the absolute liver weight in 6.25% OTNE males. In addition, the relative kidney weights of 100% OTNE male and female rats were significantly increased, and the absolute thymus weights of 100% OTNE male and female mice and relative thymus weight of 100% OTNE female mice were significantly decreased compared to their respective control groups. Histologically, the incidence of mild centrilobular hypertrophy was significantly increased in male mice treated with 100% OTNE compared to the untreated control group.

In male and female rats administered 12.5% to 50% OTNE, the incidences of minimal to mild hyperplasia and hyperkeratosis (except in 12.5% OTNE males) at the site of application were significantly greater than those in the vehicle control groups; the incidences of these lesions in 100% OTNE males and females were significantly greater than the untreated control incidences.

In the skin of mice at the site of application, the incidences of minimal to moderate hyperplasia and chronic active inflammation were significantly increased in all dosed groups. The incidences of minimal to mild hyperkeratosis were significantly increased in males administered 12.5% OTNE or greater and in all dosed groups of females. The incidences of fibrosis were significantly increased in all dosed groups of males except the 12.5% OTNE group, and in females administered 12.5% OTNE or greater. The incidences of epidermis suppurative inflammation were significantly increased in 100% OTNE males and in females administered 25% OTNE or greater. The incidences of hair follicle hyperplasia were significantly increased in males administered 50% or 100% OTNE and females administered 25% OTNE or greater. Furthermore, the incidences of minimal to mild nonneoplastic lesions noted in the skin adjacent to the site of application of male and female mice were considered secondary to the spread of the test material from the site of application rather than a systemic effect. Incidences of hyperplasia, chronic active inflammation, hyperkeratosis, and fibrosis in the skin adjacent to the site of application were significantly increased in 100% OTNE-treated male and female mice.

OTNE was not mutagenic in *Salmonella typhimurium* strains TA98, TA100, or TA102, or in *Escherichia coli* strain WP2 *uvrA*/pKM101, with or without exogenous metabolic activation. *In vivo*, increases in micronucleated reticulocytes and mature erythrocytes were observed in female B6C3F1/N mice and in mature erythrocytes in male B6C3F1/N mice following dermal application of OTNE for 3 months. In contrast, no increases in micronucleated reticulocytes were seen in male or female F344/NTac rats following dermal exposure to OTNE for 3 months. In rats, only the very young reticulocyte population is assessed in peripheral blood for micronucleus frequency due to rapid removal of damaged reticulocytes from circulation by the rat spleen.

Under the conditions of these 3-month dermal studies, the major target in F344/NTac rats and B6C3F1/N mice was the skin, site of application. Lesions were more prominent in mice than rats based upon the incidences and severities of hyperplasia, hyperkeratosis, and inflammation of the skin, site of application. Additionally, hepatic lesions were apparent in mice, but not rats. OTNE exhibited the potential to be a reproductive toxicant in male and female mice. These species differences could be attributed to dose, because mice received approximately four times the amount of OTNE on a mg/kg body weight basis than rats. In male and female rats, the lowest-observed-effect level (LOEL) of 12.5% OTNE was based on the increased incidences of skin lesions. In male and female mice, the LOEL was 6.25% OTNE, based on the increased incidences of skin lesions and increased relative liver weights.

**Findings Considered to be Toxicologically Relevant in Rats and Mice Dermally Exposed to OTNE for 3 Months**




	Male F344/NTac Rats	Female F344/NTac Rats	Male B6C3F1/N Mice	Female B6C3F1/N Mice
<b>Concentrations in 95% ethanol</b>	Untreated control, 0%, 6.25%, 12.5%, 25%, 50%, and 100% OTNE	Untreated control, 0%, 6.25%, 12.5%, 25%, 50%, and 100% OTNE	Untreated control, 0%, 6.25%, 12.5%, 25%, 50%, and 100% OTNE	Untreated control, 0%, 6.25%, 12.5%, 25%, 50%, and 100% OTNE
<b>Survival rates</b>	10/10, 10/10, 10/10, 10/10, 10/10, 10/10, 10/10	10/10, 10/10, 10/10, 10/10, 10/10, 10/10, 10/10	10/10, 10/10, 10/10, 10/10, 10/10, 10/10, 10/10	10/10, 10/10, 10/10, 10/10, 10/10, 10/10, 10/10
<b>Body weights</b>	Dosed groups similar to the respective control groups	Dosed groups similar to the respective control groups	↓ 8%, 9%, 7%, and 15% in the 6.25%, 25%, 50%, and 100% OTNE groups, respectively, compared to their control groups	Dosed groups similar to the respective control groups
<b>Clinical findings</b>	None	None	None	None
<b>Reproductive findings</b>	None	None	↓ Sperm counts, motility	↑ Cycle length, extended estrus
<b>Organ weights</b>	↑ Absolute and relative liver weights ↑ Relative kidney weight	↑ Absolute and relative liver weights ↑ Relative kidney weight	↑ Absolute and relative liver weights ↓ Absolute thymus weight	↑ Absolute and relative liver weights ↓ Absolute and relative thymus weights
<b>CYP2E1 enzyme activity</b>	None	None	None	None
<b>Clinical pathology</b>	↓ Alanine aminotransferase and alkaline phosphatase activities	↓ Alanine aminotransferase and alkaline phosphatase activities	↓ Erythrocyte count, hemoglobin concentration, and hematocrit	↓ Erythrocyte count, hemoglobin concentration, and hematocrit

**Findings Considered to be Toxicologically Relevant in Rats and Mice Dermally Exposed to OTNE for 3 months**

	Male F344/NTac Rats	Female F344/NTac Rats	Male B6C3F1/N Mice	Female B6C3F1/N Mice
<b>Nonneoplastic effects</b>	<u>Skin (site of application):</u> hyperkeratosis (0/10, 0/10, 1/10, 3/10, 4/10, 5/10, 8/10); hyperplasia (0/10, 0/10, 2/10, 4/10, 5/10, 8/10, 10/10)	<u>Skin (site of application):</u> hyperkeratosis (0/10, 0/10, 0/10, 4/10, 5/10, 7/10, 7/10); hyperplasia (0/10, 0/10, 1/10, 5/10, 7/10, 7/10, 8/10)	<u>Liver:</u> centrilobular hypertrophy (0/10, 1/10, 0/10, 2/10, 3/9, 0/10, 4/10) <u>Skin (site of application):</u> hyperplasia (0/10, 0/10, 9/10, 10/10, 9/10, 9/9, 10/10); chronic active inflammation (0/10, 0/10, 7/10, 10/10, 9/10, 9/9, 10/10); hyperkeratosis (0/10, 0/10, 2/10, 5/10, 5/10, 8/9, 10/10); fibrosis (0/10, 0/10, 4/10, 3/10, 8/10, 8/9, 10/10); epidermis, suppurative inflammation (0/10, 0/10, 0/10, 0/10, 1/10, 1/9, 5/10); hair follicle hyperplasia (0/10, 0/10, 3/10, 2/10, 3/10, 7/9, 8/10) <u>Skin (adjacent to the site of application):</u> hyperplasia (0/10, 0/10, 0/10, 2/10, 4/9, 3/10, 8/10); hyperkeratosis (0/10, 0/10, 0/10, 0/10, 0/9, 2/10, 5/10); fibrosis (0/10, 0/10, 0/10, 0/10, 1/9, 2/10, 5/10); chronic active inflammation (0/10, 0/10, 0/10, 2/10, 4/9, 2/10, 8/10); epidermis, suppurative inflammation (0/10, 0/10, 0/10, 0/10, 0/9, 1/10, 4/10); hair follicle hyperplasia (0/10, 0/10, 0/10, 1/10, 0/9, 1/10, 5/10)	<u>Skin (site of application):</u> hyperplasia (0/10, 0/10, 10/10, 10/10, 10/10, 6/6, 10/10); chronic active inflammation (0/10, 0/10, 10/10, 10/10, 10/10, 6/6, 10/10); hyperkeratosis (0/10, 0/10, 5/10, 5/10, 10/10, 6/6, 10/10); fibrosis (0/10, 0/10, 2/10, 10/10, 10/10, 4/6, 9/10); epidermis, suppurative inflammation (0/10, 0/10, 0/10, 1/10, 4/10, 4/6, 7/10); hair follicle hyperplasia (0/10, 0/10, 3/10, 0/10, 4/10, 3/6, 10/10) <u>Skin (adjacent to the site of application):</u> hyperplasia (0/10, 0/10, 4/10, 3/10, 2/10, 3/8, 10/10); hyperkeratosis (0/10, 0/10, 0/10, 1/10, 0/10, 0/8, 7/10); fibrosis (0/10, 0/10, 0/10, 3/10, 0/10, 0/8, 6/10); chronic active inflammation (0/10, 0/10, 4/10, 4/10, 2/10, 3/8, 8/10); epidermis suppurative inflammation (0/10, 0/10, 0/10, 0/10, 0/10, 0/10, 0/8, 8/10); hair follicle hyperplasia (0/10, 0/10, 0/10, 0/10, 1/10, 0/8, 3/10)
<b>Genetic toxicology</b>				
Bacterial gene mutations:			Not mutagenic in <i>Salmonella typhimurium</i> strains TA98, TA100, or TA102 or in <i>Escherichia coli</i> strain WP2 <i>uvrA</i> pKM101, with or without exogenous metabolic activation	
Micronucleated erythrocytes				
Rat peripheral blood <i>in vivo</i> :		Negative		
Mouse peripheral blood <i>in vivo</i> :		Equivocal in males; positive in females		



## INTRODUCTION



### OCTAHYDRO-TETRAMETHYL-NAPHTHALENYL-ETHANONE (OTNE)

CAS Nos. 54464-57-2 ( $\beta$ -isomer), 68155-67-9 ( $\alpha$ -isomer), 68155-66-8 ( $\gamma$ -isomer)

Chemical Formula:  $C_{16}H_{26}O$  Molecular Weight: 234.38

**Synonyms:** 1',2',3',4',5',6',7',8'-Octahydro-2',3',8',8'-tetramethyl-2'-acetonaphthone; 1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-acetonaphthone; 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)ethanone; 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one; 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one; 1-(1,2,3,4,5,6,7,8-octahydro-2,3,5,5-tetramethyl-2-naphthyl)ethan-1-one

**Trade Names:** Amberonne, Ambralux, Boisvelone, Iso Ambois Super, Iso E Super<sup>®</sup>, Isocyclemone, Isocyclemone E, Orbitone

Octahydro-tetramethyl-naphthalenyl-ethanone (OTNE) is a fragrance ingredient with an unsaturated alkyl cyclic ketone structure that is formed as a mixture of isomers (Belsito *et al.*, 2013). The main isomer is identified as 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)ethanone and is referred to as the  $\beta$ -isomer (Politano *et al.*, 2009). Two other predominant isomers within the mixture are 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)ethanone ( $\alpha$ -isomer) and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)ethanone ( $\gamma$ -isomer). A typical composition of the mixture consists of 30% to 65% by weight of the  $\beta$ -isomer (CAS No. 54464-57-2), 10% to 26%  $\alpha$ -isomer (CAS No. 68155-67-9), and 8% to 20%  $\gamma$ -isomer

(CAS No. 68155-66-8). Minor OTNE isomers also have been identified in mixtures (Wishneff, 2012). OTNE is commonly referred to by the commercial name Iso E Super<sup>®</sup>, which is the most prevalent name encountered in the literature.

## CHEMICAL AND PHYSICAL PROPERTIES

The OTNE mixture is in liquid form with a pale yellow color and an amber or woody odor. Some of the measured or calculated properties of the three primary isomers are listed in Table 1.

**TABLE 1**  
**Physical Properties of Primary OTNE Isomers**

	<b>β-Isomer</b>	<b>α-Isomer</b>	<b>γ-Isomer</b>
Boiling Point (°C)	110-117 @ 1.0-1.5 Torr 124-135 @ 2.1-2.9 Torr 312.2 ± 31.0 @ 760 Torr <sup>a</sup>	311.4 ± 31.0 @ 760 Torr <sup>a</sup>	311.4 ± 31.0 @ 760 Torr <sup>a</sup>
Vapor Pressure (Torr)	5.38 × 10 <sup>-4a</sup>	5.65 × 10 <sup>-4a</sup>	5.65 × 10 <sup>-4a</sup>
Specific Gravity	0.96-0.97 @ 20° C <sup>b</sup>	Not located	Not located
Water Solubility	1.077 mg/L @ 25° C <sup>b</sup>	2.725 mg/L @ 25° C <sup>c</sup>	2.725 mg/L @ 25° C <sup>c</sup>
Bioconcentration Factor	3,720.25 @ pH 1-10, 25° C <sup>a</sup>	4,449.43 @ pH 1-10, 25° C <sup>a</sup>	4,613.20 @ pH 1-10, 25° C <sup>a</sup>

<sup>a</sup> Calculated properties using Advanced Chemistry Development (ACD/Labs) Software V11.02 (©1994-2013 ACD/Labs)

<sup>b</sup> Scognamiglio *et al.*, 2013

<sup>c</sup> Belsito *et al.*, 2013

## PRODUCTION, USE, AND HUMAN EXPOSURE

OTNE is produced commercially by Diels-Alder condensation of β-myrcene with 3-methyl-3-pentene-2-one in the presence of aluminum chloride to give a monocyclic intermediate that is cyclized in the presence of 85% phosphoric acid (Fahlbusch *et al.*, 2003). OTNE is manufactured in a semicontinuous process with minimal potential for occupational exposure. The annual volumes of OTNE produced in North America for 2000, 2004, 2008, and 2011 were 700, 1,300, 2,100, and 2,800 tons/year, respectively (Wishneff, 2012). The total reported production volume for each of the predominant OTNE isomers (α, β, and γ) as reported in the nonconfidential 2006 Inventory Update Rule (IUR), range from 1,000,000 to less than 10,000,000 pounds per year. In 2012, the production volume of the β-isomer was 1,000,000 to 10,000,000 pounds per year in the Chemical Data Reporting database (USEPA, 2010a,b,c).

A search found more than 30 products containing OTNE for use as a perfume ingredient in soap, shampoo, cologne, liquid detergent compounds, and malodor-reducing compounds, such as fabric freshening compounds, antiperspirants or deodorants, and air freshening compounds. Typical OTNE concentrations are less than 1% in household products, and fine fragrance ingredients may contain up to 20% OTNE (Wishneff, 2012; Scognamiglio *et al.*, 2013).



For the general population, exposure to OTNE is via inhalation and the skin through the use of products (e.g., fragrances and perfumed personal care products) containing the ingredient. Additional exposures may result from ingestion of water or food containing the ingredient as a contaminant. In one human study, OTNE was detected in 34% of breast milk samples (37/110 samples) above the method detection limit, but the levels were below the method quantification limit of 1.5 ng/g lipid (Yin *et al.*, 2012). Human dermal systemic exposure to OTNE ( $\beta$ -isomer) was calculated to be 0.4604 mg/kg per day based upon the concentrations in 10 personal care and cosmetic products, the amount of the product applied, the number of applications per day of each product, and the length of time the product was present on the skin (Scognamiglio *et al.*, 2013).

Detection of OTNE in the environment (e.g., sludge, wastewater, river water, and house dust samples) provides documentation for its use as well as exposure scenarios to humans and aquatic life. OTNE was detected in the majority of house dust samples obtained from Canadian homes. OTNE was detected in 82% of the samples collected from the vacuum systems used by the participants, and concentrations ranged from not detected to 5,620 ng/g with a median concentration of 212 ng/g. In fresh house dust samples, the detection frequency was 94%. The concentration range and median concentrations extended from not detected to 125,000 ng/g and 252 ng/g, respectively (Kubwabo *et al.*, 2012; Note: the study references the trade name Iso E Super<sup>®</sup> and the  $\beta$ -isomer CASRN). OTNE was also detected in municipal wastewater and in effluents from water treatment facilities within the United States and Germany (Bester *et al.*, 2008; Klaschka *et al.*, 2013). In United States facilities with activated sludge or trickling filter wastewater treatment, OTNE influent concentrations were 3.470 and 3.250  $\mu$ g/L, respectively, and final effluent concentrations were 0.110 and 0.334  $\mu$ g/L, respectively. Thus, a 96.8% removal rate was achieved via activated sludge wastewater treatment versus 89.7% removal following trickling filter wastewater treatment (Simonich *et al.*, 2000; Note: studies reference, either through CASRN or structure, the  $\beta$ -isomer). Furthermore, studies have indicated that OTNE is degraded in environmental samples. In a river water test, degradation half-lives of 5 days or less were reported. In soil core and leachate samples, OTNE levels decreased by 60% after 3 months and were not detected within 1 year. The maximum measured bioaccumulation factor was noted to be 850 in bluegill fish. Evaluated metabolites of OTNE were more polar than the parent, suggesting that they were not likely to accumulate (Wishneff, 2012).

## REGULATORY STATUS

In the United States, OTNE is listed in the Toxic Substances Control Act (TSCA) Inventory under the 9CI name ethanone, 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl); this is specific to the  $\beta$ -isomer. In 2012, the USEPA added four of the OTNE isomers (CASRNs: 54464-57-2; 54464-59-2; 68155-66-8; 68155-67-9) to the TSCA Work Plan for Chemical Assessments (USEPA, 2012). As of 2014, the isomers are still listed in the TSCA Work Plan Update for their evaluation regarding environmental persistence and occurrence (USEPA, 2014).

## ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION, AND TOXICOKINETICS

### Experimental Animals

There are limited data on the absorption, distribution, metabolism, excretion, and toxicokinetics of OTNE in experimental animals, although OTNE disposition can be inferred from data summaries submitted to the Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH) Dossiers available in the European Chemicals Agency (ECHA) database as well as in a published summary of industry studies (Scognamiglio *et al.*, 2013). In one such report, maternal transfer was assessed in pregnant Sprague Dawley rats by gavage administration of 2 or 20 mg [ $^{14}\text{C}$ ]OTNE/kg body weight in corn oil from gestation day 14 to postnatal day 7 (ECHA, 2013a). Milk and blood samples were collected from dams on postnatal days 3 and 7 at 4, 8, and 24 hours following dose administration. Total radioactivity levels in plasma and milk decreased with time, and unmetabolized OTNE was not detected in the milk. Low levels of radioactivity were detected by whole-body radiography in the placenta and fetus following exposure of pregnant Sprague Dawley rats from gestation days 14 to 19 to 2 mg [ $^{14}\text{C}$ ]OTNE/kg body weight, suggesting minimal maternal transfer of OTNE. Radioactivity also was present in the small intestine contents, preputial gland, stomach, liver, large intestine contents, thyroid gland, and bladder of the dams.

The disposition of OTNE in male F344 rats after gavage or dermal exposure was studied by the NTP using [ $^{14}\text{C}$ ]OTNE ( $\beta$ -isomer) (Waidyanatha and Ryan, 2014).  $\beta$ -OTNE was well absorbed following gavage administration of 20 mg/kg, and the majority of the administered dose was excreted in urine (28%) and feces (39%) by 48 hours. Approximately 73% of the 20 mg/kg dose was eliminated in bile in 48 hours confirming that the fecal excretion was not due to poor absorption but biliary excretion. Additionally, approximately 80% of the dose in the bile was excreted within the first 4 hours, while the fecal excretion continued through 48 hours suggesting enterohepatic recirculation of OTNE. Radioactivity in tissues reached maximal levels between 4 and 8 hours, and the highest levels of radioactivity were found in the liver, kidney, pancreas, and adipose. The estimated elimination half-lives, based on the total radioactivity, were greater than or equal to 20 hours in blood and most tissues examined. Profiling of urine showed the presence of at least nine metabolites, although the identities of the metabolites were not determined.

Disposition was also examined by the NTP in male F344 rats following a single dermal application of 55 or 550 mg/kg [ $^{14}\text{C}$ ] $\beta$ -OTNE in ethanol to covered and uncovered dose sites after 24, 48, or 96 hours (Waidyanatha and Ryan, 2014). For comparison with the 3-month dermal studies in rats, the corresponding formulation concentrations were 0.55% and 5.5% OTNE. There was a general trend that the percent dose absorbed increased and the percent dose at dose-site skin decreased with time in both covered and uncovered groups. When the dose site was covered, approximately 14% of the applied dose was absorbed by 96 hours in both 55 and 550 mg/kg groups. When the dose site was uncovered, the total dose absorbed 96 hours postdosing was 33% and 72%, for 55 and 550 mg/kg, respectively, suggesting significant absorption due to oral grooming. Similar to gavage administration, the primary routes of excretion were through feces (4.0% to 12.3%) and urine (5.1% to 13.7%) at 96 hours in covered and uncovered animals, respectively. The highest levels of radioactivity were found in the liver, kidney, adipose, and pancreas. Blood elimination half-lives estimated for 55 and 550 mg/kg uncovered dose groups were 70 and 40 hours, respectively; half-lives for covered

dose groups were not reported due to the lack of sufficient data points to define the blood concentration versus time profiles.

## Humans

Human summary data regarding the absorption of OTNE have been submitted to REACH and are available in the ECHA database. In this *in vitro* absorption study, 1% [<sup>14</sup>C]OTNE (w/v) in ethanol was applied to human epidermis (ECHA, 2013b). Permeation was measured from 2 through 48 hours, and results indicated that approximately 29% of the applied dose was absorbed. The rate of permeation was linear with no plateau noted.

## TOXICITY

### Experimental Animals

The reported oral and dermal acute toxicity values (LD<sub>50</sub>) were greater than 5,000 mg/kg in male and female TacN(SD)fBR and Sprague Dawley rats (ECHA, 2013c,d; Scognamiglio *et al.*, 2013).

In a 28-day subchronic study in male and female Sprague Dawley rats, OTNE was administered orally at 50, 150, or 1,000 mg/kg in corn oil. A subset of animals was kept in housing an additional 14 days to assess recovery. The study summary, available in the ECHA database and summarized by Scognamiglio *et al.* (2013), indicated that no treatment-related deaths occurred, but poor grooming, decreased body weights, and increased water consumption were observed during treatment in the high dose males and females. All effects were reversed during the 14-day recovery period. Treatment-related effects were reported in high dose animals (e.g., increased cholesterol levels in males and females as well as decreased glutamic pyruvic transaminase levels in males). Increased liver weights and centrilobular hepatocyte enlargement were observed in high dose males and females. Eosinophilic inclusions in the cortical tubules were noted in mid- and high-dose males; some recovery was observed in high dose males. The report summary concluded that the no-observed-adverse-effect level (NOAEL) and no-observed-effect level (NOEL) for OTNE when administered orally for at least 4 weeks are 1,000 and 15 mg/kg body weight per day, respectively (ECHA, 2013e; Scognamiglio *et al.*, 2013).

Contact sensitization and irritancy following dermal exposure to OTNE in an acetone:olive oil (4:1) vehicle was evaluated in female BALB/c mice by the NTP (2010). To reduce the number of animals needed for the studies, the local lymph node assay (LLNA) and irritancy assay were combined. All mice treated with OTNE (0.5%, 1%, 2.5%, 5%, 25%, or 50% applied to the dorsum of the ear) demonstrated significant irritation at the site of application, as measured by swelling of the ear pinna 24 hours after the last exposure. In the LLNA, significant increases in lymph node cell proliferation were observed in the 25% and 50% groups only (172% and 467%, respectively, as compared to vehicle controls). The maximum stimulation index (SI) for these studies was 5.68 in the 50% OTNE group. The SI is the ratio of lymph node cell proliferation in the OTNE test group to that of the matched vehicle control group. A substance is considered a dermal sensitizer if at least one concentration of the test article results in a mean SI of 3

or more, although statistically significant changes in disintegrations per minute below the SI=3 threshold are also considered. To further investigate the sensitization potential of OTNE, the Mouse Ear Swelling Test was performed. In the sensitization phase, three concentrations of OTNE (0.5%, 5%, and 50%) were used, and 50% OTNE was applied during the challenge phase. OTNE did not significantly increase mouse ear thickness at either 24 or 48 hours postchallenge at any of the concentrations evaluated. These results suggest that, under the experimental conditions utilized in this study in female BALB/c mice, the positive response in the LLNA was likely due to the irritant effects of OTNE.

OTNE-induced skin hypersensitivity was examined in multiple LLNA studies with female CBA/J mice. The results are reported by the European Chemicals Agency and classify OTNE as a skin sensitizer following application of 2.5%, 5%, 10%, 25%, or 50% OTNE (v/v) in 3:1 diethyl phthalate:ethanol (ECHA 2013f,g,h). The SI values for these studies ranged from 11.3 to 34.2 when 50% OTNE was applied. The full study reports for these investigations were not available (Robust Summary Data from REACH Dossiers in the ECHA database) so it is not clear whether the doses used in these LLNA studies were nonirritating or whether the differences in the results were due to the animal strains or vehicles used.

## Humans

The majority of OTNE-related toxicity studies in humans have been to examine whether its dermal application can cause skin irritation or sensitization. When OTNE was applied in a patch test, two cases (out of 1,069 patients) of an allergic reaction were observed on day 3 or 4 of application (Frosch *et al.*, 1995). More recently, 0.2% of tested individuals (1,855 patients) were identified as sensitive to OTNE (Frosch *et al.*, 2002; Note: the study references the trade name Iso E Super® and CASRN 54464-57-2). In another evaluation, OTNE sensitization was reported in 1.7% of fragrance-sensitive individuals (178 volunteer patients) subjected to a patch test (Larsen *et al.*, 2001).

The European Chemicals Agency has reported the results of several human patch test studies, which are also summarized by Scognamiglio *et al.* (2013) and Belsito *et al.* (2013). In one study, OTNE irritation potential was examined with 20%, 40%, 60%, or 75% test article applied two times over a 96-hour period in 23 subjects (ECHA, 2013i). At 20% OTNE, minimal erythema was reported in select individuals, however, dermal irritation was negligible in 40% to 75% OTNE-treated subjects. In a different repeated patch test study conducted on 101 individuals, the potential for OTNE to induce contact sensitization was examined (ECHA, 2013j). OTNE was applied via an occluded patch, and applications were repeated three times per week for 3 weeks. Ten to 17 days after the last application, a challenge patch was applied and the response was evaluated 24, 48, and 72 hours later. Slight to mild transient erythema was observed in 17 individuals during the 3-week induction phase. During the challenge phase, four individuals experienced slight or mild erythema at the later time points.

*In vitro* studies using reconstructed human epidermis classified OTNE as an irritant to the skin (ECHA, 2013k).

## REPRODUCTIVE AND DEVELOPMENTAL TOXICITY

### Experimental Animals

There are no data on the reproductive toxicity of OTNE in the literature and limited data on developmental toxicity of OTNE in experimental animals (Politano *et al.*, 2009; ECHA, 2013l). In a preliminary study, pregnant Sprague Dawley rats were orally gavaged with 240, 480, 960, or 1,920 mg/kg OTNE (neat material) or water (control) from gestation days 7 to 17. Rats were euthanized on gestation day 21, and one rat was euthanized moribund on gestation day 16. Clinical signs in all treated animals included chromorhinorrhea, excessive salivation, and the presence of a red perioral substance. Urine stained abdominal fur was noted in the two highest dose groups, and amber colored urine was observed in the highest dose group. No statistically significant effects were noted in litter parameters.

Following the preliminary study, pregnant Sprague Dawley rats were orally gavaged with 96, 240, or 480 mg/kg body weight per day from gestation days 7 to 17 (Politano *et al.*, 2009). Rats were euthanized on gestation day 21. No treatment-related deaths were reported. Clinical signs attributed to treatment included increased salivation at all doses and an increased incidence of urine-stained abdominal fur in high dose animals. Body weight gain was lower at all dose levels from gestation days 7 to 10. Additionally, high dose dams exhibited lower body weight gain from gestation days 11 to 21. Feed consumption was lower in all dosed groups. No treatment-related effects were observed on uterine parameters (e.g., implantations); gross external, soft tissue, or skeletal malformations; or number of ossification sites/fetus per litter. The maternal and developmental NOAEL was reported as 240 mg/kg per day.

### Humans

No studies were found in the literature on the reproductive or developmental toxicity of OTNE in humans.

## CARCINOGENICITY

No carcinogenicity studies of OTNE in experimental animals or epidemiology studies in humans have been reported in the literature.

## GENETIC TOXICITY

No studies were found in the open literature on the genotoxicity of OTNE. However, little genotoxic potential for OTNE can be inferred from data submitted to REACH and available in the ECHA database. In these industry-sponsored studies, OTNE (dissolved in DMSO) was reported to be negative in bacterial mutagenicity tests that employed *Salmonella typhimurium* strains TA98, TA100, TA1535, TA1537, or TA1538 or *Escherichia coli* strain WP2 *uvrA*. OTNE concentrations ranged from 312.5 to 5,000 µg/plate, with or without induced rat liver S9 activation enzymes (ECHA, 2013m), and no cytotoxicity was reported at any of the tested concentrations. In mammalian cells, no mutagenicity was observed in mouse lymphoma L5178Y *tk*<sup>+/-</sup> cells treated with OTNE (dissolved in ethanol) at

concentrations up to 90 µg/mL in the presence of S9 and at concentrations up to 40 µg/mL without S9 (ECHA, 2013n). The effect of OTNE (dissolved in DMSO) on chromosomal aberrations was assessed in human lymphocytes with standard and extended incubation times (ECHA, 2013o). OTNE was considered to be negative for inducing chromosomal aberrations when tested at concentrations up to 125 µg/mL in the presence of S9 and at concentrations up to 50 µg/mL without S9 (ECHA, 2013n). Although these test results are freely available in the ECHA database and are summarized in Scognamiglio *et al.* (2013), lack of access to the original studies precludes independent assessment of the data or the protocols under which they were generated.

## STUDY RATIONALE

The fragrance ingredient OTNE was nominated by a private individual for toxicology testing based on its widespread use as a constituent of a fragrance mixture and the lack of toxicity data via a relevant route of exposure. In response, the NTP conducted 3-month toxicity studies of OTNE administered by dermal application to male and female F344/NTac rats and B6C3F1/N mice.

## MATERIALS AND METHODS

### PROCUREMENT AND CHARACTERIZATION

#### OTNE

OTNE (octahydro-tetramethyl-naphthalenyl-ethanone) was obtained as Iso-E Super<sup>®</sup> from International Flavors and Fragrances, Inc. (Ringwood, NJ), in one lot (RAV0276433) that was used in the 3-month dermal studies. Identity and purity analyses were conducted by the analytical chemistry laboratory at Research Triangle Institute (Research Triangle Park, NC), and purity analyses were conducted by the study laboratory at BioReliance Corporation (Rockville, MD) (Appendix F). Reports on analyses performed in support of the OTNE studies are on file at the National Institute of Environmental Health Sciences.

The chemical, a colorless to pale-yellow liquid, was identified as OTNE using infrared and proton nuclear magnetic resonance spectrometry and gas chromatography (GC) with mass spectrometry (MS) detection. All spectra were consistent with the structure of OTNE isomers. The purity of the test chemical was determined using GC with flame ionization detection (FID) and GC/MS. GC/FID analysis indicated four major peaks and nine minor peaks; each of the minor peaks was less than 1% of the total peak area. GC/MS analysis indicated mass spectra for the major peaks that were very similar, showing the same fragments with slight variations in relative abundance: These were tentatively identified as  $\beta$ -isomer,  $\alpha$ -isomer,  $\gamma$ -isomer, and 1-(1,2,3,4,5,6,7,8-octahydro-2,3,5,5-tetramethyl-2-naphthalenyl)-ethanone based on the spectra and comparison to the literature (Erman *et al.*, 2001). The overall purity of lot RAV0276433 was estimated to be greater than 96% relative to the four OTNE isomers:  $\beta$ -isomer (56.6%),  $\alpha$ -isomer (18.0%),  $\gamma$ -isomer (17.7%), and 1-(1,2,3,4,5,6,7,8-octahydro-2,3,5,5-tetramethyl-2-naphthalenyl)-ethanone (3.9%). To ensure stability, the test chemical was stored in sealed amber glass vials at room temperature under a desiccant. Reanalysis of the test chemical was performed at the end of the study by the study laboratory using GC/FID; no degradation of the test chemical was detected.

#### Ethanol

USP-grade 95% ethanol was obtained from Pharmco Products, Inc. (Brookfield, CT), in one lot (M0000) that was used as the vehicle in the 3-month dermal studies.

### PREPARATION AND ANALYSIS OF DOSE FORMULATIONS

Except for the 100% dose formulations, which were used neat, the dose formulations were prepared by mixing OTNE with 95% ethanol to give the required concentrations and stirring with a magnetic stir bar for at least 15 minutes. The dose formulations were stored in a flammable chemical storage cabinet in amber glass bottles sealed with Teflon<sup>®</sup>

silicone septa and an aluminum crimp seal under a nitrogen headspace at room temperature (~25° C). The dose formulations were prepared three times during the 3-month studies and analyzed for percent of target concentration (Table F2). All 30 dose formulations analyzed for rats and mice were within 10% of the target concentrations. Animal room samples of these dose formulations were also analyzed; 28 of 30 for rats and 26 of 30 for mice were within 10% of the target concentrations.

## **ANIMAL SOURCE**

Male and female F344/NTac rats were obtained from the commercial colony at Taconic Farms, Inc. (Germantown, NY), and B6C3F1/N mice were obtained from the NTP colony at Taconic Farms, Inc. The rationale for change of rat strain from F344/N to F344/NTac was a programmatic decision. For many years, the NTP used the inbred F344/N rat for its toxicity and carcinogenicity studies. Over a period of time, the F344/N rat exhibited sporadic seizures, idiopathic chylothorax, and consistently high rates of mononuclear cell leukemia and testicular neoplasia. Because of these issues in the F344/N rat and the NTP's desire to find a more fecund rat model that could be used in both reproductive and carcinogenesis studies for comparative purposes, a change in the rat model was explored. Following a workshop in 2005, the F344 rat from the Taconic commercial colony (F344/NTac) was used for a few NTP studies to allow the NTP to evaluate different rat models (King-Herbert and Thayer, 2006). The F344/NTac rat was used in four subchronic and two chronic studies between 2005 and 2006.

## **ANIMAL WELFARE**

Animal care and use are in accordance with the Public Health Service policy on Humane Care and Use of Animals. All animal studies were conducted in an animal facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International. Studies were approved by the BioReliance Corporation Animal Care and Use Committee and conducted in accordance with all relevant NIH and NTP animal care and use policies and applicable federal, state, and local regulations and guidelines.

## **3-MONTH STUDIES**

On receipt, rats were 3 to 4 weeks old and mice were 4 to 5 weeks old. Animals were quarantined for 12 or 13 days (rats) or 14 or 15 days (mice); rats were 5 to 6 weeks old and mice were 6 to 7 weeks old on the first day of the studies. Before the studies began, five male and five female rats and mice were randomly selected for parasite evaluation and gross observation for evidence of disease. The health of the animals was monitored during the studies according to the protocols of the NTP Sentinel Animal Program (Appendix H). All test results were negative.



Groups of 10 male and 10 female rats and mice received no treatment (untreated control) or dermal application of OTNE in 95% aqueous ethanol at concentrations of 0% (vehicle control), 6.25%, 12.5%, 25%, 50%, or 100% (neat) 5 days per week for 3 months (13 weeks). Groups of 10 male and 10 female special study rats received the same doses for 22 days. The study design included a second control group (untreated control) to allow for the appropriate comparison of the high dose group (100% OTNE) to a control group without aqueous ethanol. Formulations were administered at a volume of 0.5 mL/kg body weight (rats) or 2.0 mL/kg (mice). Thus, applied concentrations corresponded to 31.25 to 500 mg OTNE/kg body weight in rats and 125 to 2,000 mg/kg in mice. Doses were applied using a repeating pipette with a disposable tip to a consistent area that was shaved weekly. The shaved area was on the dorsal surface just posterior to the scapulae to the base of the tail and larger than the application site. The untreated control rats and mice were shaved similarly but received no liquid application, much like a sham control. Feed and water were available *ad libitum*. Rats and mice were housed individually. All animals were weighed, and clinical findings were recorded initially, weekly, and at the end of the studies. Details of the study design and animal maintenance are summarized in Table 2. Information on feed composition and contaminants is provided in Appendix G.

On days 3 and 23, blood was collected from the retroorbital plexus of special study rats for hematology and clinical chemistry analyses only (no additional evaluations in mice). Blood was collected from the retroorbital plexus and sinus of core study rats and mice, respectively, at the end of the 3-month studies for hematology and clinical chemistry (rats) analyses. Blood for hematology analyses was placed in tubes containing EDTA as the anticoagulant. Hematology parameters were determined using an ABX Pentra 60 C+ analyzer (HORIBA Instruments, Inc., Irvine, CA). For clinical chemistry analyses, blood samples were placed in serum separator tubes and centrifuged, and the serum was analyzed using a Hitachi 717 chemistry analyzer (Boehringer Mannheim, Indianapolis, IN) and commercially available reagents. The parameters measured are listed in Table 2.

The vehicle, ethanol, is metabolized by cytochrome P4502E1 (CYP2E1) to form reactive products that are associated with hepatic injury (Cedarbaum, 2011). In order to distinguish potential OTNE-related effects on the liver from ethanol-induced liver changes, CYP2E1 activity was also measured in control and dosed groups. At the scheduled euthanasia of special study rats on day 23, consistent portions of the median and left lateral liver lobes not scheduled for histologic evaluation were excised from the first five male and female rats per dose group encountered during the random order for bleeds. Comparable sections of the livers were excised from the first five male and female core study rats scheduled for necropsy at the end of the study. For mice, the entire portion of the liver not used for histologic evaluation was excised from the first five male and female mice per dose group necropsied at the end of the study. The liver portions were immediately flash frozen at  $-60^{\circ}\text{C}$  or less. The rat and mouse liver samples were shipped on dry ice to In Vitro Technologies (IVT, Baltimore, MD). Upon arrival, liver samples were stored at  $-70^{\circ} \pm 10^{\circ}\text{C}$  until processed into microsomes. IVT prepared microsomes from the livers by differential centrifugation and analyzed the liver samples for total protein by the bicinchoninic acid (BCA) method using the BCA Protein Assay Kit (Pierce Chemical Co., Rockford, IL). CYP2E1 activity was measured by monitoring lauric acid 11-hydroxylase

activity. Microsomes were incubated with [ $^{14}\text{C}$ ]lauric acid and a NADPH-regenerating system, and the rate of formation of 11-hydroxylauric acid was analyzed using a radiometric high performance liquid chromatography (HPLC) method. Two replicates of each liver sample were analyzed for all dosed and control groups.

At the end of the 3-month studies, samples were collected for sperm motility and vaginal cytology evaluations on core study rats and mice in the untreated control, vehicle control, 25%, 50%, and 100% OTNE groups. The parameters evaluated are listed in Table 2. For 16 consecutive days prior to scheduled terminal euthanasia, the vaginal vaults of the females were moistened with saline, if necessary, and samples of vaginal fluid and cells were stained. Relative numbers of leukocytes, nucleated epithelial cells, and large squamous epithelial cells were determined and used to ascertain estrous cycle stage (i.e., diestrus, proestrus, estrus, and metestrus). Male animals were evaluated for sperm count and motility. The left testis and left epididymis were isolated and weighed. The tail of the epididymis (cauda epididymis) was then removed from the epididymal body (corpus epididymis) and weighed. Test yolk (rats) or modified Tyrode's buffer (mice) was applied to slides and a small incision was made at the distal border of the cauda epididymis. The sperm effluxing from the incision were dispersed in the buffer on the slides, and the numbers of motile and nonmotile spermatozoa were counted for five fields per slide by two observers. Following completion of sperm motility estimates, each left cauda epididymis was placed in buffered saline solution. Caudae were finely minced, and the tissue was incubated in the saline solution and then heat fixed at 65° C. Sperm density was then determined microscopically with the aid of a hemacytometer. To quantify spermatogenesis, the testicular spermatid head count was determined by removing the tunica albuginea and homogenizing the left testis in phosphate-buffered saline containing 10% dimethyl sulfoxide. Homogenization-resistant spermatid nuclei were counted with a hemacytometer.

Necropsies were performed on all core study rats and mice. The heart, right kidney, liver, lung, right testis, and thymus were weighed. Tissues for microscopic examination were fixed and preserved in 10% neutral buffered formalin (eyes were first fixed in Davidson's solution), processed and trimmed, embedded in paraffin, sectioned to a thickness of 4 to 6  $\mu\text{m}$ , and stained with hematoxylin and eosin. Complete histopathologic examinations were performed by the study laboratory pathologist on rats and mice in the untreated control, vehicle control, and 100% OTNE groups. The skin at the site of application, skin adjacent to the site of application, and control skin were examined in all groups of rats and mice, and the liver was examined in all groups of rats and mice. Table 2 lists the tissues and organs routinely examined.

After a review of the laboratory reports and selected histopathology slides by a quality assessment (QA) pathologist, the findings and reviewed slides were submitted to a NTP Pathology Working Group (PWG) coordinator for a second independent review. Any inconsistencies in the diagnoses made by the study laboratory and QA pathologists were resolved by the NTP pathology peer review process. Final diagnoses for reviewed lesions represent a consensus of the PWG or a consensus between the study laboratory pathologist, NTP pathologist, QA pathologist(s), and the PWG

coordinator. Details of these review procedures have been described, in part, by Maronpot and Boorman (1982) and Boorman *et al.* (1985).

**TABLE 2**  
**Experimental Design and Materials and Methods in the 3-Month Dermal Studies of OTNE**

---

**Study Laboratory**

BioReliance Corporation (Rockville, MD)

**Strain and Species**

F344/NTac rats

B6C3F1/N mice

**Animal Source**

Taconic Farms, Inc. (Germantown, NY)

**Time Held Before Studies**

Rats: 12 (males) or 13 (females) days

Mice: 14 (males) or 15 (females) days

**Average Age When Studies Began**

Rats: 5 to 6 weeks

Mice: 6 to 7 weeks

**Date of First Dose**

Rats: December 12 (males) or December 13 (females), 2006

Mice: December 14 (males) or December 15 (females), 2006

**Duration of Dosing**

3 months (13 weeks)

**Date of Last Dose**

Rats: March 12 (males) or March 13 (females), 2007

Mice: March 14 (males) or March 15 (females), 2007

**Necropsy Dates**

Rats: March 13 (males) or March 14 (females), 2007

Mice: March 15 (males) or March 16 (females), 2007

**Average Age at Necropsy**

Rats: 18 or 19 weeks

Mice: 19 or 20 weeks

**Size of Study Groups**

10 males and 10 females

**Method of Distribution**

Animals were distributed randomly into groups of approximately equal initial mean body weights.

**Animals per Cage**

1

**Method of Animal Identification**

Tail tattoo

**Diet**

Irradiated NTP-2000 pelleted diet (Zeigler Brothers, Inc., Gardners, PA), available *ad libitum*, changed weekly

**Water**

Tap water (Washington Suburban Sanitary Commission, Potomac Plant) via automatic watering system (Edstrom Industries, Inc., Waterford, WI), available *ad libitum*

**Cages**

Polycarbonate (Lab Products, Inc., Seaford, DE), changed weekly

**TABLE 2**  
**Experimental Design and Materials and Methods in the 3-Month Dermal Studies of OTNE**

---

**Bedding**

Irradiated heat-treated, Sani-Chip hardwood bedding (P.J. Murphy Forest Products, Montville, NJ); changed weekly

**Cage Filters**

Omnishield paper, Remay 2024 (DuPont); changed every 2 weeks

**Racks**

Stainless steel (LabProducts, Inc., Seaford, DE); changed every 2 weeks

**Animal Room Environment**

Temperature:  $72^{\circ} \pm 3^{\circ}$  F

Relative humidity:  $50\% \pm 15\%$

Room fluorescent light: 12 hours/day

Room air changes:  $\geq 10$ /hour

**Doses**

Untreated control, 0% (vehicle control), 6.25%, 12.5%, 25%, 50%, or 100% (neat) OTNE

**Type and Frequency of Observation**

Observed twice daily; core study animals were weighed and clinical findings were recorded initially, on day 8, weekly thereafter, and at the end of the studies.

**Method of Euthanasia**

Carbon dioxide asphyxiation

**Necropsy**

Necropsies were performed on all core study rats and mice. Organs weighed were heart, right kidney, liver, lung, right testis, and thymus.

**Clinical Pathology**

Blood was collected from the retroorbital plexus of special study rats on days 3 and 23 and from core study rats at the end of the study for hematology and clinical chemistry. Blood was collected from the retroorbital sinus of core study mice at the end of the study for hematology.

**Hematology:** hematocrit (automated and manual); hemoglobin; erythrocyte, reticulocyte, and platelet counts; erythrocyte distribution of width; mean platelet volume; mean cell volume; mean cell hemoglobin; mean cell hemoglobin concentration; and leukocyte count and differentials

**Clinical Chemistry:** urea nitrogen, creatinine, total protein, albumin, alanine aminotransferase, alkaline phosphatase, creatine kinase, sorbitol dehydrogenase, and bile acids

**Histopathology**

Complete histopathology was performed on core study rats and mice in the untreated control, vehicle control, and 100% OTNE groups. In addition to gross lesions and tissue masses, the following tissues were examined: adrenal gland, bone (femur) with marrow, brain, clitoral gland, esophagus, eye, gallbladder (mice), Harderian gland, heart and aorta, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, liver, lung (with mainstem bronchus), lymph nodes (mandibular and mesenteric), mammary gland, nose, oral cavity and larynx, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, seminal vesicle, skin (site of application and control sites), spleen, stomach (forestomach and glandular), testis with epididymis, thymus, thyroid gland, tongue, trachea, urinary bladder, and uterus.

**Sperm Motility and Vaginal Cytology**

At the end of the studies, sperm samples were collected from male rats and mice in the untreated control, vehicle control, 25%, 50%, and 100% OTNE groups for sperm motility evaluations. The following parameters were evaluated: spermatid heads per gram testis and per testis, and epididymal spermatozoal motility and concentration. The left cauda, left epididymis, and left testis were weighed. Vaginal samples were collected for up to 16 consecutive days prior to the end of the studies from female rats and mice in the untreated control, vehicle control, 25%, 50%, and 100% OTNE groups for vaginal cytology evaluations.

**Liver Cytochrome P450 Activity**

Liver samples were collected from five male and five female special study rats per dose group on day 23 and from five male and five female core study rats and mice per dose group at the end of the studies. Livers were analyzed for total microsomal protein content and CYP2E1 activity.

---

## STATISTICAL METHODS

For all statistical comparisons, the data from the 100% OTNE groups were compared to the untreated control groups. Data from OTNE-treated groups (6.25% to 50%) were compared to the vehicle controls. With the exception of micronucleus data presented in Appendix E, statistical comparisons between the vehicle control and untreated control groups are not presented in this Toxicity Study Report. In general, there were no statistically significant differences between control groups except in two instances. First, CYP2E1 activity was decreased 36% in female rats from the vehicle control group compared to the untreated control group. Second, the mean final body weights of male mice were 7% lower in the vehicle controls compared to the untreated controls. The biological significance of these two discrepancies was considered negligible.

### Calculation and Analysis of Lesion Incidences

The incidences of lesions are presented in Appendix A as numbers of animals bearing such lesions at a specific anatomic site and the numbers of animals with that site examined microscopically. The Fisher exact test (Gart *et al.*, 1979), a procedure based on the overall proportion of affected animals, was used to determine significance between dosed and vehicle control groups and between the 100% OTNE and untreated control groups.

### Analysis of Continuous Variables

For dosed groups compared to the vehicle control groups, two approaches were employed to assess the significance of pairwise comparisons in the analysis of continuous variables. Organ and body weight data, which historically have approximately normal distributions, were analyzed with the parametric multiple comparison procedures of Dunnett (1955) and Williams (1971, 1972). Hematology, clinical chemistry, total microsomal protein, cytochrome P450 activity, spermatid, and epididymal spermatozoal data, which have typically skewed distributions, were analyzed using the nonparametric multiple comparison methods of Shirley (1977) (as modified by Williams, 1986) and Dunn (1964). Jonckheere's test (Jonckheere, 1954) was used to assess the significance of the dose-related trends and to determine whether a trend-sensitive test (Williams' or Shirley's test) was more appropriate for pairwise comparisons than a test that does not assume a monotonic dose-related trend (Dunnett's or Dunn's test). Prior to statistical analysis, extreme values identified by the outlier test of Dixon and Massey (1957) were examined by NTP personnel, and implausible values were eliminated from the analysis. Proportions of regular cycling females in each dosed group were compared to the vehicle control group using the Fisher exact test (Gart *et al.*, 1979). Tests for extended periods of estrus, diestrus, metestrus, and proestrus, as well as skipped estrus and skipped diestrus, were constructed based on a Markov chain model proposed by Girard and Sager (1987). For each dose group, a transition probability matrix was estimated for transitions among the proestrus, estrus, metestrus, and diestrus stages, with provision for extended stays within each stage as well as for skipping estrus or diestrus within a cycle. Equality of transition matrices among dose groups and between the control group and each dosed group was tested using chi-square statistics.

For comparison of the 100% (neat) group to the untreated control group, a *t*-test was used to determine significant differences in organ and body weight data, and Wilcoxon's (1945) rank sum test was used for hematology, clinical

chemistry, total microsomal protein, cytochrome P450 activity, spermatid, and epidymal spermatozoal data. Female reproductive parameters were analyzed as described for the comparison of the dosed groups to the vehicle control groups.

## QUALITY ASSURANCE METHODS

The 3-month studies were conducted in compliance with Food and Drug Administration Good Laboratory Practice Regulations (21 CFR, Part 58). In addition, as records from the 3-month studies were submitted to the NTP Archives, these studies were audited retrospectively by an independent QA contractor. Separate audits covered completeness and accuracy of the pathology data, pathology specimens, and final pathology tables. Audit procedures and findings are presented in the reports and are on file at NIEHS. The audit findings were reviewed and assessed by NTP staff, and all comments were resolved or otherwise addressed during the preparation of this Toxicity Study Report.

## GENETIC TOXICOLOGY

### Bacterial Mutagenicity Test Protocol

Testing was performed as reported by Zeiger *et al.* (1992) in the first study, and in the second study, a slightly modified protocol was used, as described below. Both studies used the same lot (RAV0276433) of OTNE that was used in the 3-month studies. OTNE was sent to the testing laboratory as a coded sample. In the first study, it was incubated with the *Salmonella typhimurium* tester strains (TA98, TA100, or TA102) either in buffer or S9 mix (metabolic activation enzymes and cofactors from Aroclor 1254-induced male Sprague Dawley rats) for 20 minutes at 37° C. Top agar supplemented with L-histidine and d-biotin was added, and the contents of the tubes were mixed and poured onto the surfaces of minimal glucose agar plates. Histidine-independent mutant colonies arising on these plates were counted following incubation for 2 days at 37° C.

In the second study, following incubation of the bacteria with OTNE for 20 minutes at 37° C, top agar supplemented with either L-histidine (for the *Salmonella* strains) or L-tryptophan (for the *E. coli* strain) and d-biotin was added, and the contents of the tubes were mixed and poured onto the surfaces of minimal glucose agar plates. Histidine- or tryptophan-independent mutant colonies arising on these plates were counted following incubation for 2 days at 37° C.

In both studies, each trial consisted of triplicate plates of concurrent positive and negative controls and of at least five doses of OTNE. In the absence of toxicity, the high dose was limited by experimental design in the first study to 10,000 µg/plate and in the second to 6,000 µg/plate.

In this assay, a positive response is defined as a reproducible, dose-related increase in histidine-independent (revertant) colonies in any one strain/activation combination. An equivocal response is defined as an increase in revertants that is not dose-related, is not reproducible, or is not of sufficient magnitude to support a determination of mutagenicity.

A negative response is obtained when no increase in revertant colonies is observed following chemical treatment. There is no minimum percentage or fold-increase required for a chemical to be judged positive or weakly positive.

### ***In vivo* Peripheral Blood Micronucleus Test Protocol in Rats and Mice**

The procedures used for the mouse and rat peripheral blood micronucleus assay have been described in detail (Dertinger *et al.*, 2004; MacGregor *et al.*, 2006; Witt *et al.*, 2008). Briefly, at the termination of the 3-month toxicity studies with OTNE, one to two drops of blood from male and female F344/NTac rats and male and female B6C3F1/N mice were collected in microtubes with EDTA and shipped on cool packs to the genetic toxicity testing laboratory for processing and fixation in ultracold methanol, as per procedures described in the MicroFlow<sup>BASIC</sup> Kit for rat blood samples or mouse blood samples (Litron Laboratories, Rochester, NY). A FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) was used to carry out the analyses of the samples. Reticulocytes were identified by the presence of an active transferrin receptor (CD71<sup>+</sup>) on the cell surface and mature erythrocytes were CD71-negative. For the rat samples, only reticulocytes with the highest CD71 activity were evaluated due to the speed and efficiency with which the rat spleen removes damaged reticulocytes from circulation. Thus, although micronucleus frequency was evaluated in both reticulocytes and erythrocytes, the appropriate cell population for this assessment in rats is the young reticulocyte population. Micronuclei were detected using propidium iodide (a DNA stain) in conjunction with RNase treatment. Approximately  $1 \times 10^6$  erythrocytes (CD71<sup>-</sup>), and 20,000 reticulocytes (CD71<sup>+</sup>) were evaluated per animal for presence of micronuclei (propidium iodide-associated fluorescence). In addition, for each blood sample, the percentage of reticulocytes in  $1 \times 10^6$  erythrocytes was determined as a measure of OTNE-associated bone marrow toxicity.

Approximately  $1 \times 10^6$  erythrocytes and 20,000 reticulocytes were scored per mouse for presence of micronuclei. Based on prior experience with the large number of cells scored using flow cytometric scoring techniques (Kissling *et al.*, 2007), it is reasonable to assume that the proportion of micronucleated reticulocytes is approximately normally distributed. The statistical tests selected for trend and for pairwise comparisons with the control group depend on whether the variances among the groups are equal. Levene's test at  $\alpha = 0.05$  is used to test for equal variances. In the case of equal variances, linear regression is used to test for a linear trend with dose and Williams' test is used to test for pairwise differences between each treatment group and the control group. In the case of unequal variances, Jonckheere's test is used to test for linear trend and Dunn's test is used for pairwise comparisons of each treatment group with the control group. To correct for multiple pairwise comparisons, the P value for each comparison with the control group is multiplied by the number of comparisons made. In the event that this product is greater than 1.00, it is replaced with 1.00. Trend tests and pairwise comparisons with the controls are considered statistically significant at  $P = 0.025$ . In the micronucleus assay, a positive response is preferably based on the observation of both a significant trend as well as an observation of at least one dose group significantly elevated over the concurrent control group. If only one statistical test (trend or pairwise) is significant, the micronucleus assay is judged to be equivocal. The absence of both a significant trend and a significant dose results in a negative call for the assay. Ultimately, the scientific staff

determines the final call after considering the results of statistical analyses, reproducibility of any effects observed, and the magnitudes of those effects.

### **Evaluation Protocol**

These are the basic guidelines for arriving at an overall assay result for assays performed by the National Toxicology Program. Statistical as well as biological factors are considered. For an individual assay, the statistical procedures for data analysis have been described in the preceding protocols. There have been instances, however, in which multiple samples of a chemical were tested in the same assay, and different results were obtained among these samples and/or among laboratories. Results from more than one aliquot or from more than one laboratory are not simply combined into an overall result. Rather, all the data are critically evaluated, particularly with regard to pertinent protocol variations, in determining the weight of evidence for an overall conclusion of chemical activity in an assay. In addition to multiple aliquots, the *in vitro* assays have another variable that must be considered in arriving at an overall test result. *In vitro* assays are conducted with and without exogenous metabolic activation. Results obtained in the absence of activation are not combined with results obtained in the presence of activation; each testing condition is evaluated separately. The Abstract of this Toxicity Study Report presents a result that represents a scientific judgment of the overall evidence for activity of the chemical in an assay.



## RESULTS

### 3-MONTH STUDY IN RATS

All rats survived to the end of the study (Table 3). Mean body weights and body weight gains of dosed (except 100% OTNE) males and females were similar to those of the respective control groups. The mean body weight gain of 100% OTNE males was significantly less than that of the untreated control group (Table 3 and Figure 1). There were no biologically significant clinical findings related to OTNE administration.

**TABLE 3**  
**Survival and Body Weights of Rats in the 3-Month Dermal Study of OTNE<sup>a</sup>**


Dose (%)	Survival <sup>b</sup>	Initial Body Weight (g)	Final Body Weight (g)	Change in Body Weight (g)	Final Weight Relative to Controls <sup>c</sup> (%)
<b>Male</b>					
Untreated control	10/10	86 ± 2	324 ± 6	239 ± 6	
Vehicle control	10/10	85 ± 2	318 ± 6	233 ± 5	
6.25	10/10	83 ± 2	308 ± 9	225 ± 9	97
12.5	10/10	83 ± 2	293 ± 5	210 ± 5	92
25	10/10	84 ± 2	307 ± 8	223 ± 7	97
50	10/10	83 ± 2	302 ± 7	219 ± 7	95
100	10/10	86 ± 2	306 ± 7	219 ± 7 <sup>†</sup>	94
<b>Female</b>					
Untreated control	10/10	82 ± 2	184 ± 4	102 ± 3	
Vehicle control	10/10	83 ± 1	187 ± 3	104 ± 2	
6.25	10/10	82 ± 2	188 ± 2	106 ± 2	101
12.5	10/10	83 ± 2	184 ± 4	102 ± 4	99
25	10/10	84 ± 1	187 ± 4	103 ± 3	100
50	10/10	83 ± 1	184 ± 3	101 ± 2	99
100	10/10	82 ± 2	180 ± 3	98 ± 2	98

<sup>†</sup> Significantly different ( $P \leq 0.05$ ) from the untreated control group by a *t*-test.

<sup>a</sup> Weights and weight changes are given as mean ± standard error. Differences between the 6.25%, 12.5%, 25%, and 50% OTNE groups and the vehicle control groups are not significant by Dunnett's test. Statistical comparisons between the two control groups are not presented.

<sup>b</sup> Number of animals surviving to the end of the study/number initially in group

<sup>c</sup> Dosed groups are compared to the vehicle control groups, except 100% OTNE groups are compared to the untreated control groups.



**FIGURE 1**  
**Growth Curves for Rats Exposed to OTNE by Dermal Application for 3 Months**

There were no changes in the hematology parameters attributable to the dermal administration of OTNE (Table B1). Serum alkaline phosphatase activities were decreased in various male and female dosed groups at all time points (days 3 and 23 and week 13). While this change was not always observed in the lower dosed groups, decreases were consistently observed in 100% OTNE males and females at all time points compared to the untreated control groups. At the end of the study (week 13), alanine aminotransferase activities were decreased in 25% OTNE or greater females and in all dosed groups of males compared to their respective control groups. The significance of these decreases is not known but may be related to an alteration in liver metabolism. Other changes in clinical chemistry results were not considered toxicologically or biologically relevant.

Mean microsomal protein yields and cytochrome P4502E1 (CYP2E1) activities were measured on day 23 and at the end of the study (week 13) to distinguish between ethanol-related liver effects and the treatment-related effects of OTNE (Table B2). Microsomal protein was significantly increased (up to 44%) at the end of the study in females from the 12.5% to 100% OTNE groups when compared to their respective controls. Microsomal protein (males) at week 13 and CYP2E1 activities in the males and females were not statistically different from controls.

Absolute and relative liver weights were significantly greater (up to 30%) in the males and females of the 50% and 100% OTNE groups (except for the absolute liver weight of 50% males) with respect to their controls (Tables 4 and C1). Relative kidney weights were significantly increased by approximately 9% in the male and female rats of the 100% OTNE groups compared to untreated controls (Table C1). Treatment-related histopathologic changes were not observed in the liver or kidney of males or females (Tables A1 and A2).

Male rats did not display any OTNE-related changes in testis and epididymis weights or sperm parameters (Table D1). Female rats administered OTNE did not display any toxicologically significant effects on cycle length, or estrous cyclicity (Table D2).

**TABLE 4**  
**Liver Weights and Liver-Weight-to-Body-Weight Ratios for Rats in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
n	10	10	10	10	10	10	10
<b>Male</b>							
Necropsy body wt	324 ± 6	318 ± 6	308 ± 9	293 ± 5	307 ± 8	302 ± 7	306 ± 7
Liver							
Absolute	13.62 ± 0.54	13.60 ± 0.48	12.81 ± 0.44	12.73 ± 0.50	13.33 ± 0.46	14.57 ± 0.74	15.93 ± 0.65 <sup>†</sup>
Relative	41.95 ± 1.17	42.77 ± 1.16	41.62 ± 0.95	43.55 ± 1.84	43.48 ± 1.38	48.04 ± 1.64 <sup>*</sup>	52.12 ± 1.83 <sup>††</sup>
<b>Female</b>							
Necropsy body wt	184 ± 4	187 ± 3	188 ± 2	184 ± 4	187 ± 4	184 ± 3	180 ± 3
Liver							
Absolute	6.50 ± 0.33	6.99 ± 0.21	6.89 ± 0.19	7.09 ± 0.27	7.51 ± 0.20	7.78 ± 0.27 <sup>*b</sup>	8.24 ± 0.18 <sup>††</sup>
Relative	35.29 ± 1.42	37.44 ± 0.67	36.60 ± 0.92	38.52 ± 1.40	40.09 ± 0.65	41.93 ± 1.35 <sup>**b</sup>	46.29 ± 1.02 <sup>††</sup>

\* Significantly different ( $P \leq 0.05$ ) from the vehicle control group by Dunnett's or Williams' test

\*\*  $P \leq 0.01$

<sup>†</sup> Significantly different ( $P \leq 0.05$ ) from the untreated control group by a *t*-test

<sup>††</sup>  $P \leq 0.01$

<sup>a</sup> Liver weights (absolute weights) and body weights are given in grams; liver-weight-to-body-weight ratios (relative weights) are given as mg liver weight/g body weight (mean ± standard error). Statistical comparisons between the two control groups are not presented.

<sup>b</sup> n = 9

In males and females administered 12.5% to 50% OTNE, the incidences of minimal to mild hyperplasia and hyperkeratosis (except 12.5% OTNE males) in the skin (site of application) were significantly greater than those of the vehicle control groups; the incidences of these lesions in 100% OTNE males and females were significantly greater than the untreated control incidences (Tables 5, A1, and A2). Hyperplasia was characterized by variably thickened epidermis compared to that of the controls (Plates 1 and 2) due to increased numbers of basal, squamous, and/or granular epidermal cells (Plates 3 and 4). Hyperplasia was graded by the following criteria: minimal (2 to 3 cell layers thick); mild (3 to 4 cell layers thick); moderate (> 5 cell layers thick without rete pegs); and marked (> 5 cell layers thick with rete pegs). Hyperkeratosis was characterized by the presence of subtle to minimal compressed keratin overlying the stratum granulosum (Plates 3 and 4).

**TABLE 5**  
**Incidences of Nonneoplastic Lesions of the Skin (Site of Application) in Rats**  
**in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Male</b>							
Number Examined Microscopically	10	10	10	10	10	10	10
Hyperkeratosis <sup>b</sup>	0	0	1 (1.0) <sup>c</sup>	3 (1.0)	4* (1.0)	5* (1.0)	8 <sup>††</sup> (1.1)
Hyperplasia	0	0	2 (1.0)	4* (1.0)	5* (1.0)	8** (1.5)	10 <sup>††</sup> (1.3)
<b>Female</b>							
Number Examined Microscopically	10	10	10	10	10	10	10
Hyperkeratosis	0	0	0	4* (1.0)	5* (1.4)	7** (1.3)	7 <sup>††</sup> (1.9)
Hyperplasia	0	0	1 (1.0)	5* (1.0)	7** (1.3)	7** (1.4)	8 <sup>††</sup> (1.9)

\* Significantly different ( $P \leq 0.05$ ) from the vehicle control group by the Fisher exact test

\*\*  $P \leq 0.01$

<sup>††</sup> Significantly different ( $P \leq 0.01$ ) from the untreated control group by the Fisher exact test

<sup>a</sup> Statistical comparisons between the two control groups are not presented.

<sup>b</sup> Number of animals with lesion

<sup>c</sup> Average severity grade of lesions in affected animals: 1=minimal, 2=mild, 3=moderate, 4=marked

### 3-MONTH STUDY IN MICE

All mice survived to the end of the study (Table 6). The final mean body weights of 6.25%, 25%, and 50% OTNE males and mean body weight gains of 6.25% and 25% OTNE males were significantly less than those of the vehicle control group; those of 100% OTNE males were significantly less than those of the untreated controls (Table 6 and Figure 2). Clinically, irritation was observed in the skin (site of application) of four males and two females administered 50% OTNE and in all males and females administered 100% OTNE. In addition, lesions considered to be ulcers were observed at the site of application in five males and two females administered 100% OTNE; these lesions were observed between day 43 in males and day 57 in females until the end of the study.

**TABLE 6**  
**Survival and Body Weights of Mice in the 3-Month Dermal Study of OTNE<sup>a</sup>**

Dose (%)	Survival <sup>b</sup>	Initial Body Weight (g)	Final Body Weight (g)	Change in Body Weight (g)	Final Weight Relative to Controls <sup>c</sup> (%)
<b>Male</b>					
Untreated control	10/10	23.1 ± 0.6	37.7 ± 1.2	14.6 ± 1.1	
Vehicle control	10/10	23.7 ± 0.2	35.0 ± 0.6	11.3 ± 0.6	
6.25	10/10	22.9 ± 0.3	32.2 ± 0.4**	9.3 ± 0.3*	92
12.5	10/10	23.4 ± 0.3	33.7 ± 1.0	10.3 ± 0.8	96
25	10/10	22.6 ± 0.3	32.0 ± 0.4**	9.4 ± 0.3*	92
50	10/10	22.8 ± 0.5	32.5 ± 0.5*	9.6 ± 0.4	93
100	10/10	23.1 ± 0.2	32.2 ± 0.4††	9.1 ± 0.4††	86
<b>Female</b>					
Untreated control	10/10	18.6 ± 0.3	28.5 ± 0.7	9.9 ± 0.5	
Vehicle control	10/10	19.1 ± 0.6	29.5 ± 0.7	10.4 ± 0.5	
6.25	10/10	18.8 ± 0.3	30.1 ± 0.7	11.3 ± 0.7	102
12.5	10/10	18.8 ± 0.2	29.2 ± 0.6	10.4 ± 0.5	99
25	10/10	18.5 ± 0.2	28.9 ± 0.3	10.4 ± 0.3	98
50	10/10	18.4 ± 0.3	29.2 ± 0.4	10.8 ± 0.4	99
100	10/10	18.4 ± 0.2	29.4 ± 0.3	11.1 ± 0.3	103

\* Significantly different ( $P \leq 0.05$ ) from the vehicle control group by Dunnett's test


\*\*  $P \leq 0.01$

†† Significantly different ( $P \leq 0.01$ ) from the untreated control group by a *t*-test

<sup>a</sup> Weights and weight changes are given as mean ± standard error. Statistical comparisons between the two control groups are not presented.

<sup>b</sup> Number of animals surviving at the end of the study/number initially in group

<sup>c</sup> Dosed groups are compared to the vehicle control groups, except 100% OTNE groups are compared to the untreated control groups.



**FIGURE 2**  
**Growth Curves for Mice Exposed to OTNE by Dermal Application for 3 Months**

When compared to the vehicle (dosed groups) or untreated (100% OTNE groups) controls, significant decreases ( $\leq 14\%$ ) in the erythrocyte counts, hemoglobin concentrations, and hematocrit values occurred in the 25% OTNE or greater males and 100% OTNE females (Table B3). Erythrocyte distribution widths, coefficients of variation of erythrocyte volumes (i.e., increased values indicate increased variation in sizes), were significantly increased in the 25% OTNE or greater males and in all dosed groups of females compared to their respective control groups. The parameters of erythrocyte count, hemoglobin concentration, and hematocrit value are quantitative estimates of the circulating erythroid mass. The changes in these parameters, paired with the changes in the red cell distribution width, were consistent with an alteration in erythropoiesis. Other changes in the erythron were not considered toxicologically or biologically relevant.

In male and female vehicle control mice at the end of the study, there was no effect on CYP2E1 activity relative to the untreated controls (Table B4). This suggests that the vehicle itself did not affect liver function. However, male and female mice did exhibit dose-dependent increases in CYP2E1 activity. Male mice treated with 25%, 50%, or 100% OTNE had significantly increased CYP2E1 activities (ranging from 35% to 80%) when compared to their respective control groups. CYP2E1 activity was also significantly increased (ranging from 26% to 65%) in all female groups administered OTNE compared to their respective control groups. These increases in CYP2E1 activity were less than twofold and not considered biologically relevant.

Absolute and relative organ weights were significantly changed in male and female mice. Absolute liver weights of all female and all male dosed groups (except 6.25% OTNE males) were increased (up to 92%) compared to their respective controls (Tables 7 and C2). Similarly, the relative liver weights of all male and female dosed groups were increased (up to 89%) compared to their respective controls. Absolute and relative heart weights were increased approximately 14% in the 50% and 100% OTNE females; the relative heart weights of 25% and 100% OTNE males were also increased, but this may be due to the decreased body weights noted in the males (Tables 6 and C2). The absolute thymus weights of males and females as well as the relative thymus weight of females were decreased by approximately 22% in the 100% OTNE groups compared to untreated controls (Table C2). In males, the absolute testis weight was decreased by 10% in the 50% OTNE group. In females, the relative lung weight of the 100% OTNE group was decreased by 21% compared to untreated controls. Histopathologic changes were not associated with alterations in organ weights, with the exception of centrilobular hypertrophy noted in 100% OTNE males (Tables A3, A4, and C2).



**TABLE 7**  
**Liver Weights and Liver-Weight-to-Body-Weight Ratios for Mice in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
n	10	10	10	10	10	10	10
<b>Male</b>							
Necropsy body wt	37.7 ± 1.2	35.0 ± 0.6	32.2 ± 0.4**	33.7 ± 1.0	32.0 ± 0.4**	32.5 ± 0.5*	32.2 ± 0.4††
Liver							
Absolute	1.64 ± 0.05	1.60 ± 0.05	1.68 ± 0.07	1.82 ± 0.09*	1.99 ± 0.09**	2.12 ± 0.03**	2.66 ± 0.07††
Relative	43.79 ± 1.34	45.72 ± 1.29	51.98 ± 1.96*	54.09 ± 2.20**	62.10 ± 2.99**	65.35 ± 1.52**	82.51 ± 1.92††
<b>Female</b>							
Necropsy body wt	28.5 ± 0.7	29.5 ± 0.7	30.1 ± 0.7	29.2 ± 0.6	28.9 ± 0.3	29.2 ± 0.4	29.4 ± 0.3
Liver							
Absolute	1.28 ± 0.04	1.37 ± 0.05	1.52 ± 0.04*	1.65 ± 0.04**	1.69 ± 0.03**	2.04 ± 0.05**	2.46 ± 0.07††
Relative	45.04 ± 1.03	46.48 ± 1.46	50.45 ± 0.76*	56.53 ± 1.22**	58.35 ± 0.61**	69.96 ± 1.26**	83.54 ± 2.31††

\* Significantly different ( $P \leq 0.05$ ) from the vehicle control group by Dunnett's or Williams' test

\*\*  $P \leq 0.01$

†† Significantly different ( $P \leq 0.01$ ) from the untreated control group by a *t*-test

<sup>a</sup> Liver weights (absolute weights) and body weights are given in grams; liver-weight-to-body-weight ratios (relative weights) are given as mg liver weight/g body weight (mean ± standard error). Statistical comparisons between the two control groups are not presented.

Male mice administered 100% OTNE displayed fewer caudal sperm and caudal sperm/mg; these findings were not associated with any histopathologic changes in the testes or epididymides (Tables 8, A3, and D3). Male mice in the 100% OTNE group also exhibited lower sperm motility (~11%) (Tables 8 and D3).

Female mice administered 100% OTNE exhibited an increase in cycle length of approximately 1 day and displayed an increased probability of extended estrus as compared to the untreated controls (Tables 9 and D4). The increased probability of extended estrus was also observed in the 25% and 50% OTNE groups as compared to the vehicle controls. When displayed as days in any given stage and presented as a percentage, the 25%, 50%, and 100% OTNE groups exhibited more time in estrus than the respective control groups.

**TABLE 8**  
**Summary of Reproductive Tissue Evaluations for Male Mice in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	25%	50%	100%
n	9	10	7	7	10
Weights (g)					
Necropsy body wt	37.8 ± 1.3	35.0 ± 0.6	32.2 ± 0.5**	32.9 ± 0.5*	32.2 ± 0.4 <sup>††</sup>
L. Cauda epididymis	0.0210 ± 0.0015	0.0196 ± 0.0011	0.0218 ± 0.0017	0.0252 ± 0.0041	0.0170 ± 0.0012 <sup>†</sup>
L. Epididymis	0.0515 ± 0.0040	0.0480 ± 0.0023	0.0615 ± 0.0068	0.0549 ± 0.0040	0.0435 ± 0.0021
L. Testis	0.1119 ± 0.0022	0.1119 ± 0.0016	0.1114 ± 0.0041	0.1085 ± 0.0038	0.1052 ± 0.0025
Spermatid measurements					
Spermatid heads (10 <sup>6</sup> /g testis)	214.10 ± 17.77	233.47 ± 16.49	252.91 ± 18.67	254.21 ± 16.20	234.12 ± 21.35
Spermatid heads (10 <sup>6</sup> /testis)	23.93 ± 1.97	26.21 ± 2.10	27.93 ± 1.79	27.57 ± 2.00	24.80 ± 2.40
Epididymal spermatozoal measurements					
Sperm motility (%)	90.8 ± 2.2	94.7 ± 0.8	91.0 ± 3.6	92.4 ± 1.9	80.6 ± 7.4
Sperm (10 <sup>6</sup> /g cauda epididymis)	169.9 ± 21.6	151.1 ± 11.2	144.3 ± 8.9	153.9 ± 29.2	112.2 ± 22.4
Sperm (10 <sup>6</sup> /cauda epididymis)	3.4 ± 0.3	2.9 ± 0.2	3.2 ± 0.4	3.5 ± 0.7	1.8 ± 0.3 <sup>††</sup>

\* Significantly different (P≤0.05) from the vehicle control group by Dunnett's test

\*\* P≤0.01

<sup>†</sup> Significantly different (P≤0.05) from the untreated control group by Wilcoxon's rank sum test

<sup>††</sup> Significantly different (P≤0.01) from the untreated control group by a *t*-test (body weights) or Wilcoxon's rank sum test (sperm/cauda epididymis)

<sup>a</sup> Data are presented as mean ± standard error. Differences between the vehicle control group and the 25% and 50% groups are not significant by Dunnett's test (tissue weights) or Dunn's test (spermatid and epididymal spermatozoal measurements). Differences between the untreated control group and the 100% group are not significant by a *t*-test (tissue weights) or Wilcoxon's rank sum test (spermatid measurements, sperm motility, and sperm/g cauda epididymis). Statistical comparisons between the two control groups are not presented.

**TABLE 9**  
**Estrous Cycle Characterization for Female Mice in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control		Vehicle Control	25%	50%	100%
Number weighed at necropsy	10	10		10	10	10
Necropsy body wt (g)	28.5 ± 0.7		29.5 ± 0.7	28.9 ± 0.3	29.2 ± 0.4	29.4 ± 0.3
Proportion of regular cycling females <sup>b</sup>	9/10		10/10	10/10	10/10	9/10
Estrous cycle length (days)	4.0 ± 0.2		4.5 ± 0.2	4.6 ± 0.2	4.5 ± 0.2	5.2 ± 0.3 <sup>††</sup>
Estrous stages (% of cycle)						
Diestrus	38.8		38.8	31.3	33.8	37.5
Proestrus	0.0		0.0	1.3	0.6	0.0
Estrus	38.1		43.1	51.3	56.3	53.1
Metestrus	15.0		11.9	10.0	6.3	6.9
Uncertain diagnosis	8.1		6.3	6.3	3.1	2.5

<sup>††</sup> Significantly different ( $P \leq 0.01$ ) from the untreated control group by Dunn's test

<sup>a</sup> Necropsy body weights and estrous cycle length data are presented as mean ± standard error. Differences between the vehicle control group and the 25% and 50% groups are not significant by Dunnett's test (body weights) or Dunn's test (estrous cycle length). Differences between the untreated control group and the 100% group are not significant by a *t*-test (body weights). By multivariate analysis of variance, dosed females do not differ significantly from the vehicle control females in the relative length of time spent in the estrous stages. Tests for equality of transition probability matrices among all groups and between the respective control group and each dosed group indicated the probability of extended estrus was significantly higher in the dose groups than the respective control groups. Statistical comparisons between the two control groups are not presented.

<sup>b</sup> Number of females with a regular cycle/number of females cycling

Compared to occurrences in the respective control groups, the incidences of several nonneoplastic lesions of the skin were significantly increased in dosed groups of males and females (Tables 10, A3, and A4). At the site of application, the incidences of minimal to moderate hyperplasia and chronic active inflammation were significantly increased in all dosed groups of males and females. The incidences of minimal to mild hyperkeratosis were significantly increased in males administered 12.5% OTNE or greater and in all dosed groups of females. The incidences of fibrosis were significantly increased in all dosed groups of males except the 12.5% OTNE group, and in females administered 12.5% OTNE or greater. The incidences of epidermis suppurative inflammation were significantly increased in 100% OTNE males and in females administered 25% OTNE or greater. The incidences of hair follicle hyperplasia were significantly increased in 50% and 100% OTNE males and females administered 25% OTNE or greater.

In the skin adjacent to the site of application, the incidences of hyperplasia, hyperkeratosis, chronic active inflammation, fibrosis, and epidermis suppurative inflammation were significantly increased in 100% OTNE males and females, and the incidence of hair follicle hyperplasia was significantly increased in 100% OTNE males (Tables 10, A3, and A4). The incidences of these lesions were also increased in most of the lower dosed groups of both sexes, sometimes significantly; these lesions were considered secondary to the spread of the test material from the site of application rather than a systemic effect. Lesions were not observed in examined control skin of male or female mice.

Compared to the vehicle controls (Plates 5 and 6), hyperplasia and hyperkeratosis (Plates 7 to 10) in the skin (site of application) were histologically similar to these lesions described in the rat; the same grading criteria were applied. Chronic active inflammation was characterized by increased numbers of scattered neutrophils, lymphocytes, and macrophages in the superficial dermis; increased numbers of mast cells and/or melanocytes were noted (Plates 8 and 10). Fibrosis was characterized by replacement of the normally present dermal collagen fibers by discrete bands of pale basophilic fibrous connective tissue and/or increased numbers of fibroblasts (Plates 9 and 10). Suppurative inflammation of the epidermis was characterized by discrete aggregates of degenerate neutrophils (pustules) within the stratum corneum and less frequently, hair follicles (Plates 9 and 10). Hair follicle hyperplasia was characterized by increased numbers of follicle profiles and often the associated adnexal structures (e.g., sebaceous glands) within the dermis (Plates 7 to 10).

In the liver, the incidence of centrilobular hypertrophy in 100% OTNE males was significantly greater than that in the untreated controls (Tables 10 and A3). There were no hepatic lesions in female mice. Centrilobular hypertrophy was of mild severity; affected hepatocytes were larger than the surrounding hepatocytes and had increased amounts of lightly eosinophilic to granular cytoplasm and loss of cytoplasmic glycogen.

**TABLE 10**  
**Incidences of Selected Nonneoplastic Lesions in Mice in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Male</b>							
Skin, Site of Application <sup>b</sup>	10	10	10	10	10	9	10
Fibrosis <sup>c</sup>	0	0	4* (1.5) <sup>d</sup>	3 (2.0)	8** (1.8)	8** (1.6)	10 <sup>††</sup> (2.0)
Hyperkeratosis	0	0	2 (1.0)	5* (1.4)	5* (1.4)	8** (1.4)	10 <sup>††</sup> (1.7)
Hyperplasia	0	0	9** (1.7)	10** (1.9)	9** (1.8)	9** (2.3)	10 <sup>††</sup> (2.8)
Inflammation, Chronic Active	0	0	7** (1.4)	10** (1.7)	9** (1.7)	9** (1.7)	10 <sup>††</sup> (2.0)
Epidermis, Inflammation, Suppurative	0	0	0	0	1 (1.0)	1 (2.0)	5 <sup>†</sup> (1.0)
Hair Follicle, Hyperplasia	0	0	3 (1.0)	2 (1.5)	3 (2.3)	7** (1.1)	8 <sup>††</sup> (1.8)
Skin Adjacent to the Site of Application	10	10	10	10	9	10	10
Fibrosis	0	0	0	0	1 (1.0)	2 (1.5)	5 <sup>†</sup> (1.4)
Hyperkeratosis	0	0	0	0	0	2 (2.0)	5 <sup>†</sup> (1.6)
Hyperplasia	0	0	0	2 (1.5)	4* (1.0)	3 (2.0)	8 <sup>††</sup> (2.3)
Inflammation, Chronic Active	0	0	0	2 (1.5)	4* (1.3)	2 (2.0)	8 <sup>††</sup> (1.8)
Epidermis, Inflammation, Suppurative	0	0	0	0	0	1 (2.0)	4 <sup>†</sup> (1.0)
Hair Follicle, Hyperplasia	0	0	0	1 (2.0)	0	1 (2.0)	5 <sup>†</sup> (1.6)
Liver	10	10	10	10	9	10	10
Centrilobular, Hypertrophy	0	1 (3.0)	0	2 (1.0)	3 (1.3)	0	4 <sup>†</sup> (2.0)

**TABLE 10**  
**Incidences of Selected Nonneoplastic Lesions in Mice in the 3-Month Dermal Study of OTNE**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Female</b>							
Skin, Site of Application	10	10	10	10	10	6	10
Fibrosis	0	0	2 (1.5)	10** (1.6)	10** (1.7)	4** (1.3)	9†† (2.0)
Hyperkeratosis	0	0	5* (1.2)	5* (1.2)	10** (1.7)	6** (1.8)	10†† (2.1)
Hyperplasia	0	0	10** (2.1)	10** (1.8)	10** (2.0)	6** (2.3)	10†† (2.8)
Inflammation, Chronic Active	0	0	10** (1.8)	10** (1.7)	10** (2.0)	6** (2.0)	10†† (2.0)
Epidermis, Inflammation, Suppurative	0	0	0	1 (1.0)	4* (1.3)	4** (1.3)	7†† (1.3)
Hair Follicle, Hyperplasia	0	0	3 (1.3)	0	4* (2.8)	3* (2.0)	10†† (2.0)
Skin Adjacent to the Site of Application	10	10	10	10	10	8	10
Fibrosis	0	0	0	3 (1.3)	0	0	6†† (1.5)
Hyperkeratosis	0	0	0	1 (1.0)	0	0	7†† (2.0)
Hyperplasia	0	0	4* (1.0)	3 (1.7)	2 (1.0)	3 (1.0)	10†† (2.1)
Inflammation, Chronic Active	0	0	4* (1.3)	4* (1.5)	2 (1.5)	3 (1.3)	8†† (1.9)
Epidermis, Inflammation, Suppurative	0	0	0	0	0	0	8†† (1.6)
Hair Follicle, Hyperplasia	0	0	0	0	1 (1.0)	0	3 (2.0)

\* Significantly different ( $P \leq 0.05$ ) from the vehicle control group by the Fisher exact test

\*\*  $P \leq 0.01$

† Significantly different ( $P \leq 0.05$ ) from the untreated control group by the Fisher exact test

††  $P \leq 0.01$

<sup>a</sup> Statistical comparisons between the two control groups are not presented.

<sup>b</sup> Number of animals with tissue examined microscopically

<sup>c</sup> Number of animals with lesion

<sup>d</sup> Average severity grade of lesions in affected animals: 1=minimal, 2=mild, 3=moderate, 4=marked


## GENETIC TOXICOLOGY

OTNE (Lot RAV0276433, the same lot used in the 3-month toxicity study with a concentration range of 100 to 10,000 µg/plate) was not mutagenic in *Salmonella typhimurium* strains TA98, TA100, or TA102, with or without exogenous metabolic activation (Table E1). A second sample of OTNE (Lot RAV0276433 with a concentration range of 100 to 6,000 µg/plate) was also shown to be nonmutagenic in *S. typhimurium* strains TA98 or TA100, as well as in *Escherichia coli* strain WP2 *uvrA*/pKM101, with and without S9 activation (Table E2).

The effect of 3 months of dermal exposure to OTNE on micronucleus frequency and erythropoiesis in F344/NTac rats and B6C3F1/N mice was examined in two experiments, a multidose experiment and a single-dose experiment. Four doses ranging from 6.25% to 50% OTNE were compared to a 95% ethanol vehicle control, whereas 100% (neat) OTNE was compared to an untreated control. No significant increases in micronucleated reticulocytes or erythrocytes


were seen in male or female F344/NTac rats following exposure to OTNE, and no changes in the percentage of reticulocytes was observed in either sex of rat (Table E3). In the multidose test in male rats, the mean frequency of micronucleated reticulocytes was significantly ( $P < 0.025$ ) elevated over the control in the two highest dose groups, but the magnitudes of the increases were very small, the trend test was not significant, and the response measured in the group that received 100% OTNE was lower than either of these two values; therefore, the response in male rat reticulocytes in the multidose test was judged to be negative. In male mice, OTNE did not increase the frequency of micronucleated reticulocytes in the multi- or single-dose experiments (Table E4). OTNE also did not increase the frequency of micronucleated mature erythrocytes in the multidose experiment. However, an increase in the frequency of micronucleated mature erythrocytes was detected in male mice exposed to 100% OTNE. Although this increase was statistically significant ( $P = 0.001$ ), the magnitude of the increase was very small ( $1.45 \pm 0.02$  in the control versus  $1.59 \pm 0.03$  in the treated group) and therefore, the result was judged to be equivocal. In female mice, OTNE did not increase the frequency of micronucleated reticulocytes in the multidose experiment. However, micronucleated reticulocytes were significantly increased ( $P = 0.005$ ) in female mice exposed to 100% OTNE. Furthermore, micronucleated mature erythrocytes were significantly increased in a dose-dependent manner ( $P < 0.001$ ) and also in the single-dose experiment ( $P < 0.001$ ). Therefore, the results of these tests in female mice were judged to be positive. The percentage of reticulocytes was significantly increased in female mice exposed to 100% OTNE ( $1.08 \pm 0.15$  in the control versus  $1.89 \pm 0.25$  in the treated group); however, the absolute percentage of reticulocytes in the 100% OTNE group was equal to or less than the percentages seen in the 12.5% to 50% OTNE-treated female mice, and other measures of reticulocyte numbers did not indicate that OTNE stimulated erythropoiesis. Considering all the data, the increase in the percentage of reticulocytes in the 100% OTNE group was not considered to be biologically significant.






**PLATE 1**

Normal epidermis (arrows) in the skin (site of application) of a vehicle control female F344/NTac rat in the 3-month dermal study of OTNE. H&E




**PLATE 2**

Higher magnification of Plate 1. Normal epidermis (arrows) consists of a single layer of squamous epithelium that is slightly keratinized. H&E




**PLATE 3**

Mild hyperplasia (long arrows) and hyperkeratosis (short arrows) in the skin (site of application) of a female F344/NTac rat dermally administered 100% OTNE for 3 months. Compared to Plate 1, the epidermis and keratin layers appear thickened. H&E




**PLATE 4**

Higher magnification of Plate 3. Compared to Plate 2, the granular cell layer (stratum granulosum) of the epidermis is thickened (hyperplasia) due to an increased number of cell layers (long arrows). Epidermal hyperplasia is accompanied by hyperkeratosis (short arrows) that consists of mild thickening of the keratin layer (stratum corneum). H&E




#### PLATE 5

Normal epidermis (arrows) in the skin (site of application) of a vehicle control female B6C3F1/N mouse in the 3-month dermal study of OTNE. H&E



#### PLATE 6

Higher magnification of Plate 5. Normal epidermis (arrows) consists of squamous epithelium (one to two layers thick) that is slightly keratinized. H&E



#### PLATE 7


Moderate hyperplasia (long arrows) and mild hyperkeratosis (short arrows) in the skin (site of application) of a female B6C3F1/N mouse dermally administered 6.25% OTNE for 3 months. Compared to Plate 5, the epidermis and keratin layers are thickened. There are increased numbers of hair follicle profiles (hair follicle hyperplasia) within the dermis (curved arrows). H&E



#### PLATE 8


Higher magnification of Plate 7. Compared to Plate 6, there is moderate thickening of the epidermal stratum granulosum (long arrows) and mild hyperkeratotic thickening of the keratin layer (short arrows). Note increased numbers of hair follicle profiles (hair follicle hyperplasia) and thickening of the follicular epithelium that is similar to that in the epidermis. There are increased infiltrates of inflammatory cells (chronic active inflammation) within the dermis. Note also that there is hyperplasia and hypertrophy of the sebaceous glands associated with the hyperplastic hair follicles (curved arrows). H&E





#### PLATE 9

Suppurative inflammation in the skin (site of application) of a female B6C3F1/N mouse dermally administered 100% OTNE for 3 months. Suppurative inflammation (long arrows) consists of multifocal aggregates of neutrophils (pustules) within the stratum corneum. Compared to Plate 5, the dermis appears diffusely pale (short arrows) due to replacement of normally present dermal collagen fibers by connective tissue (fibrosis). Note also that there is epidermal hyperplasia and hyperkeratosis, and hair follicle hyperplasia. H&E



#### PLATE 10

Higher magnification of Plate 9. Note multifocal aggregates of neutrophils (suppurative inflammation) within the stratum corneum and connective tissue (fibrosis) within the dermis (arrows). Note also epidermal hyperplasia and hyperkeratosis, hair follicle hyperplasia, and infiltrates of mononuclear inflammatory cells and neutrophils (chronic active inflammation) in the dermis extending into the subcutis. H&E

## DISCUSSION

OTNE is classified as an unsaturated alkyl cyclic ketone fragrance ingredient commonly referred to by the commercial name Iso-E Super<sup>®</sup>. Similar to other fragrance materials, OTNE is used as a perfume ingredient in soaps, shampoos, colognes, liquid detergent compounds, and malodor-reducing compounds including fabric freshening compounds, antiperspirants or deodorants, and air freshening compounds. Exposure to OTNE by the general public is primarily through dermal absorption and inhalation from products that contain the ingredient. It is estimated that OTNE is typically less than 1% in individual consumer household products with the exception of fine fragrances that may have up to 20% OTNE (Wishneff, 2012; Scognamiglio *et al.*, 2013). The predicted human dermal exposure is calculated to be 0.4604 mg/kg body weight per day (Scognamiglio *et al.*, 2013).

OTNE toxicity data is summarized in REACH Dossiers in the European Chemicals Agency (ECHA) database and in a review by the Research Institute for Fragrance Materials (Scognamiglio *et al.*, 2013); however, the full reports of these toxicity studies are not publicly available. In these summaries, there is no mention of any subchronic or chronic toxicity studies of OTNE in rodents. The current Toxicity Study Report describes the 3-month toxicity studies of OTNE administered to F344/NTac rats and B6C3F1/N mice by dermal absorption which is the primary route of human exposure. OTNE is considered to have minimal acute toxicity in rats (dermal and oral LD<sub>50</sub> > 5g/kg) (Scognamiglio *et al.*, 2013). For sufficient hazard characterization in these studies, neat OTNE (100%) was applied dermally as the highest achievable concentration to rats and mice and corresponds to approximately 500 mg OTNE/kg body weight per day and 2,000 mg/kg per day, respectively. OTNE was dissolved in 95% aqueous ethanol to achieve lower concentrations of 6.25%, 12.5%, 25%, and 50% OTNE. Because the 100% OTNE animals did not receive ethanol, two control groups were included in the study design. For the untreated controls, animals were handled similarly but did not receive any treatment at the site of application, whereas the vehicle control animals received 95% ethanol at the site of application. The untreated controls served as a comparison for the 100% OTNE group, and the vehicle controls were used for comparing data from the 6.25% to 50% OTNE groups. Statistical comparisons between control groups were conducted, and no biologically relevant differences were observed (data not shown) suggesting that dermal exposure of ethanol over this time did not interfere with our assessment of OTNE toxicity.

Results of the current 3-month studies demonstrated that the skin at the site of application was considered the primary target of OTNE toxicity across both sexes and species. Mortality was not observed in either sex or species. Small but significant decreases in body weights were observed in male mice. Organ weight changes (absolute and relative) were observed at the end of the studies; some of the organ weight changes were accompanied by histopathologic lesions.

The majority of nonneoplastic lesions following the 3-month dermal exposure of OTNE occurred in the skin at the site of application of rats and mice. In general, hyperplasia and hyperkeratosis were observed in both sexes and both

species. However, the incidences and the severities of these lesions were greater in male and female mice than in rats. Incidences of minimal to mild hyperplasia and hyperkeratosis were significantly increased in rats administered 12.5% OTNE or greater, whereas minimal to moderate hyperplasia and hyperkeratosis were observed in nearly all dosed groups of male and female mice. Furthermore, hyperplasia and hyperkeratosis in mice were accompanied by increased incidences of minimal to mild chronic active inflammation, fibrosis, epidermis suppurative inflammation, and hair follicle hyperplasia. These lesions also extended to the skin adjacent to the site of application in male and female mice and were considered secondary to the spread of the test material from the site of application rather than the result of a systemic OTNE effect. One likely explanation for the species differences in skin lesion incidences and severities is the applied dose. On a mg/kg body weight basis, as noted above, mice received doses of OTNE approximately four times higher than rats in this study. Another possibility is that mice on a C57BL/6 background have an increased susceptibility to idiopathic, spontaneous ulcerative dermatitis (Hampton *et al.*, 2012), and this increased susceptibility may have made the mice more sensitive to the irritating effects of OTNE and consequently exacerbated the severity of the skin lesions.

The skin lesions observed in the current studies have not previously been reported in the OTNE literature. However, these skin lesions were consistent with reports from a 3-month dermal study with a similar fragrance chemical, acetyl cedrene. The study summary available in Belsito *et al.* (2013) highlights that dosed rats administered acetyl cedrene [0 (water), 50, 150, or 300 mg/kg body weight per day] had evidence of skin irritation, mild chronic inflammation, and hyperkeratosis. Although the full study report is not publicly available for a side-by-side comparison with the current subchronic dermal studies, this information suggests that long-term use of fragrance compounds with an alkyl cyclic ketone structure has the potential for chronic toxicity to the skin.

The skin lesions observed in the current studies in rats and mice after dermal exposure for 3 months are consistent with evidence from human and animal irritation and sensitization studies. Previously, the NTP concluded that OTNE was an irritant and had the potential to induce skin sensitization in female BALB/c mice examined in a combined local lymph node (LLNA) and irritancy assay (NTP, 2010). In this study, all mice treated with OTNE (0.5% to 50%) demonstrated significant irritation at the site of application. In the LLNA study, significant increases in lymph node cell proliferation were observed at concentrations of 25% and 50% only, suggesting that the positive response in this assay is a nonspecific response due to the irritant effect of the chemical. Variable results have been reported with regard to the ability of OTNE to act as a sensitizer and/or an irritant, as summarized in a review from the Research Institute for Fragrance Materials (Scognamiglio *et al.*, 2013) and also in the ECHA database. For example, OTNE was classified as a skin sensitizer in CBA/J mice following application of 2.5% to 50% OTNE (ECHA, 2013f,g,h). Conversely, in guinea pig and rabbit primary irritation studies, OTNE did not produce irritation in multiple acute tests at applied doses of less than 5% (Scognamiglio *et al.*, 2013). In repeated application studies, 2.5% OTNE in ethanol caused skin irritation in guinea pigs (Belsito *et al.*, 2013). While the majority of human repeated insult patch tests indicated that OTNE is not a skin irritant, irritancy was observed in human volunteers administered OTNE at

concentrations greater than 12.5% in two cases (Belsito *et al.*, 2013). It is difficult to determine the reason for the variable responses in these studies; however, it appears that both dose and frequency of exposure may play a role.

In male and female rats, treatment-related increases in absolute and relative liver weights were observed. Increases were significant in the 50% and 100% OTNE groups. This finding was consistent with a previous summary report demonstrating increased liver weights in rats administered 1,000 mg OTNE/kg body weight by gavage for 4 weeks (ECHA, 2013e). In that same report, increased liver weights were associated with centrilobular hepatocyte enlargement. However, histologic changes were not observed in the livers of rats following dermal application of OTNE for 3 months in the current study. The lack of histologic findings in the rat liver may be due to the route of administration (oral versus dermal) as well as dose; the highest dose administered in the current study was approximately 500 mg/kg.

In the current studies, dose-related increases in the absolute and relative liver weights of male and female mice were also observed, and the increases (ranging from 62% to 92% above controls) were significant in males treated with 12.5% OTNE or greater and all dosed female groups. Unlike rats treated with OTNE, increased liver weights in dosed mice were accompanied by minimal induction of cytochrome P4502E1 (CYP2E1) activities and an increased incidence of centrilobular hypertrophy in males administered 100% OTNE. These species differences may be attributed to the fact that mice were treated with four times more OTNE on a mg/kg per day basis. Although statistically significant, the magnitudes of the CYP2E1 activity increases were less than twofold in both male and female mice and may have marginally contributed to the increased liver weights or the increased incidence of centrilobular hypertrophy. Collectively, increased liver weights accompanied by increased CYP2E1 activities and mild histopathologic changes indicate that dermal exposure to OTNE has the potential to cause some systemic toxicity. Although OTNE was administered dermally in the current studies, some oral exposure was anticipated based on animal grooming (Waidyanatha and Ryan, 2014) and could have contributed to the observed systemic toxicity in the liver. In a review of industry studies with several alkyl cyclic ketone fragrance compounds, the liver has been a common target (increased organ weights and some evidence of minimal hepatocyte hypertrophy) in several animal studies where compounds were administered dermally or by the oral route (Belsito *et al.*, 2013). These changes were reported to occur at high doses and were considered adaptive by the authors.

Other organ weight changes were observed in the current studies in the high dose groups (100% OTNE) of rats and mice. In rats, a small but significant increase in relative kidney weights was observed in the 100% OTNE male and female dose groups. Kidney lesions were not observed by histopathology in this study. However, eosinophilic inclusions in kidney cortical tubules of male rats, treated for 4 weeks with 150 or 1,000 mg/kg OTNE by gavage, were reported elsewhere (ECHA, 2013e). Likewise, the kidney has been reported as a target for toxicity in subacute and subchronic rat studies following exposure to various other alkyl cyclic ketone fragrance compounds (Belsito *et al.*, 2013). In mice, 100% OTNE elicited small but significant decreases in male and female thymus weights, although histopathologic changes were not observed and the toxicologic relevance of these weight changes is not known.

OTNE exposure via dermal application exhibited the potential to be a reproductive toxicant in male and female B6C3F1/N mice, but not in F344/NTac rats, as evidenced by fewer sperm, lower sperm motility, and alterations in estrous cyclicity. Recent reviews summarizing the toxicology information on OTNE (and other similar fragrance compounds) have not reported any toxicologic effects in rat reproductive tissues. Toxicity studies in mice that have included these endpoints are limited (Belsito *et al.*, 2013; Scognamiglio *et al.*, 2013). Nevertheless, the differential response observed between species reported here may be the result of mice receiving a higher dose compared to rats.

In studies performed by the NTP, OTNE was not mutagenic *in vitro*. This finding is consistent with industry studies demonstrating that OTNE was negative in bacterial mutagenicity tests and in mouse lymphoma L5178Y tk<sup>+</sup>/- cells treated with OTNE (ECHA, 2013m,n). Additionally, many other structurally related, unsaturated ketone fragrances have been found to be nonmutagenic *in vitro* (Belsito *et al.*, 2013). OTNE was considered negative for chromosomal aberrations when tested in human lymphocytes (ECHA, 2013n). However, in the NTP 3-month *in vivo* studies, OTNE was equivocal in male mice and positive in female mice in the micronucleus assay, which detects clastogenic and aneugenic events. These findings were based on statistically significant increases in the frequency of micronucleated mature erythrocytes in 100% OTNE male mice and, in female mice, dose-dependent increases in micronucleated mature erythrocytes and an increase in mature erythrocytes in a single-dose experiment with 100% OTNE, all of which reached statistical significance. It should be noted, however, that the statistically significant effects detected in dosed male and female mice were very small increases compared to the vehicle controls or untreated controls, which calls into question their biological significance. OTNE was negative for the micronucleus assay in male and female F344/NTac rats. Overall, this is the first study to suggest that repeated dermal application of OTNE may have genotoxic effects.

Under the conditions of these 3-month dermal studies, the major target in F344/NTac rats and B6C3F1/N mice was the skin, site of application. Lesions were more prominent in mice than rats based upon the incidences and severities of hyperplasia, hyperkeratosis, and inflammation of the skin, site of application. Additionally, hepatic lesions were apparent in mice, but not rats. OTNE exhibited the potential to be a reproductive toxicant in male and female mice. These species differences could be attributed to dose, because mice received approximately four times the amount of OTNE on a mg/kg body weight basis than rats. In male and female rats, the lowest-observed-effect level (LOEL) of 12.5% OTNE was based on the increased incidences of skin lesions. In male and female mice, the LOEL was 6.25% OTNE, based on the increased incidences of skin lesions and increased relative liver weights.

## REFERENCES

- Belsito, D., Bickers, D., Bruze, M., Calow, P., Dagli, M.L., Fryer, A.D., Greim, H., Miyachi, Y., Saurat, J.H., and Sipes, I.G. (2013). A toxicological and dermatological assessment of alkyl cyclic ketones when used as fragrance ingredients. *Food Chem. Toxicol.* **62**, S1-S44.
- Bester, K., Klasmeier, J., and Kupper, T. (2008). Emissions of OTNE (Iso-E-super) – mass flows in sewage treatment plants. *Chemosphere* **71**, 2003-2010.
- Boorman, G.A., Montgomery, C.A., Jr., Eustis, S.L., Wolfe, M.J., McConnell, E.E., and Hardisty, J.F. (1985). Quality assurance in pathology for rodent carcinogenicity studies. In *Handbook of Carcinogen Testing* (H.A. Milman and E.K. Weisburger, Eds.), pp. 345-357. Noyes Publications, Park Ridge, NJ.
- Cedarbaum, A.I. (2011). Role of CYP2E1 in ethanol-induced oxidant stress, fatty liver and hepatotoxicity. *Dig. Dis.* **28**, 802-811.
- Code of Federal Regulations (CFR) **21**, Part 58.
- Dertinger, S.D., Camphausen, K., MacGregor, J.T., Bishop, M.E., Torous, D.K., Avlasevich, S., Cairns, S., Tometsko, C.R., Menard, C., Muanza, T., Chen, Y., Miller, R.K., Cederbrant, K., Sandelin, K., Pontén, I., and Bolcsfoldi, G. (2004). Three-color labeling method for flow cytometric measurement of cytogenetic damage in rodent and human blood. *Environ. Mol. Mutagen.* **44**, 427-435.
- Dixon, W.J., and Massey, F.J., Jr. (1957). *Introduction to Statistical Analysis*, 2nd ed., pp. 276-278, 412. McGraw-Hill Book Company, Inc., New York.
- Dunn, O.J. (1964). Multiple comparisons using rank sums. *Technometrics* **6**, 241-252.
- Dunnett, C.W. (1955). A multiple comparison procedure for comparing several treatments with a control. *J. Am. Stat. Assoc.* **50**, 1096-1121.
- Erman, M., Williams, M., Whelan, P., Cárdena, C., and Atipin, M. (2001). The composition of Iso-E Super. *Perfumer Flavorist* **26**, 16-21.



European Chemicals Agency (ECHA) (2013a). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp key basic toxicokinetics.001. Study report, 2001-10-01. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-ad2f646c-2f3d-4148-bdd1-077723ea48d3\\_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-ad2f646c-2f3d-4148-bdd1-077723ea48d3](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-ad2f646c-2f3d-4148-bdd1-077723ea48d3_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-ad2f646c-2f3d-4148-bdd1-077723ea48d3)>. Last accessed on September 12, 2013.

European Chemicals Agency (ECHA) (2013b). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp key dermal absorption.001. Study report, 2001-01-04; <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-70883983-bb18-4318-a52d-f5fed32b1e10\\_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-70883983-bb18-4318-a52d-f5fed32b1e10](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-70883983-bb18-4318-a52d-f5fed32b1e10_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-70883983-bb18-4318-a52d-f5fed32b1e10)>. Last accessed on September 12, 2013.

European Chemicals Agency (ECHA) (2013c). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp key acute toxicity: oral.001. Study report, 1980-08-29. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-cbb53c2a-6567-4566-ac7c-120d3f7c8f63\\_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-cbb53c2a-6567-4566-ac7c-120d3f7c8f63](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-cbb53c2a-6567-4566-ac7c-120d3f7c8f63_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-cbb53c2a-6567-4566-ac7c-120d3f7c8f63)>. Last accessed on September 12, 2013.

European Chemicals Agency (ECHA) (2013d). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp key acute toxicity: dermal.001. Study report, 1980-08-29. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-fd7ec48a-ec1d-4378-9fa0-87f99335e98f\\_DISS-a001d05a-8c59-0cab-e044-0144f67d031.html#AGGR-fd7ec48a-ec1d-4378-9fa0-87f99335e98f](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-fd7ec48a-ec1d-4378-9fa0-87f99335e98f_DISS-a001d05a-8c59-0cab-e044-0144f67d031.html#AGGR-fd7ec48a-ec1d-4378-9fa0-87f99335e98f)>. Last accessed on September 12, 2013.

European Chemicals Agency (ECHA) (2013e). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp key repeated dose toxicity: oral.001. Study report, 1997-10-12. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-8c7e47a4-b969-4bd1-8606-02eb2f6d1f72\\_DISS-a001d05a-8c59-0cab-e04400144f67d031.html#AGGR-8c7e47a4-b969-4bd1-8606-02eb2f6d1f72](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-8c7e47a4-b969-4bd1-8606-02eb2f6d1f72_DISS-a001d05a-8c59-0cab-e04400144f67d031.html#AGGR-8c7e47a4-b969-4bd1-8606-02eb2f6d1f72)>. Last accessed on September 12, 2013.

European Chemicals Agency (ECHA) (2013f). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp key skin sensitisation.001. Study report, 2008-07-30. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-93d75f77-896b-43cb-9336-227c780478fb\\_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-93d75f77-896b-43cb-9336-227c780478fb](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-93d75f77-896b-43cb-9336-227c780478fb_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-93d75f77-896b-43cb-9336-227c780478fb)>. Last accessed on September 12, 2013.

European Chemicals Agency (ECHA) (2013g). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp NS skin sensitisation.003. Study report, 2008-07-30. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-ef39d1f0-064d-49c3-9e56-f9583df0b585\\_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-ef39d1f0-064d-49c3-9e56-f9583df0b585](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-ef39d1f0-064d-49c3-9e56-f9583df0b585_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-ef39d1f0-064d-49c3-9e56-f9583df0b585)>. Last accessed on September 12, 2013.

European Chemicals Agency (ECHA) (2013h). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp NS skin sensitisation.004. Study report, 2005-11-09. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-413b6384-5dce-40a2-a590-c6f8a066cc43\\_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-413b6384-5dce-40a2-a590-c6f8a066cc43](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-413b6384-5dce-40a2-a590-c6f8a066cc43_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-413b6384-5dce-40a2-a590-c6f8a066cc43)>. Last accessed on September 12, 2013.

European Chemicals Agency (ECHA) (2013i). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp NS skin irritation/corrosion.002. Study report, 2004-10-03. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-8053966f-162e-4bc6-8f4b-79b43a4cef90\\_DISS-a001d05a-8c59-0cab-e044-00144\\_f67d031.html#AGGR-8053966f-162e-4bc6-8f4b-79b43a4cef90](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-8053966f-162e-4bc6-8f4b-79b43a4cef90_DISS-a001d05a-8c59-0cab-e044-00144_f67d031.html#AGGR-8053966f-162e-4bc6-8f4b-79b43a4cef90)>. Last accessed on September 12, 2013.

European Chemicals Agency (ECHA) (2013j). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp NS skin sensitisation. 002. Study report, 2004-06-24. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-e895e29d-7a39-418d-a142-7f05e7f435fa\\_DISS-a001d05a-8c59-0cab-e044-00144\\_f67d031.html#AGGR-e895e29d-7a39-418d-a142-7f05e7f435fa](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-e895e29d-7a39-418d-a142-7f05e7f435fa_DISS-a001d05a-8c59-0cab-e044-00144_f67d031.html#AGGR-e895e29d-7a39-418d-a142-7f05e7f435fa)>. Last accessed on September 12, 2013.

European Chemicals Agency (ECHA) (2013k). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp key skin irritation/corrosion. 001. Study report, 2010-09-16. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-0c30a54f-3d41-4673-b1b7-4336690b0ea8\\_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-0c30a54f-3d41-4673-b1b7-4336690b0ea8](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-0c30a54f-3d41-4673-b1b7-4336690b0ea8_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-0c30a54f-3d41-4673-b1b7-4336690b0ea8)>. Last accessed on May 28, 2013.

European Chemicals Agency (ECHA) (2013l). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp supporting toxicity to reproduction: other studies.001. Study report, 2002-11-20. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-57d3ac43-af43-49f9-9738-ff58b21765c3\\_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-57d3ac43-af43-49f9-9738-ff58b21765c3](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-57d3ac43-af43-49f9-9738-ff58b21765c3_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-57d3ac43-af43-49f9-9738-ff58b21765c3)>. Last accessed on September 12, 2013.

European Chemicals Agency (ECHA) (2013m). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp key genetic toxicity in vitro.003. Study report, 1997-10-07. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-d71efec5-1810-4f2b-b765-48fa0c31e7e7\\_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-d71efec5-1810-4f2b-b765-48fa0c31e7e7](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-d71efec5-1810-4f2b-b765-48fa0c31e7e7_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-d71efec5-1810-4f2b-b765-48fa0c31e7e7)>. Last accessed on September 12, 2013.

European Chemicals Agency (ECHA) (2013n). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp key genetic toxicity in vitro.001. Study report, 1997-08-11. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-7df5870e-c2d8-46d7-8d79-08c5db840c1c\\_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-7df5870e-c2d8-46d7-8d79-08c5db840c1c](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-7df5870e-c2d8-46d7-8d79-08c5db840c1c_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-7df5870e-c2d8-46d7-8d79-08c5db840c1c)>. Last accessed on September 12, 2013.

European Chemicals Agency (ECHA) (2013o). Registered substances database: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals): Reaction Mass of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,4,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one and 1-(1,2,3,5,6,7,8,8a-octahydro-2,3,8,8-tetramethyl-2-naphthyl)ethan-1-one: Exp key genetic toxicity in vitro.002. Study report, 2010 [date not provided]. <[http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-eca5ba36-e259-4635-9223-c7d2b48cfaf7\\_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-eca5ba36-e259-4635-9223-c7d2b48cfaf7](http://apps.echa.europa.eu/registered/data/dossiers/DISS-a001d05a-8c59-0cab-e044-00144f67d031/AGGR-eca5ba36-e259-4635-9223-c7d2b48cfaf7_DISS-a001d05a-8c59-0cab-e044-00144f67d031.html#AGGR-eca5ba36-e259-4635-9223-c7d2b48cfaf7)>. Last accessed on September 12, 2013.

Fahlbusch, K.-G., Hammerschmidt, F.-J., Panten, J., Pickenhagen, W., Schatkowski, D., Bauer, K., Garbe, D., and Surburg, H. (2003). Flavors and Fragrances. In *Ullmann's Encyclopedia of Industrial Chemistry*, 7th ed., Sections 1.5.1-1.5.2. Wiley-VCH Verlag GmbH & Co., KgaA.

Frosch, P.J., Pilz, B., Andersen, K.E., Burrows, D., Camarasa, J.G., Doods-Goossens, A., Ducombs, G., Fuchs, T., Hannuksela, M., Lachapelle, J.M., Lahti, A., Maibach, H.I., Menné, T., Rycroft, R.J.G., Shaw, S., Wahlberg, J.E., White, I.R., and Wilkinson, J.D. (1995). Patch testing with fragrances: Results of a multicenter study of the European Environmental and Contact Dermatitis Research Group with 48 frequently used constituents of perfumes. *Contact Dermatitis* **33**, 333-342.

Frosch, P.J., Johansen, J.D., Menné, T., Pirker, C., Rastogi, S.C., Andersen, K.E., Bruze, M., Goossens, A., Lepoittevin, J.P., and White, I.R. (2002). Further important sensitizers in patients sensitive to fragrances. *Contact Dermatitis* **47**, 78-85.

Gart, J.J., Chu, K.C., and Tarone, R.E. (1979). Statistical issues in interpretation of chronic bioassay tests for carcinogenicity. *JNCI* **62**, 957-974.

Girard, D.M., and Sager, D.B. (1987). The use of Markov chains to detect subtle variation in reproductive cycling. *Biometrics* **43**, 225-234.

Hampton, A.L., Hish, G.A., Aslam, M.N., Rothman, E.D., Bergin, I.L., Patterson, K.A., Naik, M., Paruchuri, T., Varani, J., and Rush, H.G. (2012). Progression of ulcerative dermatitis lesions in C57BL/6CrI mice and the development of a scoring system for dermatitis lesions. *J. Am. Assoc. Lab Anim. Sci.* **51**, 586-593.

Jonckheere, A.R. (1954). A distribution-free  $k$ -sample test against ordered alternatives. *Biometrika* **41**, 133-145.

King-Herbert, A., and Thayer, K. (2006). NTP workshop: Animal models for the NTP rodent cancer bioassay: Stocks and strains-should we switch? *Toxicol. Pathol.* **34**, 802-805.

Kissling, G.E., Dertinger, S.D., Hayashi, M., and MacGregor, J.T. (2007). Sensitivity of the erythrocyte micronucleus assay: Dependence on number of cells scored and inter-animal variability. *Mutat. Res.* **634**, 235-240.

Klaschka, U., von der Ohe, P.C., Bschorer, A., Krezmer, S., Sengl, M., and Letzel, M. (2013). Occurrences and potential risks of 16 fragrances in five German sewage treatment plants and their receiving waters. *Environ. Sci. Pollut. Res. Int.* **20**, 2456-2471.

Kubwabo, C., Fan, X., Rasmussen, P.E., and Wu, F. (2012). Determination of synthetic musk compounds in indoor house dust by gas chromatography-ion trap mass spectrometry. *Anal. Bioanal. Chem.* **404**, 467-477.

Larsen, W., Nakayama, H., Fischer, T., Elsner, P., Frosch, P., Burrows, D., Jordan, W., Shaw, S., Wilkinson, J., Marks, J., Jr., Sugawara, M., Nethercott, M., and Nethercott, J. (2001). Fragrance contact dermatitis: A worldwide multicenter investigation (Part II). *Contact Dermatitis* **44**, 344-346.

MacGregor, J.T., Bishop, M.E., McNamee, J.P., Hayashi, M., Asano, N., Wakata, A., Nakajima, M., Saito J., Aidoo, A., Moore, M.M., and Dertinger, S.D. (2006). Flow cytometric analysis of micronuclei in peripheral blood reticulocytes: II. An efficient method of monitoring chromosomal damage in the rat. *Toxicol. Sci.* **94**, 92-107.

Maronpot, R.R., and Boorman, G.A. (1982). Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. *Toxicol. Pathol.* **10**, 71-80.

National Toxicology Program (NTP) (2010). NTP Report on the Assessment of Contact Hypersensitivity to Iso-E Super in Female BALB/c Mice (CASRN: 54464-57-2). Report Number IMM20702. <<http://ntp.niehs.nih.gov/?objectid=FD21FC74-C672-AC9C-5395E19CB7EB1F04>>.

Politano, V.T., Letizia, C.S., Christian, M.S., Diener, R.M., and Api, A.M. (2009). Evaluation of the developmental toxicity of 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)ethanone (OTNE) in rats. *Int. J. Toxicol.* **28**, 213-218.

Shirley, E. (1977). A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. *Biometrics* **33**, 386-389.

Scognamiglio, J., Letizia, C.S., Politano, V.T., and Api, A.M. (2013). Fragrance material review on 1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)ethanone (OTNE). *Food Chem. Toxicol.* **62**, S120-S132.

Simonich, S.L., Begley, W.M., Debaere, G., and Eckhoff, W.S. (2000). Trace analysis of fragrance materials in wastewater and treated wastewater. *Environ. Sci. Technol.* **34**, 959-965.

United States Environmental Protection Agency (USEPA) (2010a). Non-confidential 2006 IUR Records by Chemical, including Manufacturing, Processing and Use Information. CAS: 54464-57-2. <[http://cfpub.epa.gov/iursearch/2006\\_iur\\_companyinfo.cfm?chemid=3727&outchem=both](http://cfpub.epa.gov/iursearch/2006_iur_companyinfo.cfm?chemid=3727&outchem=both)>. Last accessed on September 11, 2013.

United States Environmental Protection Agency (USEPA) (2010b). Non-confidential 2006 IUR Records by Chemical, including Manufacturing, Processing and Use Information. CAS: 68155-67-9. <[http://cfpub.epa.gov/iursearch/2006\\_iur\\_companyinfo.cfm?chemid=4433&outchem=both](http://cfpub.epa.gov/iursearch/2006_iur_companyinfo.cfm?chemid=4433&outchem=both)>. Last accessed on September 11, 2013.

United States Environmental Protection Agency (USEPA) (2010c). Non-confidential 2006 IUR Records by Chemical, including Manufacturing, Processing and Use Information. CAS: 68155-66-8. <[http://cfpub.epa.gov/iursearch/2006\\_iur\\_companyinfo.cfm?chemid=4432&outchem=both](http://cfpub.epa.gov/iursearch/2006_iur_companyinfo.cfm?chemid=4432&outchem=both)>. Last accessed on September 11, 2013.

United States Environmental Protection Agency (USEPA) (2012). TSCA Work Plan for Chemical Assessments: 2012 <[http://www.epa.gov/oppt/existingchemicals/pubs/Work\\_Plan\\_Chemicals\\_Web\\_Final.pdf](http://www.epa.gov/oppt/existingchemicals/pubs/Work_Plan_Chemicals_Web_Final.pdf)>. Last accessed on March 11, 2015.

United States Environmental Protection Agency (USEPA) (2014). TSCA Work Plan for Chemical Assessments: 2014 Update: <[http://www.epa.gov/oppt/existingchemicals/pubs/TSCA\\_Work\\_Plan\\_Chemicals\\_2014\\_Update-final.pdf](http://www.epa.gov/oppt/existingchemicals/pubs/TSCA_Work_Plan_Chemicals_2014_Update-final.pdf)>. Last accessed on March 11, 2015.

Waidyanatha, S., and Ryan, K. (2014). Disposition of fragrance ingredient [ $^{14}\text{C}$ ]1-(1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethyl-2-naphthalenyl)ethanone in male Fisher rats following oral administration and dermal application. *Xenobiotica* **44**, 749-756.

Wilcoxon, F. (1945). Individual comparisons by ranking methods. *Biom. Bull.* **1**, 80-83.

Williams, D.A. (1971). A test for differences between treatment means when several dose levels are compared with a zero dose control. *Biometrics* **27**, 103-117.

Williams, D.A. (1972). The comparison of several dose levels with a zero dose control. *Biometrics* **28**, 519-531.

Williams, D.A. (1986). A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control. *Biometrics* **42**, 183-186.

Wishneff, J.E. (2012). Letter from Director, Government Affairs and Counsel, of International Fragrance Association North America to Dr. Maria Doa, regarding the response to EPA's 2012 TSCA work plan chemicals: CASRN: 54464-57-2; 54464-59-4; 68155-66-8; 68155-67-9 dated August 31, 2012. <<http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPPT-2011-0516-0020>> (click on Comment). Last accessed on September 11, 2013.

Witt, K.L., Livanos, E., Kissling, G.E., Torous, D.K., Caspary, W., Tice, R.R., and Recio, L. (2008). Comparison of flow cytometry- and microscopy-based methods for measuring micronucleated reticulocyte frequencies in rodents treated with nongenotoxic and genotoxic chemicals. *Mutat. Res.* **649**, 101-113.

Yin, J., Wang, H., Zhang, J., Zhou, N., Gao, F., Wu, Y., Xiang, J., and Shao, B. (2012). The occurrence of synthetic musks in human breast milk in Sichuan, China. *Chemosphere* **87**, 1018-1023.

Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., and Mortelmans, K. (1992). Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals. *Environ. Mol. Mutagen.* **19** (Suppl. 21), 2-141.

## **APPENDIX A**

### **SUMMARY OF LESIONS IN RATS AND MICE**

<b>TABLE A1</b>	<b>Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 3-Month Dermal Study of OTNE .....</b>	<b>A-2</b>
<b>TABLE A2</b>	<b>Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 3-Month Dermal Study of OTNE .....</b>	<b>A-4</b>
<b>TABLE A3</b>	<b>Summary of the Incidence of Neoplasms and Nonneoplastic Lesions in Male Mice in the 3-Month Dermal Study of OTNE .....</b>	<b>A-7</b>
<b>TABLE A4</b>	<b>Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 3-Month Dermal Study of OTNE .....</b>	<b>A-10</b>



TABLE A1

**Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Disposition Summary</b>							
Animals initially in study	10	10	10	10	10	10	10
Survivors							
Terminal euthanasia	10	10	10	10	10	10	10
Animals examined microscopically	10	10	10	10	10	10	10
<b>Alimentary System</b>							
Esophagus	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine large, cecum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine large, colon	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine large, rectum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine small, duodenum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine small, ileum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine small, jejunum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Liver	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Inflammation, chronic	1 (10%)						
Oral mucosa	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Pancreas	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Acinus, atrophy		1 (10%)					
Salivary glands	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Stomach, forestomach	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Stomach, glandular	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Tongue	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Cardiovascular System</b>							
Blood vessel	(10)	(10)	(0)	(0)	(0)	(0)	(9)
Heart	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Cardiomyopathy	1 (10%)	1 (10%)					1 (10%)
Infiltration cellular, histiocyte, focal							1 (10%)
Inflammation, chronic	1 (10%)						
<b>Endocrine System</b>							
Adrenal cortex	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Adrenal medulla	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Parathyroid gland	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Pituitary gland	(9)	(8)	(0)	(0)	(0)	(0)	(9)
Thyroid gland	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>General Body System</b>							
None							
<b>Genital System</b>							
Epididymis	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Preputial gland	(9)	(8)	(0)	(0)	(0)	(0)	(9)
Inflammation, chronic	2 (22%)						1 (11%)
Prostate	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Seminal vesicle	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Testes	(10)	(10)	(0)	(0)	(0)	(0)	(10)

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion

TABLE A1

## Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the 3-Month Dermal Study of OTNE

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Hematopoietic System</b>							
Bone marrow	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Lymph node	(0)	(0)	(0)	(0)	(0)	(0)	(1)
Mediastinal, hyperplasia, lymphoid, diffuse							1 (100%)
Lymph node, mandibular	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Lymph node, mesenteric	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Infiltration cellular, histiocyte	1 (10%)	1 (10%)					
Spleen	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Thymus	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Integumentary System</b>							
Mammary gland	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Skin	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Hyperplasia			1 (10%)				
Inflammation			1 (10%)				
Skin, site of application	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Hyperkeratosis			1 (10%)	3 (30%)	4 (40%)	5 (50%)	8 (80%)
Hyperplasia			2 (20%)	4 (40%)	5 (50%)	8 (80%)	10 (100%)
Inflammation							1 (10%)
<b>Musculoskeletal System</b>							
Bone	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Nervous System</b>							
Brain	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Respiratory System</b>							
Larynx	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, neutrophil	1 (10%)						
Lung	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Hemorrhage	1 (10%)						
Infiltration cellular, histiocyte							1 (10%)
Inflammation, chronic	4 (40%)	5 (50%)					5 (50%)
Interstitialium, inflammation, focal	2 (20%)	1 (10%)					
Nose	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Trachea	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Special Senses System</b>							
Eye	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Harderian gland	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Urinary System</b>							
Kidney	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Nephropathy	10 (100%)	8 (80%)	9 (90%)	10 (100%)	10 (100%)	10 (100%)	10 (100%)
Renal tubule, casts	3 (30%)		1 (10%)	1 (10%)		1 (10%)	
Urinary bladder	(10)	(10)	(0)	(0)	(0)	(0)	(10)

TABLE A2

**Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Disposition Summary</b>							
Animals initially in study	10	10	10	10	10	10	10
Survivors							
Terminal euthanasia	10	10	10	10	10	10	10
Animals examined microscopically	10	10	10	10	10	10	10
<b>Alimentary System</b>							
Esophagus	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine large, cecum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine large, colon	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine large, rectum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine small, duodenum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine small, ileum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine small, jejunum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Liver	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Inflammation, chronic	6 (60%)	5 (50%)	7 (70%)	9 (90%)	5 (50%)	5 (50%)	5 (50%)
Oral mucosa	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Pancreas	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Salivary glands	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Stomach, forestomach	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Stomach, glandular	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Tongue	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Cardiovascular System</b>							
Blood vessel	(9)	(10)	(0)	(0)	(0)	(0)	(10)
Heart	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Cardiomyopathy		1 (10%)					
<b>Endocrine System</b>							
Adrenal cortex	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Adrenal medulla	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Parathyroid gland	(9)	(10)	(0)	(0)	(0)	(0)	(10)
Pituitary gland	(7)	(4)	(0)	(0)	(0)	(0)	(10)
Pars distalis, cyst, multiple, focal	1 (14%)						
Thyroid gland	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>General Body System</b>							
None							
<b>Genital System</b>							
Clitoral gland	(9)	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, chronic		1 (10%)					
Ovary	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Uterus	(10)	(10)	(0)	(0)	(0)	(0)	(10)

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion

TABLE A2

## Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 3-Month Dermal Study of OTNE

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Hematopoietic System</b>							
Bone marrow	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Lymph node	(0)	(1)	(0)	(0)	(0)	(0)	(0)
Iliac, hyperplasia, diffuse		1 (100%)					
Lymph node, mandibular	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Lymph node, mesenteric	(9)	(10)	(0)	(0)	(0)	(0)	(10)
Infiltration cellular, histiocyte	4 (44%)	6 (60%)					5 (50%)
Spleen	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Thymus	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Integumentary System</b>							
Mammary gland	(8)	(10)	(0)	(0)	(0)	(0)	(10)
Skin	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Skin, site of application	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Hyperkeratosis				4 (40%)	5 (50%)	7 (70%)	7 (70%)
Hyperplasia			1 (10%)	5 (50%)	7 (70%)	7 (70%)	8 (80%)
Dermis, inflammation, suppurative							1 (10%)
Hair follicle, necrosis							1 (10%)
<b>Musculoskeletal System</b>							
Bone	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Nervous System</b>							
Brain	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Respiratory System</b>							
Larynx	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Lung	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Infiltration cellular, histiocyte							1 (10%)
Inflammation, chronic	2 (20%)	3 (30%)					1 (10%)
Mineralization		1 (10%)					
Interstitial, inflammation, focal	3 (30%)	1 (10%)					1 (10%)
Nose	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Trachea	(10)	(10)	(0)	(0)	(0)	(0)	(10)

TABLE A2

**Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the 3-Month Dermal Study of OTNE**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Special Senses System</b>							
Ear	(1)	(0)	(0)	(0)	(0)	(0)	(1)
Eye	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Harderian gland	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, chronic	3 (30%)	1 (10%)					3 (30%)
<b>Urinary System</b>							
Kidney	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Inflammation, chronic		2 (20%)			1 (10%)		
Mineralization		1 (10%)			2 (20%)		1 (10%)
Nephropathy	2 (20%)	1 (10%)					
Pelvis, inflammation, chronic						1 (10%)	
Urinary bladder	(9)	(9)	(0)	(0)	(0)	(0)	(10)

TABLE A3

Summary of the Incidence of Neoplasms and Nonneoplastic Lesions in Male Mice in the 3-Month Dermal Study of OTNE<sup>a</sup>

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Disposition Summary</b>							
Animals initially in study	10	10	10	10	10	10	10
Survivors							
Terminal euthanasia	10	10	10	10	10	10	10
Animals examined microscopically	10	10	10	10	10	10	10
<b>Alimentary System</b>							
Esophagus	(9)	(10)	(0)	(0)	(0)	(0)	(9)
Gallbladder	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine large, cecum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine large, colon	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine large, rectum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine small, duodenum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine small, ileum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine small, jejunum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Liver	(10)	(10)	(10)	(10)	(9)	(10)	(10)
Centrilobular, hypertrophy		1 (10%)		2 (20%)	3 (33%)		4 (40%)
Oral mucosa	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Pancreas	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Salivary glands	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Stomach, forestomach	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Stomach, glandular	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Tongue	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Cardiovascular System</b>							
Blood vessel	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Heart	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Endocrine System</b>							
Adrenal cortex	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Adrenal medulla	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Parathyroid gland	(9)	(10)	(0)	(0)	(0)	(0)	(10)
Cyst	1 (11%)	2 (20%)					
Pituitary gland	(10)	(9)	(0)	(0)	(0)	(0)	(10)
Thyroid gland	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Follicle, degeneration	1 (10%)						
<b>General Body System</b>							
None							
<b>Genital System</b>							
Epididymis	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Preputial gland	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Prostate gland	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Seminal vesicle	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Testes	(10)	(10)	(0)	(0)	(0)	(0)	(10)

TABLE A3

**Summary of the Incidence of Neoplasms and Nonneoplastic Lesions in Male Mice in the 3-Month Dermal Study of OTNE**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Hematopoietic System</b>							
Bone marrow	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Lymph node, mandibular	(9)	(10)	(0)	(0)	(0)	(0)	(9)
Lymph node, mesenteric	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Spleen	(10)	(10)	(10)	(10)	(9)	(10)	(10)
Thymus	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Integumentary System</b>							
Mammary gland	(4)	(4)	(0)	(0)	(0)	(0)	(4)
Skin	(10)	(10)	(10)	(10)	(9)	(10)	(10)
Fibrosis					1 (11%)	2 (20%)	5 (50%)
Hyperkeratosis						2 (20%)	5 (50%)
Hyperplasia				2 (20%)	4 (44%)	3 (30%)	8 (80%)
Inflammation, neutrophil							1 (10%)
Inflammation, chronic active				2 (20%)	4 (44%)	2 (20%)	8 (80%)
Epidermis, inflammation, suppurative						1 (10%)	4 (40%)
Hair follicle, hyperplasia				1 (10%)		1 (10%)	5 (50%)
Skin, site of application	(10)	(10)	(10)	(10)	(10)	(9)	(10)
Fibrosis			4 (40%)	3 (30%)	8 (80%)	8 (89%)	10 (100%)
Hyperkeratosis			2 (20%)	5 (50%)	5 (50%)	8 (89%)	10 (100%)
Hyperplasia			9 (90%)	10 (100%)	9 (90%)	9 (100%)	10 (100%)
Inflammation, chronic active			7 (70%)	10 (100%)	9 (90%)	9 (100%)	10 (100%)
Epidermis, inflammation, suppurative					1 (10%)	1 (11%)	5 (50%)
Hair follicle, hyperplasia			3 (30%)	2 (20%)	3 (30%)	7 (78%)	8 (80%)
<b>Musculoskeletal System</b>							
Bone	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Skeletal muscle	(0)	(1)	(0)	(0)	(0)	(0)	(0)
<b>Nervous System</b>							
Brain	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Granular cell tumor malignant		1 (10%)					
<b>Respiratory System</b>							
Larynx	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Lung	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Nose	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Trachea	(10)	(10)	(0)	(0)	(0)	(0)	(10)

TABLE A3

**Summary of the Incidence of Neoplasms and Nonneoplastic Lesions in Male Mice in the 3-Month Dermal Study of OTNE**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Special Senses System</b>							
Eye	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Retina, dysplasia		1 (10%)					
Retrobulbar, inflammation, neutrophil	1 (10%)						
Harderian gland	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, neutrophil		2 (20%)					1 (10%)
Inflammation, chronic							1 (10%)
<b>Urinary System</b>							
Kidney	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, chronic		1 (10%)					
Urinary bladder	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Neoplasm Summary</b>							
Animals with primary neoplasms <sup>b</sup>		1					
Total primary neoplasms		1					
Total animals with malignant neoplasms		1					
Total malignant neoplasms		1					

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion<sup>b</sup> Primary neoplasms: all neoplasms except metastatic neoplasms



TABLE A4

**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Disposition Summary</b>							
Animals initially in study	10	10	10	10	10	10	10
Survivors							
Terminal euthanasia	10	10	10	10	10	10	10
Animals examined microscopically	10	10	10	10	10	10	10
<b>Alimentary System</b>							
Esophagus	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Gallbladder	(10)	(9)	(0)	(0)	(0)	(0)	(10)
Intestine large, cecum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine large, colon	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine large, rectum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine small, duodenum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine small, ileum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Intestine small, jejunum	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Liver	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Oral mucosa	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Pancreas	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Salivary glands	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Stomach, forestomach	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Stomach, glandular	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Tongue	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Cardiovascular System</b>							
Blood vessel	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Heart	(10)	(10)	(10)	(10)	(10)	(9)	(10)
<b>Endocrine System</b>							
Adrenal cortex	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Adrenal medulla	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Parathyroid gland	(9)	(7)	(0)	(0)	(0)	(0)	(8)
Cyst							1 (13%)
Pituitary gland	(10)	(10)	(0)	(0)	(0)	(0)	(9)
Thyroid gland	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>General Body System</b>							
None							
<b>Genital System</b>							
Clitoral gland	(9)	(6)	(0)	(0)	(0)	(0)	(10)
Ovary	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Uterus	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Vagina	(10)	(10)	(0)	(0)	(0)	(0)	(10)

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion

TABLE A4

## Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 3-Month Dermal Study of OTNE

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Hematopoietic System</b>							
Bone marrow	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Lymph node	(0)	(0)	(0)	(0)	(0)	(0)	(1)
Lymph node, mandibular	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Lymph node, mesenteric	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Spleen	(10)	(10)	(10)	(10)	(10)	(8)	(10)
Thymus	(10)	(10)	(10)	(10)	(10)	(8)	(10)
Atrophy							2 (20%)
<b>Integumentary System</b>							
Mammary gland	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Skin	(10)	(10)	(10)	(10)	(10)	(8)	(10)
Fibrosis				3 (30%)			6 (60%)
Hyperkeratosis				1 (10%)			7 (70%)
Hyperplasia			4 (40%)	3 (30%)	2 (20%)	3 (38%)	10 (100%)
Inflammation, chronic active			4 (40%)	4 (40%)	2 (20%)	3 (38%)	8 (80%)
Ulcer							1 (10%)
Epidermis, inflammation, suppurative							8 (80%)
Hair follicle, hyperplasia					1 (10%)		3 (30%)
Skin, site of application	(10)	(10)	(10)	(10)	(10)	(6)	(10)
Fibrosis			2 (20%)	10 (100%)	10 (100%)	4 (67%)	9 (90%)
Hyperkeratosis			5 (50%)	5 (50%)	10 (100%)	6 (100%)	10 (100%)
Hyperplasia			10 (100%)	10 (100%)	10 (100%)	6 (100%)	10 (100%)
Inflammation, chronic active			10 (100%)	10 (100%)	10 (100%)	6 (100%)	10 (100%)
Ulcer		1 (10%)				1 (17%)	
Epidermis, inflammation, suppurative				1 (10%)	4 (40%)	4 (67%)	7 (70%)
Hair follicle, hyperplasia			3 (30%)		4 (40%)	3 (50%)	10 (100%)
<b>Musculoskeletal System</b>							
Bone	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Nervous System</b>							
Brain	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Respiratory System</b>							
Larynx	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Lung	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Nose	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Trachea	(10)	(10)	(0)	(0)	(0)	(0)	(10)

**TABLE A4**  
**Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 3-Month Dermal Study of OTNE**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Special Senses System</b>							
Eye	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Retrobulbar, inflammation, neutrophil							1 (10%)
Harderian gland	(10)	(10)	(0)	(0)	(0)	(0)	(10)
<b>Urinary System</b>							
Kidney	(10)	(10)	(0)	(0)	(0)	(0)	(10)
Nephropathy		1 (10%)					
Urinary bladder	(9)	(10)	(0)	(0)	(0)	(0)	(10)

## **APPENDIX B**

### **CLINICAL PATHOLOGY AND LIVER TOXICITY RESULTS**

<b>TABLE B1</b>	<b>Hematology and Clinical Chemistry Data for Rats in the 3-Month Dermal Study of OTNE.....</b>	<b>B-2</b>
<b>TABLE B2</b>	<b>Protein Yield and CYP2E1 Activity in the Liver of Rats in the 3-Month Dermal Study of OTNE.....</b>	<b>B-8</b>
<b>TABLE B3</b>	<b>Hematology Data for Mice in the 3-Month Dermal Study of OTNE.....</b>	<b>B-9</b>
<b>TABLE B4</b>	<b>CYP2E1 Activity in the Liver of Mice in the 3-Month Dermal Study of OTNE .....</b>	<b>B-12</b>

**TABLE B1**  
**Hematology and Clinical Chemistry Data for Rats in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Male</b>							
Hematology							
n							
Day 3	9	10	9	10	9	10	10
Day 23	10	10	9	10	10	9	10
Week 13	10	10	10	10	10	10	9
Hematocrit (auto) (%)							
Day 3	41.9 ± 0.6	41.5 ± 0.6	40.5 ± 1.5	41.7 ± 0.5	40.4 ± 1.2	40.5 ± 1.3	42.0 ± 0.3
Day 23	42.4 ± 0.6	42.1 ± 0.5	43.5 ± 0.4	42.5 ± 0.8	41.8 ± 0.7	43.2 ± 0.3	43.7 ± 0.3
Week 13	48.3 ± 0.4	48.1 ± 1.2	47.8 ± 0.4	48.0 ± 0.5	48.5 ± 0.7	47.6 ± 0.7	47.2 ± 0.5
Hematocrit (spun) (%)							
Day 3	48.3 ± 0.5	48.1 ± 0.5	49.2 ± 1.0	49.0 ± 0.6	48.3 ± 0.8	48.5 ± 0.8	49.2 ± 0.4
Day 23	50.7 ± 0.5	49.4 ± 0.5	51.4 ± 0.5*	50.4 ± 0.7	50.1 ± 0.7	51.1 ± 0.4	51.3 ± 0.5
Week 13	50.5 ± 0.6	51.2 ± 0.4	50.4 ± 0.4	50.8 ± 0.4	51.0 ± 0.4	50.7 ± 0.4	50.2 ± 0.5
Hemoglobin (g/dL)							
Day 3	13.7 ± 0.2	13.5 ± 0.2	13.3 ± 0.5	13.7 ± 0.1	13.3 ± 0.4	13.3 ± 0.4	13.8 ± 0.1
Day 23	14.2 ± 0.2	14.1 ± 0.2	14.6 ± 0.1	14.2 ± 0.3	14.1 ± 0.2	14.5 ± 0.1	14.5 ± 0.1
Week 13	16.1 ± 0.1	15.9 ± 0.4	16.0 ± 0.1	16.0 ± 0.2	16.2 ± 0.2	15.9 ± 0.2	15.8 ± 0.2
Erythrocytes (10 <sup>6</sup> /μL)							
Day 3	7.23 ± 0.09	7.08 ± 0.10	6.97 ± 0.23	7.14 ± 0.09	6.94 ± 0.19	6.95 ± 0.20	7.19 ± 0.05
Day 23	7.66 ± 0.10	7.62 ± 0.08	7.79 ± 0.08	7.51 ± 0.17	7.53 ± 0.11	7.74 ± 0.08	7.83 ± 0.07
Week 13	9.64 ± 0.08	9.66 ± 0.26	9.47 ± 0.10	9.55 ± 0.09	9.69 ± 0.13	9.49 ± 0.14	9.51 ± 0.11
Erythrocyte distribution width (%)							
Day 3	15.50 ± 0.38	15.19 ± 0.26	16.19 ± 0.32	15.49 ± 0.36	16.73 ± 0.31*	16.01 ± 0.39	15.91 ± 0.47
Day 23	13.29 ± 0.13	13.25 ± 0.19	13.03 ± 0.10	13.52 ± 0.37	13.33 ± 0.13	12.87 ± 0.08	13.50 ± 0.08
Week 13	12.83 ± 0.13	13.14 ± 0.11	12.78 ± 0.11	12.77 ± 0.14	12.99 ± 0.08	13.08 ± 0.18	13.01 ± 0.08
Reticulocytes (%)							
Day 3	3.99 ± 0.26	4.19 ± 0.24	4.02 ± 0.17	4.42 ± 0.16	4.19 ± 0.12	4.15 ± 0.40	4.58 ± 0.29
Day 23	3.48 ± 0.21	3.81 ± 0.25	2.94 ± 0.15*	3.48 ± 0.22	3.16 ± 0.11	3.47 ± 0.16	3.46 ± 0.15
Week 13	2.86 ± 0.23	2.92 ± 0.21	3.07 ± 0.18	3.02 ± 0.13	3.18 ± 0.12	3.00 ± 0.17	2.92 ± 0.10
Reticulocytes (10 <sup>3</sup> /μL)							
Day 3	288 ± 18	296 ± 16	279 ± 13	316 ± 14	291 ± 12	286 ± 26	329 ± 20
Day 23	265 ± 14	292 ± 21	230 ± 13	258 ± 11	238 ± 11	268 ± 12	271 ± 13
Week 13	276 ± 22	282 ± 21	291 ± 16	288 ± 12	308 ± 12	284 ± 15	278 ± 11
Nucleated erythrocytes (/100 leukocytes)							
Day 3	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Day 23	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Week 13	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Mean cell volume (fL)							
Day 3	58.0 ± 0.3	58.5 ± 0.2	58.0 ± 0.4	58.4 ± 0.3	58.3 ± 0.2	58.2 ± 0.3	58.3 ± 0.3
Day 23	55.3 ± 0.2	55.2 ± 0.2	55.7 ± 0.2	56.6 ± 0.6	55.6 ± 0.3	55.7 ± 0.2	55.9 ± 0.4
Week 13	50.1 ± 0.2	49.8 ± 0.1	50.5 ± 0.2	50.1 ± 0.2	50.1 ± 0.2	50.1 ± 0.3	49.7 ± 0.2
Mean cell hemoglobin (pg)							
Day 3	18.9 ± 0.1	19.1 ± 0.1	19.1 ± 0.1	19.2 ± 0.1	19.1 ± 0.1	19.1 ± 0.1	19.2 ± 0.1
Day 23	18.5 ± 0.1	18.5 ± 0.1	18.7 ± 0.1	18.8 ± 0.1	18.7 ± 0.1	18.7 ± 0.1	18.5 ± 0.1
Week 13	16.7 ± 0.1	16.5 ± 0.1	16.9 ± 0.1**	16.8 ± 0.1*	16.7 ± 0.1	16.7 ± 0.1	16.6 ± 0.1
Mean cell hemoglobin concentration (g/dL)							
Day 3	32.6 ± 0.1	32.6 ± 0.1	32.9 ± 0.2	32.7 ± 0.1	32.9 ± 0.2	32.9 ± 0.1	32.9 ± 0.1
Day 23	33.5 ± 0.1	33.6 ± 0.1	33.5 ± 0.1	33.3 ± 0.1	33.6 ± 0.1	33.6 ± 0.1	33.2 ± 0.1 <sup>†</sup>
Week 13	33.3 ± 0.1	33.1 ± 0.1	33.5 ± 0.1*	33.4 ± 0.1	33.4 ± 0.1	33.5 ± 0.1*	33.4 ± 0.0
Platelets (10 <sup>3</sup> /μL)							
Day 3	828 ± 23	806 ± 17	849 ± 46	830 ± 12	843 ± 28	831 ± 15	813 ± 25
Day 23	748 ± 14	764 ± 15	756 ± 12	782 ± 39	786 ± 46	773 ± 20	791 ± 15 <sup>†</sup>
Week 13	632 ± 17	632 ± 25	602 ± 13	610 ± 21	664 ± 12	659 ± 14	715 ± 18 <sup>††</sup>

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
Male (continued)							
Hematology (continued)							
n							
Day 3	9	10	9	10	9	10	10
Day 23	10	10	9	10	10	9	10
Week 13	10	10	10	10	10	10	9
Mean platelet volume (fL)							
Day 3	6.811 ± 0.070	6.710 ± 0.098	7.267 ± 0.365	6.850 ± 0.105	7.111 ± 0.063*	6.920 ± 0.107	7.040 ± 0.120
Day 23	6.290 ± 0.081	6.240 ± 0.070	6.244 ± 0.112	6.250 ± 0.090	6.420 ± 0.073	6.622 ± 0.213	6.440 ± 0.088
Week 13	6.310 ± 0.050	6.440 ± 0.065	6.290 ± 0.043	6.520 ± 0.077	6.460 ± 0.064	6.460 ± 0.052	6.589 ± 0.101†
Leukocytes (10 <sup>3</sup> /μL)							
Day 3	9.16 ± 0.60	8.88 ± 0.40	8.81 ± 0.43	10.29 ± 0.36*	8.28 ± 0.68	8.88 ± 0.40	8.98 ± 0.31
Day 23	10.49 ± 0.47	10.39 ± 0.41	10.81 ± 0.41	11.64 ± 1.12	10.35 ± 0.34	10.00 ± 0.32	10.89 ± 0.35
Week 13	9.55 ± 0.46	10.13 ± 0.45	9.26 ± 0.71	9.80 ± 0.48	9.38 ± 0.37	9.96 ± 0.33	10.98 ± 0.38†
Segmented neutrophils (10 <sup>3</sup> /μL)							
Day 3	1.71 ± 0.15	1.80 ± 0.09	1.46 ± 0.12	2.02 ± 0.11	1.57 ± 0.17	1.69 ± 0.12	1.66 ± 0.11
Day 23	2.57 ± 0.12	2.47 ± 0.17	2.46 ± 0.15	3.08 ± 0.64	2.42 ± 0.13	2.12 ± 0.15	2.73 ± 0.14
Week 13	2.44 ± 0.20	2.57 ± 0.19	2.42 ± 0.18	2.60 ± 0.12	2.42 ± 0.15	2.84 ± 0.15	2.95 ± 0.16
Bands (10 <sup>3</sup> /μL)							
Day 3	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Day 23	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Week 13	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Metamyelocytes (10 <sup>3</sup> /μL)							
Day 3	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Day 23	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Week 13	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Myelocytes (10 <sup>3</sup> /μL)							
Day 3	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Day 23	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Week 13	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Lymphocytes (10 <sup>3</sup> /μL)							
Day 3	7.03 ± 0.42	6.69 ± 0.34	7.00 ± 0.40	7.78 ± 0.24	6.35 ± 0.52	6.75 ± 0.29	6.96 ± 0.22
Day 23	7.43 ± 0.35	7.47 ± 0.23	7.85 ± 0.24	8.00 ± 0.52	7.41 ± 0.43	7.46 ± 0.18	7.60 ± 0.25
Week 13	6.61 ± 0.30	7.05 ± 0.36	6.37 ± 0.54	6.73 ± 0.42	6.48 ± 0.26	6.61 ± 0.37	7.37 ± 0.29
Atypical lymphocytes (10 <sup>3</sup> /μL)							
Day 3	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Day 23	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Week 13	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Monocytes (10 <sup>3</sup> /μL)							
Day 3	0.22 ± 0.03	0.21 ± 0.01	0.19 ± 0.03	0.27 ± 0.02	0.20 ± 0.03	0.20 ± 0.02	0.20 ± 0.01
Day 23	0.23 ± 0.02	0.20 ± 0.02	0.24 ± 0.02	0.28 ± 0.06	0.27 ± 0.05	0.17 ± 0.01	0.26 ± 0.02
Week 13	0.24 ± 0.04	0.25 ± 0.03	0.22 ± 0.02	0.23 ± 0.02	0.24 ± 0.03	0.26 ± 0.02	0.32 ± 0.04

**TABLE B1**  
**Hematology and Clinical Chemistry Data for Rats in the 3-Month Dermal Study of OTNE**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Male</b> (continued)							
Clinical Chemistry							
n	10	10	10	10	10	10	10
Urea nitrogen (mg/dL)							
Day 3	13.6 ± 1.1	12.9 ± 0.4	14.2 ± 0.7	13.8 ± 0.7	12.9 ± 0.7	12.7 ± 0.4	12.0 ± 0.4
Day 23	14.3 ± 0.7	15.2 ± 0.7	14.0 ± 0.8	14.8 ± 0.6	13.9 ± 0.7	14.8 ± 0.5	14.7 ± 0.4
Week 13	18.9 ± 0.6	18.9 ± 0.4	18.0 ± 0.5	19.9 ± 0.6	19.4 ± 0.6	19.0 ± 0.6	19.2 ± 0.4
Creatinine (mg/dL)							
Day 3	0.58 ± 0.01	0.59 ± 0.01	0.60 ± 0.00	0.60 ± 0.01	0.57 ± 0.02	0.60 ± 0.00	0.60 ± 0.00
Day 23	0.62 ± 0.01	0.62 ± 0.01	0.61 ± 0.01	0.60 ± 0.01	0.62 ± 0.01	0.65 ± 0.02	0.66 ± 0.02
Week 13	0.71 ± 0.01	0.72 ± 0.01	0.74 ± 0.02	0.74 ± 0.02	0.78 ± 0.01**	0.79 ± 0.02**	0.82 ± 0.01 <sup>††</sup>
Total protein (g/dL)							
Day 3	5.8 ± 0.1	5.6 ± 0.1	5.8 ± 0.1	5.7 ± 0.1	5.7 ± 0.1	5.6 ± 0.1	5.6 ± 0.1 <sup>†</sup>
Day 23	6.1 ± 0.1	6.2 ± 0.1	6.2 ± 0.1	6.2 ± 0.1	6.1 ± 0.1	6.2 ± 0.1	6.3 ± 0.1
Week 13	7.7 ± 0.1	7.7 ± 0.1	7.6 ± 0.1	7.6 ± 0.1	7.8 ± 0.1	7.7 ± 0.1	7.8 ± 0.1
Albumin (g/dL)							
Day 3	3.6 ± 0.0	3.5 ± 0.0	3.6 ± 0.0	3.6 ± 0.0	3.5 ± 0.0	3.5 ± 0.0	3.5 ± 0.0 <sup>†</sup>
Day 23	3.7 ± 0.0	3.7 ± 0.0	3.7 ± 0.0	3.6 ± 0.1	3.7 ± 0.0	3.7 ± 0.0	3.7 ± 0.0
Week 13	4.1 ± 0.0	4.1 ± 0.0	4.0 ± 0.0	4.1 ± 0.0	4.1 ± 0.0	4.1 ± 0.1	4.1 ± 0.0
Alanine aminotransferase (IU/L)							
Day 3	81 ± 2	80 ± 3	78 ± 3	79 ± 2	77 ± 2	80 ± 2	81 ± 2
Day 23	54 ± 1	62 ± 4	56 ± 2	54 ± 1	123 ± 71*	51 ± 1**	52 ± 2
Week 13	88 ± 4	91 ± 8	69 ± 2**	80 ± 4*	67 ± 2**	61 ± 2**	54 ± 1 <sup>††</sup>
Alkaline phosphatase (IU/L)							
Day 3	710 ± 7	695 ± 12	694 ± 13	697 ± 16	675 ± 11	700 ± 13	663 ± 9 <sup>††</sup>
Day 23	564 ± 13	525 ± 11	529 ± 11	515 ± 19	475 ± 23	475 ± 11*	477 ± 9 <sup>††</sup>
Week 13	349 ± 9	373 ± 10	326 ± 11*	346 ± 11*	322 ± 7**	270 ± 19**	268 ± 5 <sup>††</sup>
Creatine kinase (IU/L)							
Day 3	953 ± 88	916 ± 83	905 ± 95	907 ± 70	992 ± 114	733 ± 44	748 ± 68
Day 23	772 ± 123	526 ± 89 <sup>b</sup>	964 ± 372	587 ± 78	597 ± 80	825 ± 137	650 ± 87
Week 13	224 ± 26	261 ± 34	346 ± 48	228 ± 18	282 ± 43	281 ± 48	336 ± 56
Sorbitol dehydrogenase (IU/L)							
Day 3	28 ± 2	34 ± 4	37 ± 3	36 ± 4	29 ± 4	34 ± 4	32 ± 5
Day 23	32 ± 4	35 ± 4	37 ± 4	31 ± 4	57 ± 20	29 ± 4	33 ± 5
Week 13	56 ± 3	52 ± 3	44 ± 2	53 ± 2	52 ± 2	50 ± 3	45 ± 4 <sup>†</sup>
Bile acids (μmol/L)							
Day 3	57.0 ± 5.8	51.2 ± 6.7	39.9 ± 5.3	50.2 ± 6.8	51.3 ± 6.8	48.4 ± 6.8	48.6 ± 7.5
Day 23	51.6 ± 5.1	55.6 ± 4.5	56.2 ± 3.3	53.2 ± 3.9	43.6 ± 3.2*	44.0 ± 3.7*	47.1 ± 4.1
Week 13	8.2 ± 0.9	10.5 ± 1.9	8.0 ± 0.8	8.5 ± 1.7	5.8 ± 0.9**	5.7 ± 0.7**	8.2 ± 1.1

**TABLE B1**  
**Hematology and Clinical Chemistry Data for Rats in the 3-Month Dermal Study of OTNE**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Female</b>							
Hematology							
n							
Day 3	10	10	10	10	10	10	10
Day 23	9	9	9	9	9	10	9
Week 13	10	10	10	10	10	10	10
Hematocrit (auto) (%)							
Day 3	42.7±0.4	42.6±0.8	42.3±0.9	42.0±0.6	42.0±0.5	42.3±0.6	41.2±0.6
Day 23	43.9±0.9	43.0±0.6	43.4±0.4	44.7±0.5	44.1±0.6	43.4±0.4	44.0±0.6
Week 13	44.3±0.6	45.4±0.5	46.3±1.4	45.0±0.6	43.8±0.4	43.9±0.5	42.5±0.4 <sup>†</sup>
Hematocrit (spun) (%)							
Day 3	49.4±0.4	49.1±0.8	49.3±0.9	48.9±0.6	49.0±0.6	49.6±0.8	48.4±0.6
Day 23	53.3±1.2	52.4±0.8	53.4±1.2	53.7±0.8	54.2±1.2	52.5±0.9	54.9±1.3
Week 13	48.4±10.6	49.4±0.3	48.2±0.4	49.1±0.5	48.5±0.3	48.0±0.5	46.7±10.5 <sup>†</sup>
Hemoglobin (g/dL)							
Day 3	14.6±0.1	14.5±0.3	14.6±0.3	14.5±0.2	14.5±0.2	14.7±0.2	14.3±0.2
Day 23	15.4±0.3	15.2±0.2	15.3±0.1	15.6±0.2	15.5±0.2	15.2±0.2	15.4±0.2
Week 13	15.3±0.2	15.6±0.2	15.9±0.4	15.4±0.2	15.1±0.1	15.2±0.1	14.7±0.1 <sup>†</sup>
Erythrocytes (10 <sup>6</sup> /μL)							
Day 3	7.69±0.08	7.63±0.14	7.68±0.16	7.59±0.10	7.53±0.09	7.62±0.12	7.40±0.11
Day 23	8.13±0.18	8.01±0.12	8.03±0.08	8.20±0.09	8.14±0.10	8.02±0.08	8.06±0.11
Week 13	8.38±0.12	8.59±0.12	8.73±0.23	8.53±0.11	8.35±0.09	8.33±0.09	8.01±0.08 <sup>†</sup>
Erythrocyte distribution width (%)							
Day 3	14.35±0.34	14.26±0.19	14.25±0.26	14.45±0.26	14.23±0.28	14.30±0.37	13.96±0.24
Day 23	12.08±0.22	12.08±0.11	12.36±0.14	12.26±0.12	12.00±0.11	12.14±0.08	12.22±0.12
Week 13	11.16±0.10	11.17±0.06	11.40±0.19	11.21±0.08	11.28±0.11	11.11±0.13	11.10±0.10
Reticulocytes (%)							
Day 3	3.86±0.31	3.86±0.21	3.77±0.22	3.71±0.20	3.97±0.19	4.08±0.33	3.66±0.17
Day 23	2.87±0.17	3.11±0.10	2.82±0.11	2.52±0.09**	2.90±0.13	3.03±0.19	3.12±0.22
Week 13	2.98±0.12	2.89±0.10	2.63±0.19	3.22±0.14	3.14±0.14	3.04±0.18	3.23±0.18
Reticulocytes (10 <sup>3</sup> /μL)							
Day 3	295±21	295±18	290±20	281±14	299±15	312±27	271±13
Day 23	233±15	249±9	226±10	207±8*	235±11	242±14	252±20
Week 13	250±10	249±10	230±19	274±10	262±12	253±15	259±14
Nucleated erythrocytes (/100 leukocytes)							
Day 3	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0
Day 23	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0
Week 13	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0
Mean cell volume (fL)							
Day 3	55.4±0.2	55.8±0.1	55.2±0.2	55.4±0.2	55.8±0.2	55.6±0.3	55.6±0.3
Day 23	54.1±0.2	53.7±0.2	53.9±0.2	54.4±0.3	54.2±0.2	54.2±0.2	54.4±0.3
Week 13	52.8±0.1	52.9±0.2	53.1±0.3	52.7±0.2	52.4±0.2	52.9±0.2	53.0±0.2
Mean cell hemoglobin (pg)							
Day 3	19.0±0.1	19.0±0.1	19.0±0.1	19.1±0.1	19.3±0.1**	19.3±0.1*	19.3±0.1 <sup>†</sup>
Day 23	19.0±0.1	19.0±0.1	19.1±0.1	19.0±0.1	19.0±0.1	19.0±0.1	19.1±0.2
Week 13	18.2±0.1	18.1±0.1	18.2±0.1	18.1±0.1	18.1±0.1	18.2±0.1	18.3±0.1
Mean cell hemoglobin concentration (g/dL)							
Day 3	34.3±0.2	34.0±0.1	34.5±0.1**	34.4±0.1*	34.5±0.1*	34.7±0.1**	34.7±0.2
Day 23	35.2±0.1	35.2±0.1	35.3±0.1	34.9±0.1	35.1±0.1	35.0±0.1	35.1±0.2
Week 13	34.4±0.1	34.3±0.1	34.3±0.2	34.3±0.1	34.4±0.1	34.5±0.1	34.6±0.1
Platelets (10 <sup>3</sup> /μL)							
Day 3	767±21	759±22	784±17	726±21	723±15	745±19	733±19
Day 23	694±12	682±23	699±15	688±20	684±16	688±20	708±22
Week 13	678±58	612±17	602±18	621±9	620±8	669±21	664±15



**TABLE B1**  
**Hematology and Clinical Chemistry Data for Rats in the 3-Month Dermal Study of OTNE**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Female (continued)</b>							
Hematology (continued)							
n							
Day 3	10	10	10	10	10	10	10
Day 23	9	9	9	9	9	10	9
Week 13	10	10	10	10	10	10	10
Mean platelet volume (fL)							
Day 3	6.500 ± 0.065	6.490 ± 0.059	6.470 ± 0.073	6.420 ± 0.025	6.350 ± 0.031	6.450 ± 0.064	6.490 ± 0.098
Day 23	6.389 ± 0.123	6.256 ± 0.091	6.378 ± 0.080	6.233 ± 0.053	6.333 ± 0.075	6.330 ± 0.062	6.467 ± 0.188
Week 13	6.290 ± 0.064	6.290 ± 0.038	6.350 ± 0.081	6.420 ± 0.065	6.400 ± 0.077	6.380 ± 0.089	6.290 ± 0.086
Leukocytes (10 <sup>3</sup> /μL)							
Day 3	10.14 ± 0.30	9.59 ± 0.33	9.53 ± 0.57	9.41 ± 0.33	9.85 ± 0.51	10.27 ± 0.44	9.59 ± 0.51
Day 23	10.64 ± 0.92	10.59 ± 0.41	10.74 ± 0.26	10.79 ± 0.43	10.52 ± 0.70	10.19 ± 0.39	9.82 ± 0.47
Week 13	9.18 ± 0.72	9.13 ± 0.61	7.92 ± 0.47	8.46 ± 0.43	8.89 ± 0.30	8.51 ± 0.43	8.93 ± 0.63
Segmented neutrophils (10 <sup>3</sup> /μL)							
Day 3	2.05 ± 0.05	2.02 ± 0.10	2.00 ± 0.22	2.02 ± 0.07	2.09 ± 0.16	2.15 ± 0.1	2.07 ± 0.17
Day 23	2.42 ± 0.20	2.30 ± 0.08	2.53 ± 0.10	2.48 ± 0.07	2.42 ± 0.11	2.42 ± 0.11	2.38 ± 0.16
Week 13	2.38 ± 0.21	2.49 ± 0.25	2.36 ± 0.27	2.30 ± 0.19	2.50 ± 0.25	2.34 ± 0.09	2.63 ± 0.25
Bands (10 <sup>3</sup> /μL)							
Day 3	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Day 23	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Week 13	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Metamyelocytes (10 <sup>3</sup> /μL)							
Day 3	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Day 23	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Week 13	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Myelocytes (10 <sup>3</sup> /μL)							
Day 3	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Day 23	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Week 13	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Lymphocytes (10 <sup>3</sup> /μL)							
Day 3	7.55 ± 0.27	7.07 ± 0.24	7.10 ± 0.36	6.90 ± 0.25	7.25 ± 0.33	7.58 ± 0.34	7.08 ± 0.37
Day 23	7.68 ± 0.68	7.81 ± 0.31	7.75 ± 0.21	7.82 ± 0.33	7.59 ± 0.56	7.31 ± 0.29	6.99 ± 0.30
Week 13	6.39 ± 0.51	6.16 ± 0.35	5.17 ± 0.21	5.76 ± 0.29	5.96 ± 0.15	5.77 ± 0.33	5.84 ± 0.35
Atypical lymphocytes (10 <sup>3</sup> /μL)							
Day 3	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Day 23	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Week 13	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Monocytes (10 <sup>3</sup> /μL)							
Day 3	0.26 ± 0.01	0.26 ± 0.02	0.19 ± 0.02	0.22 ± 0.02	0.24 ± 0.03	0.24 ± 0.03	0.20 ± 0.03 <sup>†</sup>
Day 23	0.23 ± 0.04	0.21 ± 0.02	0.19 ± 0.01	0.22 ± 0.03	0.22 ± 0.02	0.21 ± 0.01	0.21 ± 0.02
Week 13	0.20 ± 0.03	0.22 ± 0.04	0.17 ± 0.02	0.19 ± 0.02	0.19 ± 0.02	0.18 ± 0.02	0.22 ± 0.04
Basophils (10 <sup>3</sup> /μL)							
Day 3	0.229 ± 0.011	0.202 ± 0.012	0.186 ± 0.018	0.215 ± 0.020	0.220 ± 0.014	0.236 ± 0.023	0.185 ± 0.019
Day 23	0.221 ± 0.036	0.192 ± 0.017	0.181 ± 0.011	0.186 ± 0.018	0.198 ± 0.023	0.189 ± 0.016	0.174 ± 0.021
Week 13	0.153 ± 0.023	0.183 ± 0.028	0.145 ± 0.022	0.153 ± 0.015	0.166 ± 0.023	0.149 ± 0.016	0.170 ± 0.024
Eosinophils (10 <sup>3</sup> /μL)							
Day 3	0.05 ± 0.01	0.04 ± 0.00	0.06 ± 0.01	0.05 ± 0.01	0.06 ± 0.01	0.07 ± 0.01	0.06 ± 0.01
Day 23	0.09 ± 0.01	0.08 ± 0.01	0.09 ± 0.01	0.08 ± 0.01	0.09 ± 0.01	0.08 ± 0.01	0.08 ± 0.01
Week 13	0.07 ± 0.01	0.08 ± 0.01	0.07 ± 0.01	0.06 ± 0.01	0.07 ± 0.01	0.06 ± 0.01	0.07 ± 0.01

**TABLE B1**  
**Hematology and Clinical Chemistry Data for Rats in the 3-Month Dermal Study of OTNE**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Female (continued)</b>							
Clinical Chemistry							
n	10	10	10	10	10	10	10
Urea nitrogen (mg/dL)							
Day 3	14.1 ± 0.6	13.6 ± 0.8	15.2 ± 0.9	15.2 ± 0.7	13.6 ± 0.5	14.0 ± 0.6	13.8 ± 0.7
Day 23	17.8 ± 0.9	17.8 ± 1.1	18.4 ± 0.9	18.3 ± 0.8	18.3 ± 0.6	18.4 ± 0.7	17.3 ± 0.5
Week 13	20.4 ± 0.6	21.1 ± 0.6	22.0 ± 0.6	22.7 ± 0.7	21.1 ± 1.0	21.2 ± 1.1	20.6 ± 1.0
Creatinine (mg/dL)							
Day 3	0.60 ± 0.00	0.59 ± 0.01	0.61 ± 0.02	0.59 ± 0.01	0.60 ± 0.00	0.61 ± 0.01	0.61 ± 0.01
Day 23	0.64 ± 0.02	0.63 ± 0.02	0.62 ± 0.01	0.65 ± 0.02	0.64 ± 0.02	0.65 ± 0.02	0.66 ± 0.02
Week 13	0.72 ± 0.01	0.66 ± 0.02	0.69 ± 0.02	0.68 ± 0.06	0.68 ± 0.01	0.68 ± 0.01	0.71 ± 0.02
Total protein (g/dL)							
Day 3	5.6 ± 0.1	5.5 ± 0.2	5.6 ± 0.2	5.4 ± 0.1	5.5 ± 0.0	5.6 ± 0.1	5.4 ± 0.1 <sup>†</sup>
Day 23	6.3 ± 0.1	6.3 ± 0.1	6.2 ± 0.1	6.3 ± 0.1	6.4 ± 0.1	6.3 ± 0.1	6.4 ± 0.1
Week 13	7.2 ± 0.1	7.1 ± 0.1	7.2 ± 0.1	7.6 ± 0.1*	7.3 ± 0.1	7.3 ± 0.1	7.4 ± 0.1
Albumin (g/dL)							
Day 3	3.6 ± 0.0	3.6 ± 0.1	3.6 ± 0.1	3.6 ± 0.0	3.6 ± 0.0	3.6 ± 0.1	3.5 ± 0.1
Day 23	3.9 ± 0.1	3.8 ± 0.0	3.8 ± 0.0	3.9 ± 0.1	3.9 ± 0.1	3.8 ± 0.1	3.8 ± 0.0
Week 13	4.0 ± 0.1	4.0 ± 0.1	4.1 ± 0.1	4.0 ± 0.2	4.0 ± 0.1	4.0 ± 0.1	4.0 ± 0.1
Alanine aminotransferase (IU/L)							
Day 3	69 ± 2	62 ± 2	62 ± 3	65 ± 2	67 ± 1	67 ± 1	68 ± 2
Day 23	52 ± 1	49 ± 1	49 ± 1	50 ± 2	50 ± 2	52 ± 2	50 ± 2
Week 13	70 ± 2	74 ± 4	71 ± 3	65 ± 2	58 ± 2**	55 ± 3**	50 ± 1 <sup>††</sup>
Alkaline phosphatase (IU/L)							
Day 3	679 ± 17	626 ± 17	628 ± 12	650 ± 11	640 ± 14	642 ± 13	576 ± 16 <sup>††</sup>
Day 23	471 ± 9	462 ± 11	479 ± 12	471 ± 9	446 ± 15	438 ± 11	395 ± 7 <sup>††</sup>
Week 13	350 ± 13	360 ± 13	334 ± 28	367 ± 13	344 ± 13	282 ± 7**	259 ± 10 <sup>††</sup>
Creatine kinase (IU/L)							
Day 3	661 ± 43	633 ± 65	876 ± 56*	676 ± 53	541 ± 45	729 ± 46	666 ± 80
Day 23	723 ± 181	733 ± 75	984 ± 148	556 ± 114	862 ± 110	928 ± 141	806 ± 163
Week 13	326 ± 63	325 ± 29	257 ± 38	250 ± 30	326 ± 58	277 ± 32	244 ± 41
Sorbitol dehydrogenase (IU/L)							
Day 3	41 ± 3	40 ± 3	33 ± 4	40 ± 4	46 ± 3	42 ± 3	40 ± 4
Day 23	41 ± 4	38 ± 3	31 ± 4	49 ± 6	36 ± 5	36 ± 6	39 ± 5
Week 13	56 ± 5	49 ± 5	52 ± 5	58 ± 3	47 ± 3	49 ± 5	46 ± 4
Bile acids (μmol/L)							
Day 3	24.6 ± 1.9	33.4 ± 4.4	30.3 ± 2.9	28.0 ± 4.7	27.4 ± 3.9	26.7 ± 3.9	23.3 ± 5.2
Day 23	34.8 ± 4.4	31.3 ± 5.2	38.1 ± 4.9	33.8 ± 4.1	29.8 ± 3.2	34.0 ± 1.9	30.1 ± 1.6
Week 13	24.8 ± 4.2	21.7 ± 3.0	26.7 ± 4.6	19.0 ± 2.0	18.3 ± 1.5	14.5 ± 1.0	14.7 ± 0.8 <sup>†</sup>

\* Significantly different (P≤0.05) from the vehicle control group by Dunn's or Shirley's test

\*\* P≤0.01

† Significantly different (P≤0.05) from the untreated control group by Wilcoxon's rank sum test

†† P≤0.01

<sup>a</sup> Data are presented as mean ± standard error. Statistical tests were performed on unrounded data. Statistical comparisons between the two control groups are not presented.

<sup>b</sup> n = 9

**TABLE B2**  
**Protein Yield and CYP2E1 Activity in the Liver of Rats in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
n	5	5	5	5	5	5	5
<b>Male</b>							
Total microsomal protein (mg/kg liver)							
Day 23	13.28 ± 1.62	10.81 ± 0.76	13.69 ± 1.72	11.74 ± 1.09	15.08 ± 1.11*	18.10 ± 0.93**	18.82 ± 2.32
Week 13	10.004 ± 0.370	13.51 ± 1.818	14.200 ± 1.243	13.414 ± 1.138	12.300 ± 0.628	10.938 ± 1.044 <sup>b</sup>	11.338 ± 0.819
CYP2E1 liver activity (nmol/minute per mg protein)							
Day 23	0.443 ± 0.035	0.403 ± 0.058	0.437 ± 0.024	0.446 ± 0.047	0.454 ± 0.026	0.432 ± 0.029	0.414 ± 0.017
Week 13	0.472 ± 0.022	0.419 ± 0.030	0.497 ± 0.032	0.452 ± 0.011	0.414 ± 0.026	0.527 ± 0.086	0.555 ± 0.819
<b>Female</b>							
Total microsomal protein (mg/kg liver)							
Day 23	13.20 ± 1.54	15.70 ± 0.74	11.64 ± 0.47*	14.96 ± 1.15	15.46 ± 1.28	15.56 ± 0.54	16.42 ± 1.34
Week 13	7.686 ± 0.657	7.412 ± 0.610	8.342 ± 0.509	9.344 ± 0.169*	10.496 ± 0.849**	13.280 ± 0.684**	12.100 ± 0.536 <sup>††</sup>
CYP2E1 liver activity (nmol/minute per mg protein)							
Day 23	0.227 ± 0.020	0.216 ± 0.034	0.232 ± 0.018	0.270 ± 0.032	0.247 ± 0.053	0.225 ± 0.026	0.286 ± 0.027
Week 13	0.528 ± 0.097	0.336 ± 0.022	0.336 ± 0.021	0.365 ± 0.018	0.362 ± 0.020	0.370 ± 0.030	0.470 ± 0.050

\* Significantly different (P≤0.05) from the vehicle control group by Dunn's or Shirley's test

\*\* P≤0.01

†† Significantly different (P≤0.01) from the untreated control group by Wilcoxon's rank sum test

<sup>a</sup> Data are presented as mean ± standard error. Statistical comparisons between the two control groups are not presented.

<sup>b</sup> n = 4

**TABLE B3**  
**Hematology Data for Mice in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Male</b>							
n	10	10	10	10	10	10	10
Hematocrit (auto) (%)	52.3 ± 0.9	53.3 ± 0.7	52.0 ± 1.3	51.2 ± 0.9	48.7 ± 0.8**	49.1 ± 0.8**	45.7 ± 0.8††
Hematocrit (spun) (%)	52.9 ± 1.0	54.5 ± 0.7	53.7 ± 1.4	51.8 ± 0.7*	49.7 ± 1.1**	51.3 ± 0.9**	47.6 ± 1.1††
Hemoglobin (g/dL)	16.7 ± 0.4	17.0 ± 0.2	16.7 ± 0.4	16.5 ± 0.3	15.7 ± 0.3**	16.0 ± 0.2**	15.0 ± 0.3††
Erythrocytes (10 <sup>6</sup> /μL)	10.76 ± 0.22	10.84 ± 0.13	10.56 ± 0.24	10.45 ± 0.17	9.94 ± 0.16**	9.98 ± 0.16**	9.26 ± 0.13††
Erythrocyte distribution width (%)	12.63 ± 0.18	12.17 ± 0.07	12.53 ± 0.11	12.34 ± 0.11	12.67 ± 0.13**	12.92 ± 0.15**	13.42 ± 0.12††
Reticulocytes (%)	3.030 ± 0.141	3.37 ± 0.12	3.27 ± 0.16	2.90 ± 0.18	3.10 ± 0.25	3.06 ± 0.14	3.100 ± 0.190
Reticulocytes (10 <sup>3</sup> /μL)	325 ± 15	366 ± 16	346 ± 19	305 ± 23	308 ± 26	304 ± 11	287 ± 19
Nucleated erythrocytes (/100 leukocytes)	0.0 ± 0.0	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.0 ± 0.0
Mean cell volume (fL)	48.6 ± 0.3	49.2 ± 0.2	49.2 ± 0.2	48.9 ± 0.2	48.9 ± 0.1	49.2 ± 0.2	49.3 ± 0.3
Mean cell hemoglobin (pg)	15.5 ± 0.1	15.7 ± 0.0	15.8 ± 0.1	15.8 ± 0.1	15.8 ± 0.0	16.0 ± 0.0**	16.2 ± 0.1††
Mean cell hemoglobin concentration (g/dL)	31.9 ± 0.2	31.9 ± 0.1	32.1 ± 0.1	32.2 ± 0.2	32.2 ± 0.1*	32.5 ± 0.1**	32.7 ± 0.1††
Platelets (10 <sup>3</sup> /μL)	688 ± 21	666 ± 23	620 ± 31	663 ± 26	716 ± 31	747 ± 16*	843 ± 37††
Mean platelet volume (fL)	5.490 ± 0.120	5.490 ± 0.041	5.360 ± 0.108	5.460 ± 0.064	5.570 ± 0.122	5.540 ± 0.070	5.410 ± 0.043
Leukocytes (10 <sup>3</sup> /μL)	5.48 ± 0.59	6.22 ± 0.43	5.47 ± 0.50	5.96 ± 0.66	5.30 ± 0.59	6.51 ± 0.54	5.78 ± 0.62
Segmented neutrophils (10 <sup>3</sup> /μL)	1.23 ± 0.14	1.45 ± 0.10	1.29 ± 0.14	1.47 ± 0.17	1.22 ± 0.13	1.71 ± 0.21	1.87 ± 0.33
Bands (10 <sup>3</sup> /μL)	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Metamyelocytes (10 <sup>3</sup> /μL)	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Myelocytes (10 <sup>3</sup> /μL)	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Lymphocytes (10 <sup>3</sup> /μL)	4.19 ± 0.47	4.71 ± 0.33	4.13 ± 0.36	4.43 ± 0.49	4.01 ± 0.47	4.72 ± 0.42	3.83 ± 0.36
Atypical lymphocytes (10 <sup>3</sup> /μL)	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Monocytes (10 <sup>3</sup> /μL)	0.04 ± 0.01	0.04 ± 0.00	0.04 ± 0.01	0.05 ± 0.01	0.05 ± 0.01	0.06 ± 0.01*	0.06 ± 0.01
Basophils (10 <sup>3</sup> /μL)	0.007 ± 0.002	0.008 ± 0.001	0.003 ± 0.002	0.004 ± 0.002	0.004 ± 0.002	0.005 ± 0.002	0.008 ± 0.001
Eosinophils (10 <sup>3</sup> /μL)	0.01 ± 0.00	0.02 ± 0.00	0.01 ± 0.00	0.02 ± 0.01	0.02 ± 0.00	0.02 ± 0.01	0.01 ± 0.00

**TABLE B3**  
**Hematology Data for Mice in the 3-Month Dermal Study of OTNE**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Female</b>							
n	10	10	10	10	10	10	10
Hematocrit (auto) (%)	50.4 ± 2.2	48.7 ± 1.9	48.0 ± 1.5	49.7 ± 1.2	49.3 ± 0.4	46.4 ± 0.7	43.6 ± 1.1 <sup>†</sup>
Hematocrit (spun) (%)	54.9 ± 1.3	52.2 ± 1.0	51.3 ± 0.4	51.5 ± 1.2	51.0 ± 0.6	48.1 ± 0.5**	46.9 ± 0.7 <sup>††</sup>
Hemoglobin (g/dL)	16.5 ± 0.7	15.9 ± 0.6	15.9 ± 0.5	16.3 ± 0.4	16.3 ± 0.2	15.4 ± 0.2	14.6 ± 0.4 <sup>†</sup>
Erythrocytes (10 <sup>6</sup> /μL)	10.42 ± 0.45	10.04 ± 0.36	9.93 ± 0.29	10.13 ± 0.22	10.16 ± 0.11	9.48 ± 0.10	8.93 ± 0.22 <sup>††</sup>
Erythrocyte distribution width (%)	12.21 ± 0.14	12.24 ± 0.08	12.61 ± 0.09*	12.65 ± 0.11**	13.03 ± 0.08**	13.35 ± 0.15**	13.35 ± 0.12 <sup>††</sup>
Reticulocytes (%)	2.810 ± 0.104	3.03 ± 0.19	3.30 ± 0.16	3.50 ± 0.12	3.10 ± 0.16	3.51 ± 0.30	3.01 ± 0.16
Reticulocytes (10 <sup>3</sup> /μL)	295 ± 20	303 ± 19	326 ± 15	354 ± 11	315 ± 18	332 ± 28	270 ± 17
Nucleated erythrocytes (/100 leukocytes)	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0
Mean cell volume (fL)	48.6 ± 0.2	48.5 ± 0.3	48.2 ± 0.3	49.0 ± 0.3	48.6 ± 0.3	48.9 ± 0.4	48.9 ± 0.2
Mean cell hemoglobin (pg)	15.9 ± 0.0	15.9 ± 0.1	16.0 ± 0.1	16.1 ± 0.1	16.0 ± 0.0	16.2 ± 0.1	16.4 ± 0.1 <sup>††</sup>
Mean cell hemoglobin concentration (g/dL)	32.9 ± 0.1	32.7 ± 0.2	33.1 ± 0.1	32.8 ± 0.1	33.0 ± 0.1	33.2 ± 0.2*	33.5 ± 0.1 <sup>††</sup>
Platelets (10 <sup>3</sup> /μL)	528 ± 37	577 ± 39	595 ± 26	608 ± 29	641 ± 28	699 ± 34*	818 ± 30 <sup>††</sup>
Mean platelet volume (fL)	5.910 ± 0.095	5.860 ± 0.180	5.740 ± 0.079	5.870 ± 0.116	5.680 ± 0.053	5.620 ± 0.051	5.840 ± 0.078
Leukocytes (10 <sup>3</sup> /μL)	5.79 ± 0.46	6.17 ± 0.29	6.83 ± 0.26	6.25 ± 0.40	6.97 ± 0.61	6.98 ± 0.63	6.61 ± 0.50
Segmented neutrophils (10 <sup>3</sup> /μL)	1.28 ± 0.11	1.41 ± 0.09	1.64 ± 0.06	1.44 ± 0.13	1.54 ± 0.16	1.63 ± 0.13	1.68 ± 0.17
Bands (10 <sup>3</sup> /μL)	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Metamyelocytes (10 <sup>3</sup> /μL)	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Myelocytes (10 <sup>3</sup> /μL)	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000
Lymphocytes (10 <sup>3</sup> /μL)	4.44 ± 0.36	4.68 ± 0.20	5.11 ± 0.22	4.71 ± 0.28	5.34 ± 0.45	5.25 ± 0.50	4.80 ± 0.37
Atypical lymphocytes (10 <sup>3</sup> /μL)	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Monocytes (10 <sup>3</sup> /μL)	0.04 ± 0.00	0.04 ± 0.01	0.06 ± 0.00	0.06 ± 0.01	0.06 ± 0.01	0.07 ± 0.01**	0.09 ± 0.01 <sup>††</sup>

**TABLE B3**  
**Hematology Data for Mice in the 3-Month Dermal Study of OTNE**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
<b>Female</b> (continued)							
n	10	10	10	10	10	10	10
Basophils ( $10^3/\mu\text{L}$ )	0.006 ± 0.002	0.011 ± 0.003	0.006 ± 0.002	0.014 ± 0.005	0.006 ± 0.002	0.009 ± 0.002	0.008 ± 0.001
Eosinophils ( $10^3/\mu\text{L}$ )	0.02 ± 0.00	0.03 ± 0.01	0.02 ± 0.00	0.03 ± 0.01	0.02 ± 0.00	0.02 ± 0.01	0.03 ± 0.00

\* Significantly different ( $P \leq 0.05$ ) from the vehicle control group by Dunn's or Shirley's test

\*\*  $P \leq 0.01$

† Significantly different ( $P \leq 0.05$ ) from the untreated control group by Wilcoxon's rank sum test

††  $P \leq 0.01$

<sup>a</sup> Data are presented as mean ± standard error. Statistical tests were performed on unrounded data. Statistical comparisons between the two control groups are not presented.

**TABLE B4**  
**CYP2E1 Activity in the Liver of Mice in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
n	4	5	5	3	5	5	5
<b>Male</b>							
CYP2E1 liver activity (nmol/minute per mg protein)	1.940 ± 0.131	1.883 ± 0.185 <sup>b</sup>	2.193 ± 0.098 <sup>c</sup>	2.063 ± 0.182	2.542 ± 0.177*	2.940 ± 0.100**	3.482 ± 0.084 <sup>††</sup>
<b>Female</b>							
CYP2E1 liver activity (nmol/minute per mg protein)	1.855 ± 0.146	1.782 ± 0.127	2.250 ± 0.086*	2.677 ± 0.090**	2.742 ± 0.068**	2.940 ± 0.149** <sup>b</sup>	2.780 ± 0.177 <sup>††</sup>

\* Significantly different ( $P \leq 0.05$ ) from the vehicle control group by Shirley's test

\*\*  $P \leq 0.01$

<sup>††</sup> Significantly different ( $P \leq 0.01$ ) from the untreated control group by Wilcoxon's rank sum test

<sup>a</sup> Data are presented as mean ± standard error. Statistical comparisons between the two control groups are not presented.

<sup>b</sup> n = 4

<sup>c</sup> n = 3

## **APPENDIX C**

### **ORGAN WEIGHTS**

### **AND ORGAN-WEIGHT-TO-BODY-WEIGHT RATIOS**

<b>TABLE C1</b>	<b>Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats in the 3-Month Dermal Study of OTNE .....</b>	<b>C-2</b>
<b>TABLE C2</b>	<b>Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice in the 3-Month Dermal Study of OTNE .....</b>	<b>C-3</b>



**TABLE C1**  
**Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
n	10	10	10	10	10	10	10
<b>Male</b>							
Necropsy body wt	324 ± 6	318 ± 6	308 ± 9	293 ± 5	307 ± 8	302 ± 7	306 ± 7
Heart							
Absolute	1.02 ± 0.02	1.02 ± 0.02	0.93 ± 0.01*	0.94 ± 0.03	0.99 ± 0.03	0.98 ± 0.03	0.98 ± 0.02
Relative	3.16 ± 0.04	3.22 ± 0.03	3.04 ± 0.06	3.21 ± 0.07	3.23 ± 0.09	3.26 ± 0.06	3.19 ± 0.05
R. Kidney							
Absolute	1.19 ± 0.03	1.20 ± 0.02	1.14 ± 0.03	1.11 ± 0.02	1.14 ± 0.03	1.18 ± 0.03	1.24 ± 0.03
Relative	3.66 ± 0.05	3.77 ± 0.06	3.71 ± 0.06	3.80 ± 0.04	3.71 ± 0.06	3.92 ± 0.07	4.04 ± 0.05 <sup>††</sup>
Liver							
Absolute	13.62 ± 0.54	13.60 ± 0.48	12.81 ± 0.44	12.73 ± 0.50	13.33 ± 0.46	14.57 ± 0.74	15.93 ± 0.65 <sup>†</sup>
Relative	41.95 ± 1.17	42.77 ± 1.16	41.62 ± 0.95	43.55 ± 1.84	43.48 ± 1.38	48.04 ± 1.64*	52.12 ± 1.83 <sup>††</sup>
Lung							
Absolute	1.78 ± 0.11	1.72 ± 0.07	1.67 ± 0.10	1.60 ± 0.05	1.70 ± 0.08	1.57 ± 0.05	1.60 ± 0.05
Relative	5.47 ± 0.27	5.40 ± 0.19	5.39 ± 0.21	5.49 ± 0.22	5.52 ± 0.19	5.19 ± 0.11	5.29 ± 0.16
R. Testis							
Absolute	1.543 ± 0.102	1.453 ± 0.020	1.427 ± 0.035	1.409 ± 0.024	1.478 ± 0.029	1.452 ± 0.032	1.467 ± 0.025
Relative	4.762 ± 0.301	4.580 ± 0.047	4.645 ± 0.081	4.816 ± 0.083	4.824 ± 0.079	4.831 ± 0.141	4.806 ± 0.058
Thymus							
Absolute	0.347 ± 0.056	0.302 ± 0.033	0.394 ± 0.075	0.271 ± 0.015	0.274 ± 0.015	0.303 ± 0.026	0.359 ± 0.074
Relative	1.068 ± 0.172	0.943 ± 0.094	1.280 ± 0.248	0.921 ± 0.044	0.896 ± 0.052	0.990 ± 0.065	1.155 ± 0.224
<b>Female</b>							
Necropsy body wt	184 ± 4	187 ± 3	188 ± 2	184 ± 4	187 ± 4	184 ± 3	180 ± 3
Heart							
Absolute	0.71 ± 0.03	0.73 ± 0.01	0.72 ± 0.01	0.71 ± 0.02	0.74 ± 0.02	0.73 ± 0.01	0.73 ± 0.02
Relative	3.86 ± 0.12	3.91 ± 0.04	3.83 ± 0.05	3.87 ± 0.09	3.97 ± 0.11	3.95 ± 0.08	4.06 ± 0.07
R. Kidney							
Absolute	0.74 ± 0.02	0.78 ± 0.02	0.78 ± 0.02	0.77 ± 0.02	0.78 ± 0.02	0.80 ± 0.01	0.78 ± 0.02
Relative	4.00 ± 0.06	4.18 ± 0.08	4.13 ± 0.07	4.18 ± 0.07	4.18 ± 0.09	4.32 ± 0.03	4.34 ± 0.07 <sup>††</sup>
Liver							
Absolute	6.50 ± 0.33	6.99 ± 0.21	6.89 ± 0.19	7.09 ± 0.27	7.51 ± 0.20	7.78 ± 0.27 <sup>*b</sup>	8.24 ± 0.18 <sup>††</sup>
Relative	35.29 ± 1.42	37.44 ± 0.67	36.60 ± 0.92	38.52 ± 1.40	40.09 ± 0.65	41.93 ± 1.35 <sup>**b</sup>	46.29 ± 1.02 <sup>††</sup>
Lung							
Absolute	1.14 ± 0.04	1.13 ± 0.04	1.11 ± 0.04	1.26 ± 0.11	1.21 ± 0.06	1.13 ± 0.04	1.12 ± 0.06
Relative	6.20 ± 0.20	6.07 ± 0.27	5.89 ± 0.18	6.77 ± 0.50	6.44 ± 0.27	6.14 ± 0.25	6.20 ± 0.34
Thymus							
Absolute	0.292 ± 0.017	0.252 ± 0.020	0.249 ± 0.020	0.252 ± 0.017	0.252 ± 0.013	0.265 ± 0.016	0.255 ± 0.008
Relative	1.598 ± 0.105	1.343 ± 0.095	1.320 ± 0.098	1.361 ± 0.084	1.347 ± 0.063	1.442 ± 0.094	1.421 ± 0.047

\* Significantly different (P≤0.05) from the vehicle control group by Dunnett's or Williams' test

\*\* P≤0.01

† Significantly different (P≤0.05) from the untreated control group by a *t*-test

†† P≤0.01

<sup>a</sup> Organ weights (absolute weights) and body weights are given in grams; organ-weight-to-body-weight ratios (relative weights) are given as mg organ weight/g body weight (mean ± standard error). Statistical comparisons between the two control groups are not presented.

<sup>b</sup> n=9

**TABLE C2**  
**Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	6.25%	12.5%	25%	50%	100%
n	10	10	10	10	10	10	10
<b>Male</b>							
Necropsy body wt	37.7 ± 1.2	35.0 ± 0.6	32.2 ± 0.4**	33.7 ± 1.0	32.0 ± 0.4**	32.5 ± 0.5*	32.2 ± 0.4††
Heart							
Absolute	0.19 ± 0.01	0.18 ± 0.00	0.17 ± 0.00	0.17 ± 0.01	0.18 ± 0.01	0.18 ± 0.01	0.19 ± 0.00
Relative	5.06 ± 0.21	4.99 ± 0.09	5.27 ± 0.16	5.16 ± 0.14	5.71 ± 0.17*	5.46 ± 0.24	5.74 ± 0.10†
R. Kidney							
Absolute	0.35 ± 0.02	0.35 ± 0.01	0.32 ± 0.01	0.34 ± 0.01	0.34 ± 0.01	0.33 ± 0.01	0.33 ± 0.02
Relative	9.24 ± 0.40	10.00 ± 0.21	9.98 ± 0.20	10.27 ± 0.22	10.54 ± 0.34	10.09 ± 0.18	10.20 ± 0.63
Liver							
Absolute	1.64 ± 0.05	1.60 ± 0.05	1.68 ± 0.07	1.82 ± 0.09*	1.99 ± 0.09**	2.12 ± 0.03**	2.66 ± 0.07††
Relative	43.79 ± 1.34	45.72 ± 1.29	51.98 ± 1.96*	54.09 ± 2.20**	62.10 ± 2.99**	65.35 ± 1.52**	82.51 ± 1.92††
Lung							
Absolute	0.29 ± 0.02	0.30 ± 0.02	0.29 ± 0.02	0.31 ± 0.02	0.27 ± 0.02	0.26 ± 0.02	0.27 ± 0.02
Relative	7.69 ± 0.38	8.49 ± 0.51	8.98 ± 0.59	9.34 ± 0.60	8.45 ± 0.63	8.12 ± 0.48	8.44 ± 0.50
R. Testis							
Absolute	0.127 ± 0.004	0.128 ± 0.002	0.120 ± 0.005	0.127 ± 0.004	0.120 ± 0.002	0.115 ± 0.004*	0.119 ± 0.004
Relative	3.397 ± 0.131	3.661 ± 0.086	3.734 ± 0.156	3.780 ± 0.103	3.760 ± 0.072	3.544 ± 0.078	3.693 ± 0.121
Thymus							
Absolute	0.050 ± 0.003	0.050 ± 0.003	0.043 ± 0.002	0.042 ± 0.004	0.041 ± 0.003	0.041 ± 0.002	0.039 ± 0.003†
Relative	1.338 ± 0.082	1.424 ± 0.098	1.346 ± 0.073	1.233 ± 0.078	1.268 ± 0.082	1.273 ± 0.075	1.202 ± 0.078
<b>Female</b>							
Necropsy body wt	28.5 ± 0.7	29.5 ± 0.7	30.1 ± 0.7	29.2 ± 0.6	28.9 ± 0.3	29.2 ± 0.4	29.4 ± 0.3
Heart							
Absolute	0.14 ± 0.00	0.15 ± 0.01	0.15 ± 0.00	0.16 ± 0.01	0.16 ± 0.00	0.17 ± 0.00*	0.16 ± 0.01††
Relative	4.85 ± 0.08	5.08 ± 0.18	5.12 ± 0.13	5.36 ± 0.20	5.47 ± 0.09	5.68 ± 0.16*	5.55 ± 0.16††
R. Kidney							
Absolute	0.21 ± 0.01	0.22 ± 0.01	0.21 ± 0.00	0.23 ± 0.01	0.22 ± 0.01	0.24 ± 0.01	0.23 ± 0.01
Relative	7.51 ± 0.20	7.39 ± 0.21	7.13 ± 0.19	8.00 ± 0.32	7.57 ± 0.23	8.11 ± 0.23	7.84 ± 0.21
Liver							
Absolute	1.28 ± 0.04	1.37 ± 0.05	1.52 ± 0.04*	1.65 ± 0.04**	1.69 ± 0.03**	2.04 ± 0.05**	2.46 ± 0.07††
Relative	45.04 ± 1.03	46.48 ± 1.46	50.45 ± 0.76*	56.53 ± 1.22**	58.35 ± 0.61**	69.96 ± 1.26**	83.54 ± 2.31††
Lung							
Absolute	0.30 ± 0.02	0.29 ± 0.02	0.26 ± 0.01	0.32 ± 0.02	0.27 ± 0.03	0.26 ± 0.02	0.24 ± 0.02
Relative	10.41 ± 0.74	9.86 ± 0.75	8.71 ± 0.52	10.91 ± 0.76	9.44 ± 0.85	8.91 ± 0.54	8.22 ± 0.69†
Thymus							
Absolute	0.056 ± 0.002	0.058 ± 0.003	0.057 ± 0.002	0.053 ± 0.003	0.049 ± 0.004	0.052 ± 0.002	0.046 ± 0.002††
Relative	1.982 ± 0.056	1.966 ± 0.102	1.924 ± 0.095	1.815 ± 0.075	1.706 ± 0.137	1.766 ± 0.078	1.548 ± 0.090††

\* Significantly different (P≤0.05) from the vehicle control group by Dunnett's or Williams' test

\*\* P≤0.01

† Significantly different (P≤0.05) from the untreated control group by a *t*-test

†† P≤0.01

<sup>a</sup> Organ weights (absolute weights) and body weights are given in grams; organ-weight-to-body-weight ratios (relative weights) are given as mg organ weight/g body weight (mean ± standard error). Statistical comparisons between the two control groups are not presented.



## **APPENDIX D**

### **REPRODUCTIVE TISSUE EVALUATIONS AND ESTROUS CYCLE CHARACTERIZATION**

<b>TABLE D1</b>	<b>Summary of Reproductive Tissue Evaluations for Male Rats in the 3-Month Dermal Study of OTNE .....</b>	<b>D-2</b>
<b>TABLE D2</b>	<b>Estrous Cycle Characterization for Female Rats in the 3-Month Dermal Study of OTNE .....</b>	<b>D-2</b>
<b>TABLE D3</b>	<b>Summary of Reproductive Tissue Evaluations for Male Mice in the 3-Month Dermal Study of OTNE .....</b>	<b>D-3</b>
<b>TABLE D4</b>	<b>Estrous Cycle Characterization for Female Mice in the 3-Month Dermal Study of OTNE .....</b>	<b>D-3</b>

**TABLE D1**  
**Summary of Reproductive Tissue Evaluations for Male Rats in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	25%	50%	100%
n	10	10	10	10	10
Weights (g)					
Necropsy body wt	325 ± 6	318 ± 6	307 ± 8	302 ± 7	306 ± 7
L. Cauda epididymis	0.1850 ± 0.0051	0.1884 ± 0.0066	0.1782 ± 0.0051	0.1736 ± 0.0087	0.1809 ± 0.0072
L. Epididymis	0.4790 ± 0.0190	0.4457 ± 0.0145	0.4608 ± 0.0100	0.4580 ± 0.0202	0.4507 ± 0.0141
L. Testis	1.5291 ± 0.0222	1.4998 ± 0.0315	1.5005 ± 0.0233	1.5015 ± 0.0340	1.5300 ± 0.0360
Spermatid measurements					
Spermatid heads (10 <sup>6</sup> /g testis)	105.01 ± 5.31	129.89 ± 7.50	118.07 ± 10.87	122.10 ± 13.34	108.85 ± 6.97
Spermatid heads (10 <sup>6</sup> /testis)	160.52 ± 8.41	194.42 ± 11.31	177.51 ± 16.75	182.77 ± 19.24	167.21 ± 12.74
Epididymal spermatozoal measurements					
Sperm motility (%)	85.2 ± 3.4	80.5 ± 5.8	89.4 ± 2.1	87.5 ± 2.4	74.8 ± 9.0
Sperm (10 <sup>6</sup> /g cauda epididymis)	335.6 ± 14.4	326.8 ± 45.2	349.5 ± 20.2	321.7 ± 36.2	371.3 ± 30.7
Sperm (10 <sup>6</sup> /cauda epididymis)	62.1 ± 3.4	61.1 ± 8.3	61.8 ± 2.9	58.0 ± 7.0	66.2 ± 5.1

<sup>a</sup> Data are presented as mean ± standard error. Differences between the vehicle control group and the 25% and 50% groups are not significant by Dunnett's test (body and tissue weights) or Dunn's test (spermatid and epididymal spermatozoal measurements). Differences between the untreated control group and the 100% group are not significant by a *t*-test (body and tissue weights) or Wilcoxon's rank sum test (spermatid and epididymal spermatozoal measurements). Statistical comparisons between the two control groups are not presented.

**TABLE D2**  
**Estrous Cycle Characterization for Female Rats in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	25%	50%	100%
Number weighed at necropsy	10	10	10	10	10
Necropsy body wt (g)	184 ± 4	187 ± 3	187 ± 4	184 ± 3	180 ± 3
Proportion of regular cycling females <sup>b</sup>	10/10	9/10	10/10	10/10	10/10
Estrous cycle length (days)	5.0 ± 0.1	4.9 ± 0.2	4.8 ± 0.1	4.7 ± 0.2	4.9 ± 0.1
Estrous stages (% of cycle)					
Diestrus	60.0	61.3	53.1	53.1	59.4
Proestrus	11.9	8.8	10.6	15.0	13.8
Estrus	26.3	25.6	30.6	24.4	23.1
Metestrus	0.0	0.0	0.0	0.0	0.0
Uncertain diagnosis	1.9	4.4	5.6	7.5	3.8

<sup>a</sup> Necropsy body weights and estrous cycle length data are presented as mean ± standard error. Differences between the vehicle control group and the 25% and 50% groups are not significant by Dunnett's test (body weights) or Dunn's test (estrous cycle length). Differences between the untreated control group and the 100% group are not significant by a *t*-test (body weights) or Dunn's test (estrous cycle length). By multivariate analysis of variance, dosed females do not differ significantly from the vehicle control females in the relative length of time spent in the estrous stages. Tests for equality of transition probability matrices among all groups and between the respective control group and each dosed group indicated treated females did not spend significantly more time in a given estrous stage than did the respective control group. Statistical comparisons between the two control groups are not presented.

<sup>b</sup> Number of females with a regular cycle/number of females cycling

**TABLE D3**  
**Summary of Reproductive Tissue Evaluations for Male Mice in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	25%	50%	100%
n	9	10	7	7	10
Weights (g)					
Necropsy body wt	37.8 ± 1.3	35.0 ± 0.6	32.2 ± 0.5**	32.9 ± 0.5*	32.2 ± 0.4 <sup>††</sup>
L. Cauda epididymis	0.0210 ± 0.0015	0.0196 ± 0.0011	0.0218 ± 0.0017	0.0252 ± 0.0041	0.0170 ± 0.0012 <sup>†</sup>
L. Epididymis	0.0515 ± 0.0040	0.0480 ± 0.0023	0.0615 ± 0.0068	0.0549 ± 0.0040	0.0435 ± 0.0021
L. Testis	0.1119 ± 0.0022	0.1119 ± 0.0016	0.1114 ± 0.0041	0.1085 ± 0.0038	0.1052 ± 0.0025
Spermatid measurements					
Spermatid heads (10 <sup>6</sup> /g testis)	214.10 ± 17.77	233.47 ± 16.49	252.91 ± 18.67	254.21 ± 16.20	234.12 ± 21.35
Spermatid heads (10 <sup>6</sup> /testis)	23.93 ± 1.97	26.21 ± 2.10	27.93 ± 1.79	27.57 ± 2.00	24.80 ± 2.40
Epididymal spermatozoal measurements					
Sperm motility (%)	90.8 ± 2.2	94.7 ± 0.8	91.0 ± 3.6	92.4 ± 1.9	80.6 ± 7.4
Sperm (10 <sup>6</sup> /g cauda epididymis)	169.9 ± 21.6	151.1 ± 11.2	144.3 ± 8.9	153.9 ± 29.2	112.2 ± 22.4
Sperm (10 <sup>6</sup> /cauda epididymis)	3.4 ± 0.3	2.9 ± 0.2	3.2 ± 0.4	3.5 ± 0.7	1.8 ± 0.3 <sup>††</sup>

\* Significantly different (P≤0.05) from the vehicle control group by Dunnett's test

\*\* P≤0.01

<sup>†</sup> Significantly different (P≤0.05) from the untreated control group by Wilcoxon's rank sum test

<sup>††</sup> Significantly different (P≤0.01) from the untreated control group by a *t*-test (body weights) or Wilcoxon's rank sum test (sperm/cauda epididymis)

<sup>a</sup> Data are presented as mean ± standard error. Differences between the vehicle control group and the 25% and 50% groups are not significant by Dunnett's test (tissue weights) or Dunn's test (spermatid and epididymal spermatozoal measurements). Differences between the untreated control group and the 100% group are not significant by a *t*-test (tissue weights) or Wilcoxon's rank sum test (spermatid measurements, sperm motility, and sperm/g cauda epididymis). Statistical comparisons between the two control groups are not presented.

**TABLE D4**  
**Estrous Cycle Characterization for Female Mice in the 3-Month Dermal Study of OTNE<sup>a</sup>**

	Untreated Control	Vehicle Control	25%	50%	100%
Number weighed at necropsy	10	10	10	10	10
Necropsy body wt (g)	28.5 ± 0.7	29.5 ± 0.7	28.9 ± 0.3	29.2 ± 0.4	29.4 ± 0.3
Proportion of regular cycling females <sup>b</sup>	9/10	10/10	10/10	10/10	9/10
Estrous cycle length (days)	4.0 ± 0.2	4.5 ± 0.2	4.6 ± 0.2	4.5 ± 0.2	5.2 ± 0.3 <sup>††</sup>
Estrous stages (% of cycle)					
Diestrus	38.8	38.8	31.3	33.8	37.5
Proestrus	0.0	0.0	1.3	0.6	0.0
Estrus	38.1	43.1	51.3	56.3	53.1
Metestrus	15.0	11.9	10.0	6.3	6.9
Uncertain diagnosis	8.1	6.3	6.3	3.1	2.5

<sup>††</sup> Significantly different (P≤0.01) from the untreated control group by Dunn's test

<sup>a</sup> Necropsy body weights and estrous cycle length data are presented as mean ± standard error. Differences between the vehicle control group and the 25% and 50% groups are not significant by Dunnett's test (body weights) or Dunn's test (estrous cycle length). Differences between the untreated control group and the 100% group are not significant by a *t*-test (body weights). By multivariate analysis of variance, dosed females do not differ significantly from the vehicle control females in the relative length of time spent in the estrous stages. Tests for equality of transition probability matrices among all groups and between the respective control group and each dosed group indicated the probability of extended estrus was significantly higher in the dosed groups than the respective control groups. Statistical comparisons between the two control groups are not presented.

<sup>b</sup> Number of females with a regular cycle/number of females cycling



## APPENDIX E

### GENETIC TOXICOLOGY

TABLE E1	Mutagenicity of OTNE in <i>Salmonella typhimurium</i> .....	E-2
TABLE E2	Mutagenicity of OTNE in Bacterial Tester Strains.....	E-3
TABLE E3	Frequency of Micronuclei in Peripheral Blood Erythrocytes of Rats Following Dermal Application of OTNE for 3 Months.....	E-4
TABLE E4	Frequency of Micronuclei in Peripheral Blood Erythrocytes of Mice Following Dermal Application of OTNE for 3 Months .....	E-5



**TABLE E1**  
**Mutagenicity of OTNE in *Salmonella typhimurium*<sup>a</sup>**

Strain	Dose (µg/plate)	Without S9	With 10% rat S9
<b>TA102</b>	0	293 ± 6	396 ± 27
	100	349 ± 11	349 ± 16
	333	373 ± 14	434 ± 29
	1,000	382 ± 18	352 ± 16
	3,333	352 ± 4	322 ± 13
	10,000	362 ± 20 <sup>b</sup>	320 ± 9 <sup>b</sup>
	Trial summary	Negative	Negative
Positive control <sup>c</sup>		1,354 ± 12	1,495 ± 44
<b>TA100</b>	0	144 ± 6	152 ± 12
	100	122 ± 6	153 ± 10
	333	118 ± 8	129 ± 8
	1,000	125 ± 8	115 ± 7
	3,333	104 ± 3 <sup>b</sup>	94 ± 1 <sup>b</sup>
	10,000	117 ± 2 <sup>b</sup>	98 ± 8 <sup>b</sup>
	Trial summary	Negative	Negative
Positive control		448 ± 9	917 ± 36
<b>TA98</b>	0	19 ± 1	29 ± 0
	100	21 ± 1	34 ± 5
	333	22 ± 1	21 ± 3
	1,000	23 ± 2	29 ± 1
	3,333	23 ± 1 <sup>b</sup>	23 ± 3 <sup>b</sup>
	10,000	16 ± 1 <sup>b</sup>	27 ± 2 <sup>b</sup>
	Trial summary	Negative	Negative
Positive control		137 ± 21	441 ± 197

<sup>a</sup> Study was performed at BioReliance Corporation using lot RAV0276433. Data are presented as revertants/plate (mean ± standard error) from three plates. 0 µg/plate was the solvent control. The detailed protocol is presented by Zeiger *et al.* (1992).

<sup>b</sup> Precipitate on plate

<sup>c</sup> The positive controls in the absence of metabolic activation were sodium azide (TA100), 4-nitro-*o*-phenylenediamine (TA98), and mitomycin-C (TA102). The positive control for metabolic activation with all strains was 2-aminoanthracene, except 2-aminoanthracene or sterigmatocystin was used for TA102.

**TABLE E2**  
**Mutagenicity of OTNE in Bacterial Tester Strains<sup>a</sup>**

Strain	Dose (µg/plate)	Without S9	Without S9	With 10% rat S9	With 10% rat S9
<b>TA100</b>					
	0	92 ± 6	90 ± 1	91 ± 11	103 ± 6
	100	72 ± 5	50 ± 1	100 ± 5	111 ± 6
	350	60 ± 8	54 ± 3	86 ± 8	73 ± 5
	1,000	68 ± 1	57 ± 4	61 ± 6	51 ± 6
	1,500	65 ± 3	56 ± 7	38 ± 8 <sup>b</sup>	52 ± 4
	3,000	65 ± 5	51 ± 1	45 ± 2 <sup>b</sup>	50 ± 8
	6,000	58 ± 3	57 ± 4	26 ± 5 <sup>c</sup>	26 ± 3 <sup>c</sup>
Trial summary		Negative	Negative	Negative	Negative
Positive control <sup>d</sup>		782 ± 23	793 ± 23	506 ± 14	452 ± 13
<b>TA98</b>					
	0	22 ± 1	16 ± 1	24 ± 3	30 ± 4
	100	22 ± 4	15 ± 2	23 ± 1	29 ± 5
	350	17 ± 7	20 ± 1	24 ± 2	25 ± 3
	1,000	13 ± 3	14 ± 2	24 ± 1	25 ± 2
	1,500	13 ± 1	17 ± 2	23 ± 2	28 ± 4
	3,000	18 ± 3	23 ± 2	25 ± 4	23 ± 4
	6,000	17 ± 3	22 ± 3	15 ± 4 <sup>e</sup>	25 ± 2 <sup>e</sup>
Trial summary		Negative	Negative	Negative	Negative
Positive control		528 ± 30	639 ± 32	1,395 ± 26	1,419 ± 25
<b><i>Escherichia coli</i> WP2 <i>uvrA</i>/pKM101</b>					
	0	155 ± 5	144 ± 4	222 ± 13	197 ± 9
	100	148 ± 4	158 ± 6	222 ± 4	241 ± 1
	350	171 ± 5	160 ± 14	190 ± 9	206 ± 12
	1,000	146 ± 5	143 ± 4	170 ± 11	168 ± 9
	1,500	141 ± 8	151 ± 2	160 ± 6	183 ± 9
	3,000	142 ± 11	158 ± 3	148 ± 5	159 ± 10
	6,000	158 ± 10	149 ± 9	146 ± 13 <sup>e</sup>	157 ± 18 <sup>e</sup>
Trial summary		Negative	Negative	Negative	Negative
Positive control		3,171 ± 58	3,090 ± 59	1,598 ± 60	1,685 ± 63

<sup>a</sup> Study was performed at ILS, Inc., using lot RAV0276433. Data are presented as revertants/plate (mean ± standard error) from three plates. 0 µg/plate was the solvent control.

<sup>b</sup> Slight toxicity

<sup>c</sup> Slight toxicity and precipitate on plate

<sup>d</sup> The positive controls in the absence of metabolic activation were sodium azide (TA100), 4-nitro-*o*-phenylenediamine (TA98), and methyl methanesulfonate (*E. coli*). The positive control for metabolic activation with all strains was 2-aminoanthracene.

<sup>e</sup> Precipitate on plate

**TABLE E3**  
**Frequency of Micronuclei in Peripheral Blood Erythrocytes of Rats Following Dermal Application**  
**of OTNE for 3 Months<sup>a</sup>**

	Dose (%)	Number of Rats with Erythrocytes Scored	Micronucleated PCEs/ 1,000 PCEs <sup>b</sup>	P Value <sup>c</sup>	Micronucleated NCEs/ 1,000 NCEs <sup>b</sup>	P Value <sup>d</sup>	PCEs <sup>b</sup> (%)	P Value <sup>d</sup>
<b>Male</b>								
Vehicle control <sup>e</sup>	0	5	0.38 ± 0.06		0.08 ± 0.01		1.20 ± 0.07	
OTNE	6.25	5	0.43 ± 0.08	0.431	0.07 ± 0.01	0.980	1.18 ± 0.03	1.000
	12.5	5	0.36 ± 0.03	0.509	0.04 ± 0.01	0.993	1.23 ± 0.03	1.000
	25	5	0.65 ± 0.07	0.021	0.05 ± 0.00	0.996	1.29 ± 0.07	1.000
	50	5	0.50 ± 0.06	0.022	0.05 ± 0.01	0.997	1.00 ± 0.08	0.022
			P = 0.045 <sup>f</sup>		P = 0.963 <sup>f</sup>		P = 0.025 <sup>f</sup>	
Untreated control		5	0.38 ± 0.04		0.09 ± 0.01		1.12 ± 0.05	
OTNE	100	5	0.43 ± 0.09	0.320	0.04 ± 0.01	0.969	1.11 ± 0.07	0.850
Untreated control		5	0.38 ± 0.04		0.09 ± 0.01		1.12 ± 0.05	
Vehicle control	0	5	0.38 ± 0.06	0.502	0.08 ± 0.01	0.621	1.20 ± 0.07	0.400
<b>Female</b>								
Vehicle control	0	5	0.58 ± 0.15		0.08 ± 0.03		0.79 ± 0.07	
OTNE	6.25	5	0.40 ± 0.06	0.690	0.04 ± 0.01	1.000	0.84 ± 0.12	1.000
	12.5	5	0.55 ± 0.21	0.653	0.06 ± 0.02	1.000	1.07 ± 0.11	0.375
	25	5	0.58 ± 0.06	0.688	0.06 ± 0.01	1.000	0.69 ± 0.04	1.000
	50	5	0.52 ± 0.09	0.707	0.03 ± 0.00	1.000	0.70 ± 0.05	1.000
			P = 0.454 <sup>f</sup>		P = 0.910 <sup>g</sup>		P = 0.214 <sup>g</sup>	
Untreated control		5	0.53 ± 0.07		0.07 ± 0.02		0.96 ± 0.06	
OTNE	100	5	0.45 ± 0.05	0.677	0.10 ± 0.02	0.116	1.29 ± 0.34	0.465
Untreated control		5	0.53 ± 0.07		0.07 ± 0.02		0.96 ± 0.06	
Vehicle control	0	5	0.58 ± 0.15	0.385	0.08 ± 0.03	0.412	0.79 ± 0.07	0.112

<sup>a</sup> Study was performed at ILS, Inc. The detailed protocol is presented by Dertinger *et al.* (2004), MacGregor *et al.* (2006), and Witt *et al.* (2008). PCE=polychromatic erythrocyte; NCE=normochromatic erythrocyte

<sup>b</sup> Mean ± standard error

<sup>c</sup> Pairwise comparison of 6.25%, 12.5%, 25%, and 50% groups with the vehicle control group, values are significant at P≤0.025 by Williams' test; 100% (neat) group with the untreated control group or vehicle control group with the untreated control group, values are significant at P≤0.05 by Williams' test.

<sup>d</sup> Pairwise comparison with the vehicle control group, values are significant at P≤0.025 by Williams' test (6.25%, 12.5%, 25%, and 50% males) or Dunn's test (6.25%, 12.5%, 25%, and 50% females); 100% (neat) group with the untreated control group or vehicle control group with the untreated control group, values are significant at P≤0.05 by Williams' test.

<sup>e</sup> 95% ethanol

<sup>f</sup> Dose-related trend; significant at P≤0.025 by linear regression

<sup>g</sup> Dose-related trend; significant at P≤0.025 by Jonckheere's test

**TABLE E4**  
**Frequency of Micronuclei in Peripheral Blood Erythrocytes of Mice Following Dermal Application of OTNE for 3 Months<sup>a</sup>**

	Dose (%)	Number of Mice with Erythrocytes Scored	Micronucleated PCEs/ 1,000 PCEs <sup>b</sup>	P Value <sup>c</sup>	Micronucleated NCEs/ 1,000 NCEs <sup>b</sup>	P Value <sup>c</sup>	PCEs <sup>b</sup> (%)	P Value <sup>c</sup>
<b>Male</b>								
Vehicle control <sup>d</sup>	0	5	2.42 ± 0.16		1.47 ± 0.02		1.46 ± 0.08	
OTNE	6.25	5	2.55 ± 0.24	0.397	1.48 ± 0.04	0.703	1.52 ± 0.12	0.620
	12.5	5	2.78 ± 0.30	0.471	1.43 ± 0.04	0.787	1.58 ± 0.08	0.651
	25	5	2.43 ± 0.20	0.501	1.39 ± 0.05	0.820	1.52 ± 0.04	0.695
	50	5	2.24 ± 0.14	0.518	1.49 ± 0.02	0.477	1.47 ± 0.05	0.717
			P = 0.865 <sup>e</sup>		P = 0.442		P = 0.851	
Untreated control		5	2.66 ± 0.14		1.45 ± 0.02		1.60 ± 0.06	
OTNE	100	5	2.29 ± 0.15	0.805	1.59 ± 0.03	0.001	2.00 ± 0.20	0.066
Untreated control		5	2.66 ± 0.14		1.45 ± 0.02		1.60 ± 0.59	
Vehicle control	0	5	2.42 ± 0.16	0.707	1.47 ± 0.02	0.235	1.46 ± 0.08	0.190
<b>Female</b>								
Vehicle control	0	5	2.13 ± 0.12		1.01 ± 0.02		1.52 ± 0.12	
OTNE	6.25	5	1.76 ± 0.10	0.877	1.01 ± 0.02	0.472	1.51 ± 0.09	1.000
	12.5	5	2.15 ± 0.05	0.887	1.07 ± 0.04	0.064	2.06 ± 0.13	0.053
	25	5	1.95 ± 0.14	0.912	1.08 ± 0.02	0.039	1.84 ± 0.21	0.056
	50	5	1.85 ± 0.12	0.924	1.15 ± 0.01	0.001	1.96 ± 0.14	0.045
			P = 0.856		P < 0.001		P = 0.050	
Untreated control		5	1.98 ± 0.14		1.03 ± 0.04		1.08 ± 0.15	
OTNE	100	5	2.88 ± 0.23	0.005	1.27 ± 0.01	< 0.001	1.89 ± 0.25	0.031
Untreated control		5	1.98 ± 0.14		1.03 ± 0.04		1.08 ± 0.15	
Vehicle control	0	5	2.13 ± 0.12	0.230	1.01 ± 0.02	0.581	1.52 ± 0.12	0.048

<sup>a</sup> Study was performed at ILS, Inc. The detailed protocol is presented by Dertinger *et al.* (2004), MacGregor *et al.* (2006), and Witt *et al.* (2008). PCE=polychromatic erythrocyte; NCE=normochromatic erythrocyte

<sup>b</sup> Mean ± standard error

<sup>c</sup> Pairwise comparison of 6.25%, 12.5%, 25%, and 50% groups with the vehicle control group, values are significant at P≤0.025 by Williams' test; 100% (neat) group with the untreated control group or vehicle control group with the untreated control group, values are significant at P≤0.05 by Williams' test.

<sup>d</sup> 95% ethanol

<sup>e</sup> Dose-related trend; significant at P≤0.025 by linear regression



## **APPENDIX F**

### **CHEMICAL CHARACTERIZATION AND DOSE FORMULATION STUDIES**

<b>PROCUREMENT AND CHARACTERIZATION .....</b>	<b>F-2</b>
<b>PREPARATION AND ANALYSIS OF DOSE FORMULATIONS .....</b>	<b>F-2</b>
<b>FIGURE F1 Infrared Absorption Spectrum of OTNE .....</b>	<b>F-4</b>
<b>FIGURE F2 Proton Nuclear Magnetic Resonance Spectrum of OTNE .....</b>	<b>F-5</b>
<b>TABLE F1 Preparation and Storage of Dose Formulations in the 3-Month Dermal Studies of OTNE .....</b>	<b>F-6</b>
<b>TABLE F2 Results of Analyses of Dose Formulations Administered to Rats and Mice in the 3-Month Dermal Studies of OTNE .....</b>	<b>F-7</b>

# CHEMICAL CHARACTERIZATION AND DOSE FORMULATION STUDIES

## PROCUREMENT AND CHARACTERIZATION

### OTNE

OTNE (octahydro-tetramethyl-naphthalenyl-ethanone) was obtained as Iso-E Super<sup>®</sup> from International Flavors and Fragrances, Inc. (Ringwood, NJ), in one lot (RAV0276433) that was used in the 3-month dermal studies. Identity and purity analyses were conducted by the analytical chemistry laboratory at Research Triangle Institute (Research Triangle Park, NC), and purity analyses were conducted by the study laboratory at BioReliance Corporation (Rockville, MD). Reports on analyses performed in support of the OTNE studies are on file at the National Institute of Environmental Health Sciences.

The test article, a colorless to pale-yellow liquid, was identified as OTNE by the analytical chemistry laboratory using infrared (IR) and proton nuclear magnetic resonance (NMR) spectrometry and gas chromatography (GC) with mass spectrometry (MS) detection. All spectra were consistent with the structure of OTNE isomers. Representative IR and NMR spectra are presented in Figures F1 and F2, respectively.

The purity of the test chemical was determined by the analytical chemistry laboratory using GC with flame ionization detection (FID) and GC/MS. The GC systems included a gas chromatograph (Hewlett-Packard, Palo Alto, CA), an Equity<sup>®</sup>-5, 30 m × 0.32 mm, 0.25 µm film (Supelco, Inc., Bellefonte, PA) column, an oven temperature program of 60° C for 20 minutes, then 10° C/minute to 200° C, held for 26 minutes, helium carrier gas at a flow rate of 1 or 2 mL/minute, with flame ionization or mass spectrometry (Agilent Technologies, Santa Clara, CA) detection.

GC/FID analysis indicated four major peaks and nine minor peaks; each of the minor peaks was less than 1% of the total peak area. GC/MS analysis indicated mass spectra for the major peaks that were very similar, showing the same fragments with slight variations in relative abundance: These were tentatively identified as β-isomer, α-isomer, γ-isomer, and 1-(1,2,3,4,5,6,7,8-octahydro-2,3,5,5-tetramethyl-2-naphthalenyl)ethanone based on the spectra and comparison to the literature (Erman, 2001). The overall purity of lot RAV0276433 was estimated to be greater than 96% relative to the four OTNE isomers: β-isomer (56.6%), α-isomer (18.0%), γ-isomer (17.7%), and 1-(1,2,3,4,5,6,7,8-octahydro-2,3,5,5-tetramethyl-2-naphthalenyl)ethanone (3.9%).

To ensure stability, the test chemical was stored in sealed amber glass vials at room temperature under a desiccant. Reanalysis of the test chemical was performed at the end of the study by the study laboratory using GC/FID by a method similar to that described previously; no degradation of the test chemical was detected.

### Ethanol

USP-grade 95% ethanol was obtained from Pharmco Products, Inc. (Brookfield, CT), in one lot (M0000) that was used as the vehicle in the 3-month dermal studies.

## PREPARATION AND ANALYSIS OF DOSE FORMULATIONS


Except for the 100% dose formulations, which were used neat, the dose formulations were prepared by mixing OTNE with 95% ethanol to give the required concentrations and stirring with a magnetic stir bar for at least 15 minutes (Table F1). The dose formulations were stored in a flammable chemical storage cabinet in amber glass bottles sealed with Teflon<sup>®</sup> silicone septa and an aluminum crimp seal under a nitrogen headspace at room temperature (~25° C). The dose formulations were prepared three times during the 3-month studies.

Stability studies of 12.5% in 95% ethanol formulations made with lot RAV0276433 were performed by the analytical chemistry laboratory using GC/FID by a method similar to that described previously. Stability was


confirmed for at least 42 days at ambient temperatures and for at least 3 hours under simulated animal room conditions.

The dose formulations were analyzed three times by the study laboratory using GC/FID by a system similar to that previously described. All 30 of the dose formulations analyzed for rats and mice were within 10% of the target concentrations (Table F2). Animal room samples of these dose formulations were also analyzed; 28 of 30 for rats and 26 of 30 for mice were within 10% of the target concentrations.





**FIGURE F1**  
**Infrared Absorption Spectrum of OTNE**



**FIGURE F2**  
**Proton Nuclear Magnetic Resonance Spectrum of OTNE**

**TABLE F1**  
**Preparation and Storage of Dose Formulations in the 3-Month Dermal Studies of OTNE**

---

**Preparation**

Except for the 100% (neat) dose, the dose formulations were prepared by mixing OTNE with 95% ethanol to give the required concentrations and stirred with a magnetic stir bar for at least 15 minutes. The dose formulations were prepared three times during the 3-month studies.

**Chemical Lot Number**

RAV0276433

**Maximum Storage Time**

42 days

**Storage Conditions**

The dose formulations were stored in a flammable storage cabinet in amber glass bottles sealed with Teflon<sup>®</sup> silicone septa and an aluminum crimp seal under a nitrogen headspace at room temperature (~25° C).

**Study Laboratory**

BioReliance Corporation (Rockville, MD)

---

**TABLE F2**  
**Results of Analyses of Dose Formulations Administered to Rats and Mice in the 3-Month Dermal Studies of OTNE**

Date Prepared	Date Analyzed	Target Concentration (% v/v)	Determined Concentration <sup>a</sup> (% v/v)	Difference from Target (%)
December 5, 2006	December 6, 2006	6.25	6.48	+4
		6.25	6.56	+5
		12.5	12.2	-2
		12.5	12.6	+1
		25	25.5	+2
		25	24.8	-1
		50	48.8	-2
		50	52.0	+4
		100	102	+2
		100	104	+4
	January 21, 2007 <sup>b</sup>	6.25	6.13	-2
		6.25	6.27	0
		12.5	12.4	-1
		12.5	12.1	-3
		25	24.7	-1
		25	24.8	-1
		50	49.7	-1
		50	49.0	-2
		100	104	+4
		100	102	+2
	January 29, 2007 <sup>c</sup>	6.25	8.45	+35
		6.25	8.66	+39
		12.5	12.7	+2
		12.5	12.9	+3
		25	27.2	+9
		25	27.1	+8
		50	57.2	+14
		50	54.9	+10
		100	99.4	-1
		100	98.4	-2

**TABLE F2**  
**Results of Analyses of Dose Formulations Administered to Rats and Mice in the 3-Month Dermal Studies**  
**of OTNE**

Date Prepared	Date Analyzed	Target Concentration (% v/v)	Determined Concentration (% v/v)	Difference from Target (%)
January 2, 2007	January 2, 2007	6.25	6.47	+4
		6.25	6.42	+3
		12.5	12.4	-1
		12.5	12.4	-1
		25	24.8	-1
		25	24.7	-1
		50	49.0	-2
		50	48.8	-2
		100	97.1	-3
		100	96.9	-3
	February 15, 2007 <sup>b</sup>	6.25	6.80	+9
		6.25	6.94	+11
		12.5	12.7	+2
		12.5	12.9	+3
		25	26.7	+7
		25	29.0	+16
		50	50.5	+1
		50	51.8	+4
		100	101	+1
		100	103	+3
	February 15, 2007 <sup>c</sup>	6.25	6.90	+10
		6.25	6.90	+10
		12.5	13.0	+4
		12.5	13.3	+6
		25	29.4	+18
		25	27.4	+10
		50	51.5	+3
		50	53.5	+7
		100	100	0
		100	101	+1

**TABLE F2**  
**Results of Analyses of Dose Formulations Administered to Rats and Mice in the 3-Month Dermal Studies of OTNE**

Date Prepared	Date Analyzed	Target Concentration (% v/v)	Determined Concentration (% v/v)	Difference from Target (%)
February 2, 2007	February 6, 2007	6.25	6.33	+1
		6.25	6.16	-1
		12.5	12.4	-1
		12.5	12.5	0
		25	24.9	0
		25	25.0	0
		50	48.9	-2
		50	49.9	0
		100	100.8	+1
		100	101.3	+1
	March 20, 2007 <sup>b</sup>	6.25	6.43	+3
		6.25	6.61	+6
		12.5	12.8	+2
		12.5	12.6	+1
		25	25.0	0
		25	25.2	+1
		50	51.0	+2
		50	51.4	+3
		100	102	-2
		100	99	-1
	March 20, 2007 <sup>c</sup>	6.25	6.49	+4
		6.25	6.63	+6
		12.5	12.9	+3
		12.5	12.8	+2
		25	25.6	+2
		25	25.5	+2
		50	52.1	+4
		50	51.3	+3
		100	100	0
		100	101	+1

<sup>a</sup> Results of duplicate analyses

<sup>b</sup> Animal room samples for rats

<sup>c</sup> Animal room samples for mice



**APPENDIX G**  
**INGREDIENTS, NUTRIENT COMPOSITION,**  
**AND CONTAMINANT LEVELS**  
**IN NTP-2000 RAT AND MOUSE RATION**

**TABLE G1    Ingredients of NTP-2000 Rat and Mouse Ration ..... G-2**  
**TABLE G2    Vitamins and Minerals in NTP-2000 Rat and Mouse Ration..... G-2**  
**TABLE G3    Nutrient Composition of NTP-2000 Rat and Mouse Ration..... G-3**  
**TABLE G4    Contaminant Levels in NTP-2000 Rat and Mouse Ration ..... G-4**



**TABLE G1**  
**Ingredients of NTP-2000 Rat and Mouse Ration**

Ingredients	Percent by Weight
Ground hard winter wheat	22.26
Ground #2 yellow shelled corn	22.18
Wheat middlings	15.0
Oat hulls	8.5
Alfalfa meal (dehydrated, 17% protein)	7.5
Purified cellulose	5.5
Soybean meal (49% protein)	5.0
Fish meal (60% protein)	4.0
Corn oil (without preservatives)	3.0
Soy oil (without preservatives)	3.0
Dried brewer's yeast	1.0
Calcium carbonate (USP)	0.9
Vitamin premix <sup>a</sup>	0.5
Mineral premix <sup>b</sup>	0.5
Calcium phosphate, dibasic (USP)	0.4
Sodium chloride	0.3
Choline chloride (70% choline)	0.26
Methionine	0.2

<sup>a</sup> Wheat middlings as carrier

<sup>b</sup> Calcium carbonate as carrier

**TABLE G2**  
**Vitamins and Minerals in NTP-2000 Rat and Mouse Ration<sup>a</sup>**

	Amount	Source
<b>Vitamins</b>		
A	4,000 IU	Stabilized vitamin A palmitate or acetate
D	1,000 IU	D-activated animal sterol
K	1.0 mg	Menadione sodium bisulfite complex
$\alpha$ -Tocopheryl acetate	100 IU	
Niacin	23 mg	
Folic acid	1.1 mg	
<i>d</i> -Pantothenic acid	10 mg	<i>d</i> -Calcium pantothenate
Riboflavin	3.3 mg	
Thiamine	4 mg	Thiamine mononitrate
B <sub>12</sub>	52 $\mu$ g	
Pyridoxine	6.3 mg	Pyridoxine hydrochloride
Biotin	0.2 mg	<i>d</i> -Biotin
<b>Minerals</b>		
Magnesium	514 mg	Magnesium oxide
Iron	35 mg	Iron sulfate
Zinc	12 mg	Zinc oxide
Manganese	10 mg	Manganese oxide
Copper	2.0 mg	Copper sulfate
Iodine	0.2 mg	Calcium iodate
Chromium	0.2 mg	Chromium acetate

<sup>a</sup> Per kg of finished product

**TABLE G3**  
**Nutrient Composition of NTP-2000 Rat and Mouse Ration**

Nutrient	Mean $\pm$ Standard Deviation	Range	Number of Samples
Protein (% by weight)	14.6 $\pm$ 0.40	14.2 – 15.0	3
Crude fat (% by weight)	8.1 $\pm$ 0.29	7.8 – 8.3	3
Crude fiber (% by weight)	8.8 $\pm$ 0.52	8.5 – 9.4	3
Ash (% by weight)	4.7 $\pm$ 0.23	4.4 – 4.8	3
<b>Amino Acids (% of total diet)</b>			
Arginine	0.783 $\pm$ 0.070	0.670 – 0.970	22
Cystine	0.220 $\pm$ 0.024	0.150 – 0.250	22
Glycine	0.701 $\pm$ 0.041	0.620 – 0.800	22
Histidine	0.352 $\pm$ 0.077	0.270 – 0.680	22
Isoleucine	0.546 $\pm$ 0.044	0.430 – 0.660	22
Leucine	1.095 $\pm$ 0.067	0.960 – 1.240	22
Lysine	0.711 $\pm$ 0.114	0.310 – 0.860	22
Methionine	0.409 $\pm$ 0.046	0.260 – 0.490	22
Phenylalanine	0.628 $\pm$ 0.040	0.540 – 0.720	22
Threonine	0.505 $\pm$ 0.043	0.430 – 0.610	22
Tryptophan	0.150 $\pm$ 0.028	0.110 – 0.200	22
Tyrosine	0.401 $\pm$ 0.061	0.280 – 0.540	22
Valine	0.665 $\pm$ 0.043	0.550 – 0.730	22
<b>Essential Fatty Acids (% of total diet)</b>			
Linoleic	3.95 $\pm$ 0.259	3.49 – 4.55	22
Linolenic	0.30 $\pm$ 0.032	0.21 – 0.35	22
<b>Vitamins</b>			
Vitamin A (IU/kg)	3,560 $\pm$ 53.5	2,950 – 3,950	3
Vitamin D (IU/kg)	1,000 <sup>a</sup>		
$\alpha$ -Tocopherol (ppm)	80.6 $\pm$ 22.03	27.0 – 124.0	22
Thiamine (ppm) <sup>b</sup>	7.7 $\pm$ 0.89	7.0 – 8.7	22
Riboflavin (ppm)	7.6 $\pm$ 2.89	4.20 – 17.50	22
Niacin (ppm)	78.9 $\pm$ 9.08	66.4 – 98.2	22
Pantothenic acid (ppm)	26.9 $\pm$ 12.63	17.4 – 81.0	22
Pyridoxine (ppm) <sup>b</sup>	9.54 $\pm$ 1.99	6.44 – 13.7	22
Folic acid (ppm)	1.62 $\pm$ 0.48	1.15 – 3.27	22
Biotin (ppm)	0.32 $\pm$ 0.10	0.20 – 0.704	22
Vitamin B <sub>12</sub> (ppb)	53.6 $\pm$ 39.6	18.3 – 174.0	22
Choline (ppm) <sup>b</sup>	2,846 $\pm$ 485	1,820 – 3,790	22
<b>Minerals</b>			
Calcium (%)	0.888 $\pm$ 0.028	0.865 – 0.919	3
Phosphorus (%)	0.532 $\pm$ 0.018	0.516 – 0.552	3
Potassium (%)	0.666 $\pm$ 0.030	0.626 – 0.733	22
Chloride (%)	0.386 $\pm$ 0.039	0.300 – 0.474	22
Sodium (%)	0.189 $\pm$ 0.016	0.160 – 0.222	22
Magnesium (%)	0.216 $\pm$ 0.062	0.185 – 0.490	22
Sulfur (%)	0.170 $\pm$ 0.029	0.116 – 0.209	14
Iron (ppm)	186 $\pm$ 9.2	135 – 311	22
Manganese (ppm)	51.4 $\pm$ 10.28	21.0 – 73.1	22
Zinc (ppm)	53.4 $\pm$ 8.46	43.3 – 78.5	22
Copper (ppm)	7.01 $\pm$ 2.562	3.21 – 16.3	22
Iodine (ppm)	0.503 $\pm$ 0.206	0.158 – 0.972	22
Chromium (ppm)	0.694 $\pm$ 0.276	0.330 – 1.380	21
Cobalt (ppm)	0.256 $\pm$ 0.164	0.098 – 0.864	20

<sup>a</sup> From formulation

<sup>b</sup> As hydrochloride (thiamine and pyridoxine) or chloride (choline)

**TABLE G4**  
**Contaminant Levels in NTP-2000 Rat and Mouse Ration<sup>a</sup>**

	Mean ± Standard Deviation <sup>b</sup>	Range	Number of Samples
<b>Contaminants</b>			
Arsenic (ppm)	0.31 ± 0.080	0.24 – 0.40	3
Cadmium (ppm)	0.06 ± 0.001	0.06 – 0.06	3
Lead (ppm)	0.11 ± 0.009	0.10 – 0.12	3
Mercury (ppm)	<0.02		3
Selenium (ppm)	0.21 ± 0.041	0.18 – 0.26	3
Aflatoxins (ppb)	<5.00		3
Nitrate nitrogen (ppm) <sup>c</sup>	10.4 ± 0.693	10.0 – 11.2	3
Nitrite nitrogen (ppm) <sup>c</sup>	<0.61		3
BHA (ppm) <sup>d</sup>	<1.0		3
BHT (ppm) <sup>d</sup>	<1.0		3
Aerobic plate count (CFU/g)	10 ± 0.0	10	3
Coliform (MPN/g)	3.0 ± 0.0	3.0	3
<i>Escherichia coli</i> (MPN/g)	<10		3
<i>Salmonella</i> (MPN/g)	Negative		3
Total nitrosamines (ppb) <sup>e</sup>	4.4 ± 3.33	2.0 – 8.2	3
<i>N</i> -Nitrosodimethylamine (ppb) <sup>e</sup>	1.7 ± 0.61	1.0 – 2.1	3
<i>N</i> -Nitrosopyrrolidine (ppb) <sup>e</sup>	2.7 ± 2.94	1.0 – 6.1	3
<b>Pesticides (ppm)</b>			
α-BHC	<0.01		3
β-BHC	<0.02		3
γ-BHC	<0.01		3
δ-BHC	<0.01		3
Heptachlor	<0.01		3
Aldrin	<0.01		3
Heptachlor epoxide	<0.01		3
DDE	<0.01		3
DDD	<0.01		3
DDT	<0.01		3
HCB	<0.01		3
Mirex	<0.01		3
Methoxychlor	<0.05		3
Dieldrin	<0.01		3
Endrin	<0.01		3
Telodrin	<0.01		3
Chlordane	<0.05		3
Toxaphene	<0.10		3
Estimated PCBs	<0.20		3
Ronnel	<0.01		3
Ethion	<0.02		3
Trithion	<0.05		3
Diazinon	<0.10		3
Methyl chlorpyrifos	0.075 ± 0.058	0.020 – 0.135	3
Methyl parathion	<0.02		3
Ethyl parathion	<0.02		3
Malathion	0.095 ± 0.129	0.020 – 0.244	3
Endosulfan I	<0.01		3
Endosulfan II	<0.01		3
Endosulfan sulfate	<0.03		3

<sup>a</sup> All samples were irradiated. CFU=colony-forming units; MPN=most probable number; BHC=hexachlorocyclohexane or benzene hexachloride

<sup>b</sup> For values less than the limit of detection, the detection limit is given as the mean.

<sup>c</sup> Sources of contamination: alfalfa, grains, and fish meal

<sup>d</sup> Sources of contamination: soy oil and fish meal

<sup>e</sup> All values were corrected for percent recovery.

## APPENDIX H

### SENTINEL ANIMAL PROGRAM

METHODS .....	H-2
RESULTS .....	H-2

# SENTINEL ANIMAL PROGRAM

## METHODS

Rodents used in the National Toxicology Program are produced in optimally clean facilities to eliminate potential pathogens that may affect study results. The Sentinel Animal Program is part of the periodic monitoring of animal health that occurs during the toxicologic evaluation of test compounds. Under this program, the disease state of the rodents is monitored via sera or feces from extra (sentinel) or dosed animals in the study rooms. The sentinel animals and the study animals are subject to identical environmental conditions. Furthermore, the sentinel animals come from the same production source and weanling groups as the animals used for the studies of test compounds.

In the 3-month studies, blood samples were collected from five male and five female rats and mice at study termination. Blood samples were allowed to clot, and the serum was separated. The serum samples were processed appropriately, sent to BioReliance Corporation (Rockville, MD), and evaluated for the presence of pathogens. The laboratory methods and agents for which testing was performed are tabulated below; the times at which samples were collected during the studies are also listed.

### Method and Test

### Time of Collection

#### **RATS**

##### ELISA

PVM (pneumonia virus of mice)	Study termination
RCV/SDA (rat coronavirus/sialodacryoadenitis virus)	Study termination
Sendai	Study termination

##### Immunofluorescence Assay

Parvovirus	Study termination
------------	-------------------

#### **MICE**

##### ELISA

Ectromelia virus	Study termination
EDIM (epizootic diarrhea of infant mice)	Study termination
GDVII (mouse encephalomyelitis virus)	Study termination
LCM (lymphocytic choriomeningitis virus)	Study termination
MAd-1 (mouse adenoma virus-1)	Study termination
MHV (mouse hepatitis virus)	Study termination
MMV VP2 (mouse minute virus-viral protein 2)	Study termination
MPV VP2 (mouse parvovirus-viral protein 2)	Study termination
PVM	Study termination
Reovirus	Study termination
Sendai	Study termination

## RESULTS

All test results were negative.